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Abstract 
Volatile compounds (VCs) hold the potential to diagnose and monitor disease states 
in a cost effective, rapid, and most importantly non-invasive manner. Gas 
chromatography mass spectrometry (GC-MS) has been in use since the 1960s and 
remains the gold standard for qualitative VC analysis. Within this thesis three novel 
methods and/or utilisations of mass spectrometry are described. 
Chapter 2 describes and benchmarks a metal oxide sensor (MOS) coupled to a 
standard GC-MS instrument. Testing this system to the headspace of 12 stool samples 
the sensor detected a mean 1.6 more peaks per sample then the MS. This superior 
sensitivity exhibited by the MOS sensor should allow for greater discriminatory abilities 
to differentiate samples into clinically relevant groups. 
It has become increasingly important to qualitatively and quantitatively assess the VCs 
for use in monitoring health. Chapter 3 describes a novel method for the quantification 
of VCs from the headspace of stool samples analysed using GC-MS is presented. 
Using 13C labelled carbon compounds as internal standards a method has been 
designed which quantifies the compounds within in the stool; 15 compounds were 
quantified.  
The EDX110 dressing has been developed by Edixomed Ltd; uses hydrogel 
technology to generate nitric oxide (NO) to enhance wound healing. A series of 
experiments first allowed for the development of a robust and reproducible method of 
real-time quantification. The effect of pH was assessed using citric acid buffered with 
sodium citrate, pH values 3, 3.6, 4.2, 4.8, 5.4, and 6.2 were all analysed. NO production 
showed an inverse correlation; pH 3 producing 81 µg of NO and pH 6.2 only producing 
7 µg. Except for pH 3 nitrous acid (HONO) and nitrogen dioxide (NO2) remained 
relatively consistent across the pH values with a median 3 and 0.9 µg respectively.  
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Aims and objectives 
Mass spectrometry (MS) is a technique that dates back over 100 years and has been 
used over that time for numerous applications. MS is a technique that is continuously 
evolving and is more relevant today than it ever has been thanks to advances in the 
technology. In recent decades there has been growing interest in using MS for the 
biomedical sector, particularly to detect volatile compounds. Within this thesis 3 pieces 
of work have been carried out which use MS for biomedical applications. 
Chapter 1 describes several real-time and non-real-time MS techniques, and reports 
on the current literature in which these techniques have been used for biomedical 
applications. This chapter also points out some of the benefits and challenges 
associated with each MS technique.  
Chapter 2 introduces and benchmarks a novel gas chromatography mass 
spectrometry (GC-MS) instrument coupled to a metal oxide sensor which provide a 
binary output. This is the first time that these two types of detectors have been coupled 
in this way. This instrument is tested to a range of standards, health participant stool 
samples, and bacterial culture headspace, all pre-concentrated with solid phase micro 
extraction. This allows advantage to be taken of the superior sensitivity of the sensor 
while maintaining the qualitative GC-MS output. 
Chapter 3 utilises GC-MS with a previously unreported technique to quantify 
compounds within stool using carbon 13 (13C) labelled compounds as internal 
standards. This technique allows us to calculate the quantity of compound in the stool 
not just the headspace. Sodium hydroxide was also used to raise the pH of the stool 
prior to analysis. This allowed us to quantify trimethylamine and provided qualitative 
data on alkaline stool which has also not previously been reported.  
Chapter 4 describes the development of a new method to quantify the products of a 
chemical reaction in real-time using SIFT-MS. Edixomed Ltd have developed a smart 
dressing that produces nitric oxide (NO) by the acidification of nitrite. NO is a known 
vasodilator and this dressing has been shown in clinical trials to promote better wound 
healing versus the standard care pathway. This chapter will not only seek to quantify 
products of the dressing reaction but also attempt to underpin some of the 
mechanisms of the reaction. 
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The work within this thesis will demonstrate that this 100-year-old technique has the 
potential to provide new insights into disease states and can be used to help develop 
new ways of treatment. 
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Chapter 1: A review of mass spectrometry (MS) for 
detection of volatile compounds (VCs) for biomedical 
applications. 
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1.1.0 Introduction 
In 1989, a letter to the Lancet records the case of a dog becoming increasingly 
interested with a lesion on the owner’s skin, after seeking clinical advice the lesion 
was confirmed to be a melanoma [1]. Since then numerous studies have been 
conducted attempting to demonstrate dogs ability for diagnosing disease from the 
smell of a sample, blood [2], urine [3–5], stool [6], breath [7,8], and tissue [9,10] 
samples have all been used for such work. Commonly dogs are assessed for their 
ability to diagnose cancer, and many of these studies have been included in critical 
reviews [11,12]. Dogs have also been assessed for their ability to detect C. difficile 
[13] and diabetic alert dogs are also used to alert their owners to hyper/hypoglycaemic 
episodes [14].  
It is fair to state that many of these studies suffer from flaws in experimental design 
such as the use of inappropriate controls as in Pickel et al., 2004 in which materials 
such as gauze and rubber gloves are used [9]; or McCulloch et al., 2006 who collected 
breath on polypropylene tubes which were stored at room temperature for 60 days, 
with no available information on sample viability over this duration and no evidence 
that the tubes are capable of capturing breath volatiles [7]. Reproducibility is also an 
issue both within individual studies in which multiple dogs are used and from study to 
study, for example Amundson, 2014 attempted to detect lung cancer from breath and 
reported a sensitivity of 61.8%-67.6% and specificity of 8.3%-16.7% [15]. Ehmann et 
al., 2012 also used breath to detect lung cancer and reported a sensitivity of 71% and 
specificity of 93% [8].  
There is though on balance enough evidence to suggest that the dogs are responding 
to alterations in the volatile compounds (VCs) emitted from the samples; so much so 
that many traditional laboratory investigations have been conducted on the premise 
that VCs may be useful in the diagnoses of disease. 
Understanding the pathways by which VCs are generated in the body is the key to 
understanding the mechanisms by which VCs can have clinical utility. Miekisch et al., 
2004 describe the mechanism of production for many families of compounds found on 
breath [16]. For instance acetone is a very commonly occurring compound on breath 
and is generally accepted to be derived from the decarboxylation of acetyl-CoA by the 
liver [16]. Elevated breath acetone is considered an indicator of beta-hydrobutyrate in 
the blood [17] and has been attributed to type 1 and type 2 diabetes in a number of 
studies [18–23]. However despite the biochemical mechanisms for breath acetone 
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being understood there are limits to its clinical utility, primarily due the fact that the 
acetone levels on the breath of healthy participants is so variable [23].  
Shirasu and Touhara, 2011 briefly outline the basis for the use of VCs in breath, skin 
and sweat, urine, and faeces [24]. In short breath VCs are derived from ingestion of 
food, beverages, and cigarettes as well as gases in the atmosphere and blood borne 
compounds that are exhaled. Skin VCs are mostly derived from sweat, in this case 
most of the VCs from internal metabolism are altered from the bacteria on the skin. 
Urinary VCs are primarily derived from metabolic process throughout the body and 
contain a wide variety of functional groups such as ketones, alcohols, and furans; 
importantly it is possible for urinary VCs to be affected by ingested food and 
beverages, and are frequently diluted by water. Stool is primarily comprised of bacteria 
which generate a significant amount of VCs this gives stool excellent potential to 
diagnose gastro intestinal disorders [24]. Amann et al., 2014 lay out all the compounds 
found in breath, skin emanations, urine, faeces, and saliva from heathy humans in a 
“megatable”. This paper states that 874 compounds have been reported on breath, 
279 compounds from urine, 504 form skin emanations, 353 from saliva, 130 
compounds from blood, and 381 compounds from faeces [25]. Breath would seem, at 
first to have the most compounds, however, there are likely to be more studies 
conducted using breath as it is the most acceptable, instant, and cost-effective form 
of testing; thus more compounds have been identified versus other bodily excretions.  
Within this project several mass spectrometry techniques and instruments will be 
assessed for their utility within the biomedical forum. This will include analysis of 
biological samples; and the evaluation of smart dressings which use generation of 
volatile oxides of nitrogen for improved wound healing. 
1.1.1 Introduction to mass spectrometry (MS)  
The primary function of mass spectrometry (MS) is to identify compounds within a 
substance and in some cases quantify compounds in a substance. The overall 
mechanisms along with applications and variations of MS is laid out in the book Mass 
Spectrometry: principles and applications [26], which describes multiple methods of 
mass spectrometry including different quadrupoles and detector types. The work 
presented in this thesis has been carried out on a gas chromatography mass 
spectrometry (GC-MS) instrument and selected ion flow tube mass spectrometer 
(SIFT-MS), both of which utilise a similar standard single quadrupole mass analyser. 
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Figure 1.1 shows a schematic of a standard quadrupole with detector; the analyte 
compound is ionised at the source, this is usually done by chemical (CI) or electron 
ionisation (EI) techniques, though there are multiple variants of this such as secondary 
electro-spray ionisation (SESI) as in Gaisl et al., 2018 [27]. MS is a technique in which 
chemical species are ionized and sorted dependant on their mass to charge ratio 
(m/z). In a standard quadrupole detector (as in figure 1.1) the ion beams are focused 
by the first lens. The trajectory of the ion in the electric field allows separation of the 
ions according to the m/z [26]. A second lens focuses this beam to the detector. Again, 
there are a number of different detectors commercially available; however, in general 
the basic principles are the same in that the detection is dependent on the m/z and 
velocity of the ion and the signal is proportional to the abundance of ions.  
 
Figure 1.1 schematic of a standard quadrupole mass spectrometer as adapted from Kicman et al with 
© permission from Elsevier 2007 [28] 
Mass spectrometry has been used for many applications over the years since its 
inception in the late 1800s [29] including environmental [30], biomedical [31–33], 
security[34–36], forensics[37–39], space exploration[40–42], agri-food [43,44] and 
numerous others. Even within the biomedical field there are numerous applications for 
MS including proteomics [45,46] and metabolomics [47–49]. 
Moreover, MS is used in many different instruments for example GC-MS, SIFT-MS, 
ion-mobility MS (I-MS), and liquid chromatography MS (LC-MS) Each have their own 
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advantages and limitations and are better suited for certain applications over others. 
For instance breath analysis in many cases can be improved by the use of real-time 
on-line techniques such as SIFT-MS and proton transfer reaction MS (PTR-MS) both 
of which negate the need for sample pre-concentration which can introduce 
contaminants or degrade the sample [50]. Ratiu et al., 2017 present a review of mass 
spectrometry techniques for VC analysis of compounds generated by bacteria [51]; 
this review details many of the general advantages and disadvantages associated with 
the various techniques but also compares the costs of the different instruments.  
This following review will outline the principles and mechanisms of the various mass 
spectrometry techniques and biomedical applications for them. Table 1.1 shows the 
acronyms for the instruments included in this chapter. 
Acronym Meaning 
GC-MS Gas chromatography mass spectrometry 
GC-MS-MS 
Gas chromatography tandem mass 
spectrometry 
GC-TOF-MS 
Gas chromatography time of flight mass 
spectrometry 
GC-GC-TOF-MS 
Two-dimensional gas chromatography time 
of flight mass spectrometry 
PTR-MS Proton transfer reaction mass spectrometry  
PTR-TOF-MS 
Proton transfer reaction time of flight mass 
spectrometry 
SIFT-MS Selected ion flow tube mass spectrometry 
FAIMS 
Field asymmetric ion mobility mass 
spectrometry 
Table 1.1 the acronyms and meanings for the instruments and pre-concentrating methods that will be 
discussed throughout this review. 
1.2.0 Non-real-time mass spectrometry techniques  
1.2.1 Sample pre-concentrating methods 
Sample pre-concentration techniques such as solid phase micro-extraction (SPME) 
and thermal desorption (TD) are required for GC-MS analysis to ensure sufficient 
analyte concentration is introduced to the column.  
SPME offers time and cost efficiency, simplicity, reliability, and is easily portable [52]. 
Additionally, this technique does not exhaust the sample and allows direct input to the 
GC column. Garner et al., 2007 used this technique to identify 297 compounds from 
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stool samples and demonstrate the potential for disease diagnosis using this 
technique [53]. Figure 1.2 shows a diagram of how a sample is pre-concentrated using 
a standard SPME fibre though it is important to note there are many variants on this 
technique which have undergone recent review [54]. Most commonly the sample is 
placed in a headspace vial allowing sufficient empty space to allow the fibre to enter 
the vial while not touching the sample. The needle of the SPME holder pierces the vial 
septa, the fibre can then be safely exposed to the gases in the vial, the VCs then bind 
to the fibre; the optimal duration of fibre exposure will be dependent on the sample 
type, analysis method, and analyte target. Before the fibre is removed it must first be 
retracted into the fibre holder, the fibres are delicate and easily broken if not properly 
handled. To introduce the sample to the GC-MS the needle of the SPME holder 
pierces the septa of the injector port the fibre is then exposed to the inlet liner which 
is heated, the heating of the fibre drives the VCs off the fibre and onto the column and 
the chromatography phase can begin.  
 
 
Figure 1.2 diagram of the operation of a solid phase micro-extraction technique. Diagram taken from 
Schmidt and Podmore (open access creative commons ©), 2015 [55] 
There are many adsorbent coatings that can be used for SPME fibres many of which 
have described in a review by Silva et al [52]; the most appropriate adsorbent will be 
dependent on the target analyte(s). The most common adsorbent for complex matrices 
such as urine is PDMS, this strikes the balance between being able to adsorb a wide 
range of compounds while not falling having such a strong affinity to compounds that 
reuse becomes problematic due to carry over [52]. A 2012 study compared six 
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different SPME adsorbents PDMS, PA, DVB/CAR/PDMS, CAR/PDMS, CW/DVB, and 
PDMS/DVB. Each of these was used to analyse the urine of breast cancer patients. 
By comparing the number of identified compounds, the chromatographic peak areas, 
and relative standard deviations CAR/PDMS had the greatest extraction efficiency 
[56].  
TD is a significantly more intricate technique which requires loading the TD tubes by 
flowing the gas to be analysed through the tube at a known flow rate to balance 
maximum sensitivity versus the possibility of overloading the tube. Figure 1.3 shows 
a diagram of a typical TD tube; the tube housing is traditionally glass or stainless steel. 
There are numerous sorbent materials that can be used to pack the TD tubes, these 
include: porous polymers, carbon blacks, molecular sieves, and activated charcoal. 
However, by far the most commonly used and most versatile is Tenax TA which a 
hydrophobic porous polymer. The mechanism of sorbent trapping has been described 
in a 2000 review [57]; there are three classified pore sizes macropore, mesopore, and 
micropore. Macropores have a multilayer adsorption which causes the vapour to enter 
a condensed phase and thus Henry’s Law can apply. Micropores tend to hold the 
molecules more strongly as the molecule is held by more than one side of the pore. 
There is often a secondary sorbent bed to prevent breakthrough; this is where the 
analyte compounds are not retained in the tube. Breakthrough means that either the 
primary absorption bed is over capacity or compounds are being displaced [57].  
One of the main advantages of TD is that once loaded the tubes can be stored for 
significant lengths of time provided correct tube fittings and storage is used. Kang and 
Thomas, 2016 report that stored at -80oC breath samples retained 94% of the VCs 
after 1.5 months [58]. Harshman et al. performed a stability study using Tenax TA to 
trap compounds from breath samples; they found that after 14 days all the compounds 
were still present regardless of storage conditions and when stored below 4oC the 
compounds kept for 31 days [59] In order to desorb the compounds on to the GC 
column a TD unit is required, an example of a direct injection and two stage desorb is 
shown in shown in Figure 1.4. The short path TD process is similar to a direct injection, 
the needle pierces the septa of the GC inlet once the pressures are stable the heating 
block heats the tube to desorb the VCs, which enter the GC oven via the needle there 
is a cryo-trap mounted in the GC oven which holds the VCs while the GC phase starts 
(Chromatography phase is discussed in section 1.2.2). The two stage desorb requires 
a separate unit, in this instance the tube is heated and the VCs are, as with the direct 
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desorb, held onto an internal trap. The VCs are then desorbed onto the heated transfer 
line which connects to the GC column.  
 
 
 
Figure 1.3 a diagram of an example thermal desorption tube glass wool keeps the adsorbent material 
in place while still allowing air flow through the tube.  
 
Figure 1.4 a simple schematic showing both short path and 2 stage thermal desorption processes, 
image used with © permission from Elsevier 2017 from Li and Zhu [60]. 
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The drawback of TD as a pre-concentration method is that the initial cost of the thermal 
desorption unit is expensive; additionally, there is substantial method development 
required for optimal results. While the TD tubes and SPME fibres are a similar cost the 
time of analysis for TD per sample is generally double that of SPME. However, despite 
these drawbacks the enhanced sensitivity of this method is considered by many to be 
worth the additional costs and time [57].  
1.2.2 Gas chromatography (GC) 
Gas chromatography is a technique used to separate compounds from a matrix, using 
a column to do so.  The mobile phase is an inert gas, most commonly helium or 
hydrogen which is used to carry the analyte compounds through the column. The 
stationary phase is usually a solid adsorbent which, can be polar or non-polar. The 
polarity of the column will have a significant impact on the elution order of compounds 
due to the affinity of the compound with the column. The order in which the compounds 
elute out are determined primarily by the chemical properties of the compound, as well 
as the affinity the compound has for the solid phase. The GC column is housed in an 
oven, as the oven temperature ramps up the compounds will begin flowing through 
the column the rate of travel is usually determined by the boiling point of the 
compound, in general lighter molecular weight compounds will flow elute out first due 
to having lower boiling, though this is not always the case.  
There are many detectors that can be used in conjunction with GC,  the most common 
is MS, and flame ionisation detectors (FID); other examples of detectors are metal 
oxide sensors [61], electron capture, flame photometric, nitrogen phosphorus, and 
thermal conductivity [62]. 
1.2.3 Gas chromatography mass spectrometry (GC-MS). 
Gas chromatography mass spectrometry (GC-MS) is a very common analytical 
technique and is still considered a gold standard for qualitative gas analysis. There is 
such a vast quantity of biomedical based GC-MS papers that it is difficult to 
overestimate the role that GC-MS has played in the advancement of volatile analysis. 
GC-MS utilises two phases; the chromatography phase separates the compounds in 
the sample (see section 1.2.2).  
The compounds are ionised as they enter the mass analyser which allows a spectrum 
to be mapped based on the mass to charge ratio (m/z) of the product ions which allows 
the detection phase to take place. This ionisation process makes this technique ideal 
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for identifying the compounds present in complex matrices such as stool and urine 
headspace. The national institute of standards and technology (NIST) library software 
provides identification of the compounds present by comparing the spectra produced 
from the ionised products of the analyte with those in the library. A full description of 
how this match is calculated has been published [63]; in short three values are used 
for the identification, the match, reverse-match (R-match) and probability value. The 
match directly compares the unknown spectrum to the library spectrum; the R-match 
also does this however ignores peaks in the unknown that are not in the library 
spectrum. The probability compares the hits adjacent to the unknown in the hit list to 
give a relative probability.  Most modern GC-MS instruments have reported limits of 
detection (LOD) in the femtogram region however in reality when running a normal 
sample using a general method in total ion count most users report closer to the 
picogram LOD [64]. 
While GC-MS provides excellent sensitivity and is the most commonly used qualitative 
method of trace gas detection quantification requires considerable method 
development and analysis.  
There have been numerous publications over many years attempting to utilise GC-MS 
for diagnostic purposes. For instance Tait et al., 2013 used SPME GC-MS to identify 
Clostridium difficile from the headspace of stool samples with reported sensitivity and 
specificity of 83.1% and 100% respectively [65]. This study identified 2-fluoro-4-
methylphenol, isobutyric acid, butyric acid, isocaproic acid, and p-cresol as the key 
compounds [65]. Another group also used SPME GC-MS to differentiate causes of 
diarrhoea and found that 5-methyl-2-furancarboxaldehyde was associated with 
Clostridium difficile and that this association improved when coupled with the absence 
of 3-methylindole (X2=22.2, p=0.000002 and X2=20.4, p=0.000002 respectively)[66]. 
Though it is worth noting that the total number of participants in this study was 35 with 
only six confirmed Clostridium difficile patients.  
Colorectal cancer (CRC) is an excellent target for a diagnostic test based on VCs; 
currently the best method for diagnosing CRC is by colonoscopy, a procedure that is 
costly and very invasive. Moreover patients are less likely to come forward with 
symptoms due to embarrassment [67]. Therefore, if a VC test using urine or breath 
could be developed for the detection of CRC it may allow more accurate targeting of 
colonoscopy candidates and prevent many unnecessary procedures. 
13 
 
Altomare et al, 2013 used automated TD GC-MS to analyse the breath from 78 
participants (37 cancer patients) in an attempt to differentiate colorectal cancer from 
healthy controls. The resultant VC patterns were fed into the probabilistic neural 
network which had an 85% overall accuracy; while this accuracy dropped during a 
validation phase to 76% this is still an encouraging result  [68]. Amal et al., 2016 also 
used breath, and demonstrated that acetone and ethyl acetate were increased in CRC 
patients versus controls and that ethanol and 4-methyl octane were decreased in CRC 
patients [69].  
1.2.4 Gas chromatography tandem mass spectrometry (GC-MS-MS) 
GC-MS-MS utilises two mass analysers in succession; the ions enter the first 
quadrupole and are filtered; from there the ions are focused into a collision cell which 
sits between the two quadrupoles. In the collision cell the ions are further fragmented 
before entering the second quadrupole, and finally the detector (as shown in Figure 
1.5). McLafferty, 1980 sets out the mechanisms for MS-MS analysers [70]. Overall 
tandem mass spectrometry has greater selectivity and sensitivity over a single 
quadrupole MS. Moreover MS-MS lends itself to the analysis of heavier molecules due 
to the second fragmentation phase. Wang et al., 2015 used GC-MS-MS to study the 
pharmacokinetics of Longu Rendan pills, a Chinese medicine used to prevent heat 
stroke and motion sickness. Using this technique, the team determined the 
concentrations of menthol, isoborneol, and borneol. They were able to determine the 
pharmacokinetics of the drug by feeding the drug to rats and analysing the plasma 
using the MS-MS technique [71].  
 
Figure 1.5 a simple schematic of a tandem mass spectrometer (image with © permission from Fisher 
Scientific [72]) 
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Lomonaco, 2018 used MS-MS to detect a range of ketones and aldehydes at an LOD 
of less than 200 pptv. This technique was then used to determine carbonyl compounds 
in the breath of heart failure patients; they were able to derivatize on-sorbent [73]. 
Aldehyde and ketone concentrations are important as they are a feature of oxidative 
stress which is linked to a number of diseases such as diabetes, liver diseases, and 
heart failure.  
Despite the benefits of GC-MS-MS, namely the increased sensitivity and specificity 
and superior ability to identify heavier mass molecules versus a single quadrupole, it 
is not a commonly used technique for biomedical investigations as the bulky 
equipment, extra expense, and often time consuming analysis is not optimally suited 
to the biomedical forum, where rapidity, low cost, and ease of use are often required 
attributes.  
1.2.5 Gas chromatography time of flight mass spectrometry (GC-TOF-MS) 
Time of flight (TOF) MS differs from standard MS as TOF does not use a quadrupole; 
in TOF-MS the ions are accelerated in a magnetic field so that all ions of the same 
charge have the same kinetic energy. These accelerated ions enter a field free drift 
region which is at a constant distance; the time it takes to cross this drift region will 
vary dependant on the m/z of the ion (see Figure 1.6). This gives TOF a higher 
acquisition rate versus quadrupole mass spectrometry, which in turn allows for 
excellent resolution particularly in semi-co-eluting compounds [74]. Moreover TOF-MS 
detectors have spectral continuity, this means that 5000 full mass range spectra can 
be analysed per second; spectral continuity means that concentration changes from 
peak elution does not affect the spectral continuity. This spectral continuity allows for 
greater performance of the deconvolution algorithms needed to identify a compound. 
As a result a TOF detector generally yields more accurate compound identification 
versus its quadrupole counterpart [74].   
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Figure 1.6 a diagram of a time of flight mass spectrometer (image from Plocoste et al 2016 open 
access cc ©) 
Baranska et al., 2016 analysed the breath samples from 1630 participants (170 
irritable bowel syndrome (IBS) patients, 153 controls, and 1307 general population), 
16 VOCs that could predict IBS in 89.4% of cases [75]. Similarly, Pijls et al., 2016 
identified a set of 11 volatiles to discriminate patients with chronic liver disease (CLD) 
from those with compensated cirrhosis (CIR). Over the course of this study the group 
claim a recorded data matrix of 3718 individual compounds from 152 chromatograms 
[76]. While these results are very encouraging both these examples lack details 
around the identification of the VCs. Neither paper offers a clear criterion by which a 
positive compound identification was achieved, for instance a set software matching 
threshold. Also, there is no verification with standards or retention indices.  
VC analysis has enormous potential for clinical utility particularly when used in 
conjunction with other tests. Smolinska et al., 2018 performed GC-TOF-MS analysis 
of breath samples from 184 patients and correlated these results with the results of 
microbiome tests from faecal samples in Crohn’s disease patients [77]. This group 
demonstrated a link between the metabolites found on the breath and the microbiome 
found in the stool, either directly form the bodies metabolic processes or indirectly in 
the form of microbiota metabolites. This type of analysis should help provide a deeper 
mechanistic understanding of how the VCs can be clinically useful but also the 
pathogenesis of gastrointestinal diseases.  
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1.2.6 Two-dimensional gas chromatography time of flight mass spectrometry 
(GC-GC-TOF-MS)  
The GC process is described in section 1.2.2; GC-GC couples 2 GC columns together 
one after another. Coupling together two columns allows better separation of 
compounds versus a standalone GC column. GC-GC is exceptionally good at 
separating out chemical families e.g. acids, ketones, and aldehydes etc.; additionally, 
GC-GC is also capable of separating the chemical isomers. Usually the two columns 
will use differing modes of separation such as polar and non-polar (see section 1.2.2). 
This system avoids co-elution problems whilst maintaining high sensitivity and 
specificity; moreover the ability to adjust and tune the parameters mean there is 
greater ability to optimise methods for the target range of analytes compared to a 
single GC column [78]. TOF-MS is a rapid detector which is much better suited to GC-
GC chromatography phases [79].  
Rees et al., 2017 utilise this technique to determine the hypoxia VC signature of 
Aspergillus fumigatus, using SPME as a pre-concentration method. They were able to 
show the difference between early hypoxia and late hypoxia and early and late 
normoxia (normal oxygen level) [80]. By obtaining comprehensive VC data from this 
method this group was able to differentiate the oxygenation state of aspergillus 
fumigatus using 19 VCs however, more importantly this data obtained allowed the 
group to postulate possible pathways by which the fungus can continue metabolism 
under hypoxic conditions, involving 2,3-butandione and 3-hydroxy-2-butanone [80]. 
The idea of postulating metabolic pathways using VC profiles is important as this could 
provide crucial information in the pathogenesis of any number of disease states 
including infections, cancers, and metabolic disorders.  
The same group also carried out similar work by characterising the VC metabolome 
of Klebsiella pneumoniae grown in human blood. In this instance the group used the 
GC-GC-TOF-MS and were able to identify compounds not previously reported as 
being produced by Klebsiella pneumoniae. This was done by comparing the sterile 
human blood sample compared to blood from the same participant inoculated with K 
pneumoniae; there was an increase in the production of VCs in the inoculated blood. 
By their own admission the authors acknowledge that their study is limited by only 
using the blood from one participant, nor were they able to compare the VCs produced 
by other strains of bacteria grown under the same conditions [81]. Despite the limited 
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sample size this study is still important as once again it demonstrates the utility of a 
powerful analytical technique such as GC-GC-TOF-MS.  
1.2.7 Gas Chromatography-Sensor systems and sensor arrays for biomedical 
applications 
A conventional GC-MS has been reported as being  coupled to a metal oxide sensor 
(MOS); the full assessment of this novel analytical instrument is described in full detail 
in chapter 2 though the work has been published [61]. The MOS in the majority of 
cases display superior sensitivity to the mass spectral analyser, this has the potential 
to enhance the discriminatory capabilities whilst providing qualitative data 
simultaneously. A similar technique was used by Khalid et. al., (2013) in this case a 
30 m GC column was used for the chromatography phase in a conventional GC oven, 
however in this instance there was no MS, instead the column interfaced directly to a 
MOS sensor [82]. This method was successful in differentiating bladder cancer 
patients from patients with other urological conditions, the leave-one-out cross-
validation predictive value for cancer patients was very high at 95.8%, this dropped 
only slightly for the control group to 94.6% [82]. While these numbers came from a 
small cohort (24 cancer, 74 controls) the numbers are very encouraging. The per 
sample run time for the method used in Khalid et. al. (2013) is 42 minutes, however 
the use of a high speed multi capillary column can be used to reduce this time as in 
McGuire et. al. (2014) who also used a GC column interfaced to a MOS sensor, on 
this occasion the use of a high speed multi capillary column was able to reduce the 
run time per sample down to 10 minutes [83]. McGuire et. al. (2014) analysed C.difficile 
positive stool samples and C.difficile negative stool samples and were able to 
differentiate the positive and negative samples with a sensitivity and specificity of 85% 
and 80% respectively [83].      
Bartolazzi et. al. (2010), used a sensor array to analyse the VCs from five different 
cancer cell lines: three melanoma lines, synovial sarcoma, and thyroid cancer. An 
array of eight quartz microbalance sensors were used parallel to conventional GC-MS. 
The quartz microbalance sensors used metalloporphyrins to be activated copper, 
cobalt, zinc, iron, tin, and chromium were used as the metals [84]. This group found 
that the sensor array data provided good clustering and differentiation of the five cell 
lines; the parallel GC-MS analysis revealed 14 compounds that were most likely to be 
the cause of the clustering from the cell line [84]. 
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Sensors and sensor array can have greater sensitivity versus MS techniques (as 
discussed in chapter 2). This means that sensitive sensor can enhance the 
differentiation of samples into clinically relevant groups, usually sensor outputs rely on 
pattern recognition techniques for data analysis. Moreover, sensors are rarely able to 
provide qualitative data to support the findings or infer mechanisms by which a change 
in the VCs present in a sample may occur. Despite this though the use of sensors 
could prove important in the development of high throughput, cost effective, and 
accurate clinical tests. 
1.2.8 Summary and comparison of non-real time techniques 
The chromatography phase of these techniques allows for the separation of 
compounds which is what makes the identification of compounds possible. However, 
this data is crucial to unlocking the mechanisms by which the VCs are created 
chromatographic methods require considerable development. Moreover, there are 
important decisions to be made about sample preparation and pre-concentration to 
ensure most efficient VC extraction without introducing confounding variables. In 
addition, GC-GC methods can have relatively long per sample analysis time.  
 Advantages Limitations 
GC-MS • Still considered the gold 
standard for VC qualitative 
analysis. 
• Capable of providing detailed 
data from complex matrices. 
• The most cost-effective method 
of non-real time MS analysis. 
• Can tailor pre-concentration 
methods to suit the sample 
being analysed. 
• Generally easy to operate once 
set up and data easy to 
analyse. 
• Samples require pre-processing 
and pre-concentration which 
can be time consuming and 
expensive. 
• Method development requires 
experienced users. 
• Sample analysis can range from 
30-60mins and require blank 
runs and QC qualification which 
limits throughput. 
GC-MS-MS • Much greater selectivity versus 
GC-MS. 
• Can measure a wide mass 
range including peptides 
• Enhanced signal-to noise ratio 
• Can provide more accurate 
identification of compounds 
versus GC-MS 
• Can require derivitization of 
metabolites. 
• Both expensive and has a large 
lab. footprint. 
•  Also requires experienced 
personnel for both method 
development and data analysis.  
GC-TOF-MS • Great mass resolution allows 
for more accurate 
identification of compounds. 
• Has a theoretically unlimited 
upper mass range. 
• Very high sensitivity. 
• At high signal-to-noise levels 
reproducibility suffers. 
• Poor detector linearity compared 
to a standard quadrupole MS. 
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 Advantages Limitations 
• More consistent performance 
for low concentration 
compounds. 
• Rapid acquisition rates. 
GC-GC-TOF-MS • All advantages of GC-TOF-MS. 
• Compatible with single GC 
injection techniques. 
• Can provide sharper better 
resolved peaks. 
• The combination of GC-GC 
with a TOF-MS is considered 
the most powerful tool for 
quantitative VC analysis. 
 
• Disadvantages of GC-TOF-MS. 
• Long sample run times. 
• Special software is required. 
• If the modulation between the two 
columns is not properly set 
then separation is 
compromised. 
 
 
GC-Sensors • Low cost. 
• Highly sensitive. 
• Rapid throughput. 
• Easy to operate. 
• Easy to customise for purpose. 
• Lack of standardisation 
• No qualitative data 
• Analysis of data can require 
skilled personnel to set up 
• Low specificity (though high 
specificity sensor can be used). 
Table 1.2 the advantages and limitations of the GC non-real time techniques discussed in 
chapter 1 section 2.  
Table 1.2 summarises the advantages and limitations for the non-real time techniques 
discussed in this chapter. The distilled conclusion is that as the analytical power of the 
instrument increases so too does the cost, laboratory foot print, time, and effort 
required to analyse samples. Despite this GC-MS and related techniques are 
unparalleled for the qualitative analysis of VCs.  
1.3.0 Real time mass spectrometry techniques 
The use of real-time mass spectrometry is still a relatively new and emerging analytical 
method. These techniques can be highly sensitive and are better suited to providing 
quantitative data. Moreover, the sample analysis time can be reduced to seconds and 
in many cases, there is no need to pre-concentrate or prepare samples. However, the 
real time techniques often lack detailed qualitative data and thus elucidating metabolic 
data is difficult.    
1.3.1 Selected ion flow tube mass spectrometry (SIFT-MS) 
Selected ion flow tube mass spectrometry (SIFT-MS) provides real-time quantitative 
analysis of gases and is capable of detecting a wide variety of analytes in the low part 
per billion (ppb) range with the new generation of instruments reporting part per trillion 
levels of sensitivity for selected analytes [85]. In contrast to GC-MS SIFT-MS has no 
chromatographic phase. The SIFT-MS generates the reagent ions H3O+, NO+, or O2+ 
by mixing air and water vapour in a microwave plasma source. These reagents are 
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selected by the front quadrupole and the ions used will be determined by their reactivity 
with the pre-selected analyte compounds. These reagents then enter the flow tube 
where they are reacted with the sample (see Figure 1.7). This soft chemical ionisation 
process forms ionised molecules which then are selected through a second 
quadrupole and on to the MS detector. 
 
 
 
   
Figure 1.7 schematic of a SIFT-MS as adapted from siftms.com cc 3.0 copyright licence agreement 
[86] the reagent ions are generated by a mix of water and air in the microwave plasma. The ions are 
then filtered by the first quadrupole into the flow tube where they are mixed with the sample and 
carrier gas. The second quadrupole filters the desired molecules based on the selected m/z. 
Due to the real-time quantitative output and no requirement for pre-concentration step 
SIFT-MS is ideally suited for assessment of breath VCs and bacterial headspace 
analysis, numerous papers exist on both applications; Spanel and Smith 2013, provide 
a review of SIFT-MS in breath analysis [87].  
SIFT-MS offers real-time direct analysis and has excellent sensitivity, thus breath 
analysis has been used in attempts to diagnose many different disease states such 
as: breast cancer [88], liver disease [89], malignant biliary strictures [90], renal failure 
[91], chronic kidney disease [92], Crohn’s disease and ulcerative colitis [93], 
inflammatory bowel disease [94,95], and gastro oesophageal cancer [96]. 
Breath was analysed on SIFT-MS in a study looking at the difference in VCs resulting 
from gastro-intestinal disorders including inflammatory bowel disease (IBD), Crohn’s 
disease (CD), ulcerative colitis (UC), and ileal pouch anal anastomosis (IPAA) [97]. 
This group were able to determine that IBD could be differentiated from CD, UC, and 
21 
 
IPAA. Just as importantly they showed that CD and UC could not be differentiated 
from one another and that the VC profile was not altered by the inflammation in IPAA 
[97]. In 2017 Demirjian et al. used SIFT-MS breath analysis to attempt to identify a 
breath-print in patients with end stage renal disease (ESRD); this work showed that 
they were able to distinguish renal disease patients from healthy controls with a C 
statistic of 0.99 [91]. While this is a very encouraging result it should be noted that only 
86 patients with renal disease were analysed and only 25 healthy volunteers served 
as controls. Moreover, patients either had ESRD or were completely healthy as such 
this does not give a realistic analogue for clinic patients. While it would be beneficial 
to be able to identify the different grades of renal disease from the early stages onward, 
that process would require numerous patients with a range of clinical stages of disease 
which, would be time consuming and very costly.  
SIFT-MS has been used for the online breath monitoring of acetone, isoprene, and 
acetic acid while the patient was undergoing surgery ranging in time from 20 minutes 
to 60 minutes [98]. The results of this work showed that with the exception of isoprene 
the compounds remained relatively stable; isoprene however doubled in concentration 
in most cases over the course of the surgery [98]. This work shows that SIFT-MS is 
not only useful single sample analysis but also continuous monitoring over time. 
Sovova et al., 2013 used continuous monitoring of bacteria from three species 
(Serratia rubidea, Serritia marcescens, and E. coli). Ammonia, ethanol, acetaldehyde, 
propanol, acetone, and acetic acid were quantitatively analysed for a continuous 24 
hr period [99]. This group were able to determine that the bacterial species could be 
determined by the headspace composition; for instance, the presence of propanol was 
indicative of an E. coli population. This work also demonstrates that growth and death 
of the bacterial cultures could be monitored without interfering with the sample [99]. 
Similarly air changes in the atmospheric compounds can also be monitored over time, 
as in Prince, Milligan, and McEwan, 2010 who monitored toluene, 1,3-butadiene, 
benzene, ethanol, and ethene over a five day period [100]. The group monitored 
emissions from the Syft Technologies factory in order to remove organic compound, 
the inlet gas was heated to 300oC. This group were able to record 1,3-butadiene at a 
level of 9 pptv with ±4 pptv precision and demonstrated the capabilities of SIFT-MS 
for the online real time monitoring of VCs [100].  
The SIFT-MS allows not only the concentration of selected compounds to be 
calculated but also a full scan can show the m/z peaks present in the sample which 
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can be indicative of the compounds present. As shown by the examples discussed the 
rapid, real-time, non-invasive nature of breath testing makes it an ideal candidate for 
clinical utility.  
1.3.2 Proton transfer reaction mass spectrometry (PTR-MS) 
PTR-MS is similar technique to SIFT-MS in that there is a real-time soft chemical 
ionisation of compounds that results in less fragmentation of compounds than that of 
traditional quadrupole MS. As with SIFT-MS in most cases there is no need for sample 
preparation. Even the generation of H3O+ is similar to that of the SIFT-MS, however in 
a PTR-MS system there is no filtering quadrupole and no flow tube (see Figure 1.8). 
Instead the ions and analyte VCs are mixed in a drift cell, this drift cell has controlled 
pressure, temperature, and magnetic field thus there is no need for carrier gas which 
results in a claimed sensitivity several orders of magnitude greater than SIFT-MS 
[101]. The resulting ions are focused to a beam which are accelerated through different 
vacuum stages to account for the large pressure difference between the reaction 
chamber and the quadrupole mass spectrometer (see Figure 1.8).  
 
 
Figure 1.8 a simple schematic of a PTR-MS  with permission © 2009 American Chemical Society 
from Blake, Monks, and Ellis 2009 [102]. 
Winkler, Herbig, and Ingrid (2013) demonstrated how this real-time technique with its 
excellent sensitivity (pptv) could be used to elucidate metabolism of VCs in the body 
[103]. In this paper isotope labelled ethanol was ingested and the breath was 
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monitored using a PTR-MS instrument, after 10 minutes metabolic products from the 
breakdown of the labelled ethanol could be seen (deuterated acetone and isoprene).  
del Rio et al., 2015 compared the breath of cirrhosis patients pre and post liver 
transplant using PTR-MS. Overall the group showed that limonene, methanol, 2-
pentanone, 2-butanone, and carbon disulphide were all decreased following 
successful transplant. While limonene had the best individual diagnostic ability (ROC 
0.91) this was enhanced when combined with methanol and 2-pentanone (ROC 0.95) 
[104]. This paper demonstrates nicely that while there may be a VC that serves well 
as a biomarker the likelihood is that a combination of markers will allow for greater 
discriminatory capabilities. More recently Zou et al., 2018 used an ultrasonic 
nebulization technique to analyse urine using PTR-MS; this was used to analyse 
methanol, acetaldehyde, and acetone from healthy human urine which yielded a 
recovery of 88.89% and 94.54% this percentage was based on concentrations 
obtained from the groups previous work [105]. This method requires only 0.66mL of 
urine making it ideal for patients struggling to provide a full sample [105]. Moreover, 
this method yields LODs in the low µg/L (tested with standards of methanol (LOD 4.47 
µg/L, acetaldehyde LOD 1.98 µg/L, and acetone LOD 3.47 µg/L), and can give a full 
scan result in 34 seconds.  
1.3.3 Proton transfer reaction time of flight mass spectrometry (PTR-TOF-MS) 
Another variant of the PTR-MS is with the use of a TOF-MS detector instead of a 
traditional single quadrupole MS. This retains all the benefits of the PTR system and 
combines it with the greater resolution and mass range of the TOF-MS detector.  
In a study using this system to test coeliac disease patients from healthy controls 
Aprea et al., 2014 were unable to find any significant difference between the 2 groups. 
However, their coeliac disease patients were all following a gluten free diet and were 
asymptomatic thus it is unsurprising that there would be little difference between the 
groups. Ideally the patients would have unmanaged symptoms or be suspected of 
having coeliac disease with an unconfirmed diagnosis but of course this would raise 
ethical issues because it would involve potentially delaying treatment, or encouraging 
known ceoliacs to eat gluten [106].  
A more recent study also used PTR-TOF-MS to investigate dietary impact; Kistler et 
al., 2016 found that in mice, diet induced obesity altered the VC profile [107]. This 
group found that when keto-bodies were present as were markers of lipid peroxidation. 
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(Methylthio) methanethiol was also reduced which is indicative of a link between 
metabolic changes and reproduction [107]. This paper suggests that breath can be 
used to not only diagnose potential metabolic changes early but also monitor the 
progression and regression of these changes in obesity cases. Again, this is an 
example of how powerful analytical techniques can serve to better our understanding 
of metabolic processes by determining how and why metabolites are generated in the 
body. This idea is further supported by work done in 2017 on patients with chronic 
kidney disease (CKD) in which ammonia was found to be elevated in stage 1 CKD 
patients in the later stages (2-4) isoprene, pentanal, and heptanal were also elevated, 
while methylamine was lower in patients versus controls (either patients post-
transplant, or with acute infections) [108]. This suggests that it would be possible to 
detect the early metabolic changes associated with CKD and thus begin monitoring 
the condition early. The idea of being able to detect a disease such as CKD in the 
early stages often is crucial for improved recovery outcomes.  
1.3.4 Field asymmetric Ion mobility mass spectrometry (FAIMS) 
One drawback to both the quadrupole and time-of-flight mass detectors is the need 
for high vacuum conditions, this requirement adds bulk, expense, and additional 
equipment maintenance. FAIMS circumvents this obstacle by being able to perform 
analysis at atmospheric pressure and has been found to be functional at above 1500 
torr [109]. Guevremont and Purves (1999) detail the mechanism of action for FAIMS 
[110] see Figure 1.9 taken from [111]. In short, the gas flow is ionized with a UV photo-
ionization (photons are injected into the ion channel) or corona discharge source 
(which generates a reagent ion) before entering a magnetic field which causes the 
ions to drift, this allows separation of ions depending on their electrical properties. 
Once in the detector region the ions are deflected toward the detector, this ion beam 
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can be focused by using the electrical field to narrow the ion cloud [110,112]. 
 
Figure 1.9 taken from Rutolo et al, 2014 [111] published in open access journal © cc shows a 
schematic for the mechanism by which a FAIMS system operates. 
In section 1.3.3 it was noted Aprea et al., 2014 used PTR-TOF-MS to investigate 
coeliac disease patients with little success. Arasaradnam et al. also in 2014 published 
work in which they attempt to differentiate coeliac disease from IBS. The FAIMS 
instrument in this instance was able to differentiate coeliac and IBS patients with a 
ROC of 0.91 [113]. While all the participants in this case were patients with diagnosed 
conditions and very few other variations were considered it nevertheless demonstrates 
the point that the ability to distinguish between diseases with overlapping symptoms 
has the most clinical utility.  The paper also makes the point that an at home breath 
test for patients with chronic gastrointestinal conditions could be very useful for 
monitoring treatment compliance. The same group a year later used breath samples 
to determine if inflammatory bowel disease (IBD) could be differentiated from healthy 
controls. In this case the test had a sensitivity and specificity of 0.74 and 0.75 
respectively [114], FAIMS is ideally suited to this type of testing as it can be done at 
the point-of-care.   
FAIMS was also tested for the rapid detection of C. difficile infections and was found 
to have a ROC score of 0.86 on blinded samples [115]; this was done by training an 
algorithm with a batch of samples; then a second batch of samples was used to test 
this algorithm with double blind samples. Double blind validation of a new method is 
something that is rarely reported and yet is absolutely crucial to the development of a 
clinically useful test. By taking this extra measure the group show how the test could 
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be applied clinically; the benefit of FAIMS is that once everything is set up it can be 
operated by semi-skilled personnel.  
1.3.5 Summary and comparisons of real-time techniques 
Table 1.3 summarises the advantages and limitations of real time MS techniques, in 
general these techniques are able to provide accurate quantification (with the 
exception of FAIMS) at very low levels making them ideal for trace VC analysis. As 
such these instruments all have numerous applications such as: agri-food, 
environment, and, as discussed in this chapter, biomedical. Since these instruments 
offer rapid real time outputs, they are ideally suited for breath analysis and numerous 
studies have been performed to reflected this (see sections 1.3.1-1.3.4 for examples) 
However, the real time techniques usually require target analytes in order to achieve 
quantification. Moreover, the qualitative data obtained by these instruments is usually 
only indicative of the compounds present and offers no concrete identification. 
Perhaps though, the biggest challenge faced by real time MS is the overlap of 
compounds with the same m/z value [50].  
 
 Advantages Limitations 
SIFT-MS • Provides real time 
quantification of compounds. 
• Simple to operate. 
• Easy to interpret data. 
• Can discriminate isomers. 
• Highly sensitive (pptv levels) 
• Can detect compounds GC-
MS can-not such as amines 
and thermally unstable 
compounds. 
• High throughput 
• No sample pre-processing. 
• Multiple reagent ions 
• Quantification relies on having a 
target analyte with known kinetic 
parameters. 
• Very expensive ca. £250,000. 
• Difficult to get meaningful 
qualitative data. 
• Having two quadrupoles under 
vacuum can mean more 
maintenance. 
PTR-MS • No front quadrupole means 
cost is reduced versus SIFT-
MS and PYR-TOF-MS 
• High throughput. 
• Can provide quantification 
within 20% accuracy without 
compound indentification. 
• Provides real time 
quantification of known 
compounds. 
• Can be used in conjunction 
to with GC methods. 
• More sensitive then SIFT-
MS. 
• Easy to maintain. 
• Only use the H3O+ reagent ion. 
• LOD determination requires 
instrument calibration with 
standards. 
• Possible interference from other 
compounds with same m/z ratio. 
• Low mass resolution means 
separation of isomers is not 
possible. 
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 Advantages Limitations 
PTR-TOF-MS • High throughput. 
• Greater mass resolution 
means isomers can be 
resolved even in complex 
matrices. 
• No front quadrupole means 
the instrument in smaller 
than SIFT-MS. 
• Can rapidly detect the full 
mass spectrum in one TOF 
pulse. 
• Data can be mined to find 
unexpected compounds. 
• Easy to maintain. 
• Greater sensitivity versus 
SIFT-MS. 
• Comparable cost to SIFT-MS. 
• Data processing can be 
complicated and time consuming. 
• Not as sensitive as PTR-MS. 
• Still vulnerable to m/z overlap in 
complex matrices. 
FAIMS • Compared to other real time 
techniques FAIMS is 
inexpensive. 
• High throughput. 
• No vacuum means very 
small lab. footprint. 
• Can be easily interfaced with 
other techniques such as 
GC, ESI, TD, and SPME. 
• Very easy to operate. 
 
• Data processing can be difficult 
and is not standardised. 
• Reproducibility and calibration 
across instruments are difficult. 
• Ions can be separated differently 
across different instruments 
which makes method validation 
and centralised data processing 
challenging. 
• Prone to contamination from high 
concentration of compounds, 
• Humidity and contamination from 
the purge air are also common. 
• Difficult to interpret instrument 
performance from non-
experienced users. 
• Does not provide quantitative 
outputs. 
Table 1.3 advantages and limitations of the real time MS techniques discussed in chapter 1 section 3. 
1.4.0 Overview  
Sections 1.2 and 1.3 gives multiple examples of a number of applications for MS 
techniques in the biomedical sector.  
While the chromatography based non real-time techniques require more sample 
preparation and in general by their nature take longer per sample analysis time; the 
metabolic insights they are capable of delivering with their qualitative data makes the 
cost to benefit worthwhile. Moreover, these techniques do require a reasonable skill 
level to operate and maintain. However, the qualitative data and the identification of 
VCs is crucial to understanding the metabolic changes that take place during disease 
states and thus understanding how VCs can be used in the clinical forum. The quality 
of data that can be collected from these instruments makes the shortcomings 
worthwhile.   
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Real-time techniques are in general simple to operate and can be done by semi-skilled 
operators. While non-real time techniques can also be easy to operate, they do require 
significantly more method development which does require expertise. The analysis 
time per sample of real-time techniques is very short (usually 2-3 minutes), which 
makes these techniques ideal for high throughput clinical laboratories. There is also 
the option to bring the patient to the instrument for breath analysis. However, the data 
collected from real-time techniques requires the use of algorithms or pattern 
recognition methods for differentiation. Moreover, in order to obtain quantitative data 
from the SIFT-MS target compounds must be identified. In the clinical setting this will 
require rigorous biomarker identification and validation. 
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Chapter 2: Assessment of a combined gas 
chromatography mass spectrometer sensor (GC-MSS) 
system for detecting biologically relevant volatile 
compounds (VCs). 
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2.1.0 Introduction 
There is increasing interest in the design and fabrication of compact volatile 
compounds (VCs) sensor systems for disease diagnosis. Electronic nose (E-nose) 
systems based on: conducting polymers [116], cantilevers [117,118], ceramic sensors 
[119], colorimetric arrays [120],  and GC-sensor systems [121–125] for volatile 
detection with potential applications in disease diagnoses have, for instance, been 
reported. GC-sensor systems, using metal oxide semiconductor (MOS) sensors, have 
shown promise for detecting gastrointestinal and urinary tract diseases [126–129]. 
MOS sensors are low cost and easy to manufacture while maintaining high sensitivity 
and stability. 
MOS gas sensor technology has been extensively investigated in the past few 
decades in research ranging from food odour sensing [130–133] to explosives 
detection [134] and waste management odour analysis [135]. Much of this research 
utilises ‘E-nose’ technology which uses an array of sensors combined with pattern 
recognition systems [130,131,133]. 
The idea of combining MOS sensors with a gas chromatography (GC) column to 
separate mixtures of compounds and record the analyte responses was first 
investigated in 1962 [123]. This makes compound identification easier once retention 
times (RT) (for a particular system) are known, and allows for analysis of more 
complex mixtures of gases, when compared to a sensor array alone. The development 
of MOS sensors has seen intensive research over several decades, whilst the 
combined MOS sensor-GC systems has received relatively little attention. Povarov 
and Lopatnikov, 2016 estimate only 20 papers on the subject were published between 
1960 and 2010 [124]. Current research has been focused on the development of 
miniaturized portable devices, frequently using micro-machined GC columns for 
separation prior to MOS sensor detection. Systems of this type have been used for a 
range of applications including detection of lung cancer associated volatiles [125], 
ethylene and low molecular weight. hydrocarbons [136], aromatic volatiles [137], 
hydrogen fluoride vapours [138], benzene, toluene and xylene [139] and hydrogen, 
methane and carbon monoxide [140]. Such devices could provide quick, easy, on-site 
analysis potentially in the hands of unskilled operators. Systematic studies have been 
carried out on quantifying the relationship between sensor response and factors such 
as type of volatile compound, metal oxide additives and surface structure [141,142]. 
Numerous studies comparing detector types have been reported, for example Mildner-
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Szkudlarz and Jelen, 2008 who compared a solid phase micro extraction (SPME)-fast 
GC-FID with an MOS e-nose array, and SPME direct to MS [143]; despite this there 
are no cases we could find in which the MOS sensor is integrated into the same system 
as a common detector type (e.g. MS or FID). A small number of publications have also 
reported the limit of detection (LOD) of MOS sensor-GC systems, [144] for five 
alcohols, acetaldehyde, acetone and ethyl acetate, which reports detection limits of 
several ppb and [145] for hydrogen fluoride, with detection limits of 800 ppb.  
This investigation will assess the sensing abilities of a MOS sensor comprising a 
binary mixture of ZnO and SnO2 when used as a secondary detector for a Clarus 500 
GC-MS (the combination of this MOS sensor with GC has previously been 
demonstrated as highly sensitive and effective [83,126,129]. This combined GC-MS 
MOS sensor system is referred to as gas chromatography mass spectrometer sensor 
(GC-MSS) system. A broad and diverse range of volatile organic compounds (VOCs) 
were measured, and their limits of detection determined using standards. Volatiles 
from the headspace of stool and bacteria in broth have also been analysed. 
2.2.0 Methods 
2.2.1 Sensor preparation and sensor chamber  
The details of the sensor substrate design and manufacture and the coating procedure 
are described in detail by Vaughan et al., 2013 [146]. In short, a 3 mm alumina 
substrate was screen printed with gold interdigitated electrodes (four pairs of 
interpenetrating bars, electrode gap 100 µm) on one side and with a platinum heater 
track on the reverse. This was wire bonded to a TO39 transistor can. The sensor 
substrate was coated with a metal oxide paste comprising 50% zinc oxide nanopowder 
<100 nm (Sigma Aldrich), and 50% tin oxide (IV) nanopowder <100 nm (Sigma 
Aldrich) (by weight) using the doctor blade technique detailed in [146–148].  
An aluminium chamber (volume 5 cm3) was used to house the sensor with a PTFE 
mount to hold the sensor in place (see Figure 2.4). The GC column (see GCMS and 
sensor set up section for details) enters the sensor chamber directly opposite the 
sensor and is positioned circa 5mm from the sensor surface (Figure 2.4). A purge gas 
(100% synthetic air 287478-L-C from BOC Ltd) with a constant flow rate of 180 mL/min 
was used for all the experiments described herein. The sensor operating temperature 
was 450oC; with a column flow of 3.1 mL/min at 40oC dropping to 1.6 mL/min at 240oC. 
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Figure 2.10 the aluminium sensor chamber with bespoke sensor mounted on PTFE interfaced with 
the GC column; purge gas (synthetic air) flows through the chamber at 180 mL/min.  
2.2.2 GC-MS and sensor setup 
A Clarus 500 GC-MS (Perkin Elmer) with single quadrupole detector was used for all 
samples with the GC output split by S-Swafer technology (Perkin-Elmer) 50% going 
to the MS and 50% to the MOS sensor. The GC method was as follows: 40oC initial 
oven temperature, held for 2 minutes followed by a temperature ramp of 10oC/minute 
up to 240oC and hold at 240oC for 8 minutes. A Zebron ZB-624 column, 60 m length, 
I.D: 0.52 mm, film thickness: 1.40 m, helium carrier gas at 22.8 psi, 31.5 cm/s. 
 
2.2.3 Standard solutions 
The 29 organic compound standards used in this investigation were divided into four 
solutions (detailed in the supplementary materials along with solubility for each 
compound) to avoid co-elution and significant in-solution reactions. Stock solutions in 
deionised water were made for each of these groups at a concentration of 10 g/L, 1 
g/L, and 0.1 g/L according to the solubility of the compounds in the solution. From 
these original stock solutions serial 10-fold dilutions were made and each one 
analysed within 8 hours of preparation.  
GC column in 
Synthetic air purge gas 
in 180 mL/min 
Synthetic air purge 
gas out 
PTFE sensor mount 
Metal oxide coated 
sensor 
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All chemicals used for this phase of testing are shown in Table 2.4 with grade and 
supplier. Compound groups were as follows: 
Solution 1: Starting stock 10 g/L 
Compound Solubility in water 
 Methanol Miscible 
Ethanol Miscible 
Propanol Miscible 
Butanol 73 g/L (25oC) 
Acetone Miscible 
Phenol 83 g/L (25oC) 
Solution 2: Starting stock 1 g/L 
Compound Solubility in water 
Acetaldehyde Miscible 
Propanal 540 g/L (20oC) 
Ethyl methanoate 88.2 g/L (25oC) 
Butanal 76 g/L (20oC) 
2-Butanone 290 g/L (20oC) 
Ethyl propanoate 25 g/L (15oC) 
Ethyl butanoate 4.9 g/L (20oC) 
Butyl propanoate 1.5 g/L (20oC) 
 
Solution 3: Starting stock 0.1 g/L 
Compound Solubility in water 
Furan 10g/L (25oC) 
2,3-Butadione 200 g/L (20oC) 
Dimethyl disulphide 2.5 g/L (20oC) 
Pyrrole 45 g/L (25oC) 
Benzaldehyde 6.95 g/L (25oC) 
Benzyl alcohol 42.9 g/L (25oC) 
p-Cresol 21.5 g/L (25oC) 
2-Nitrotoluene 0.44 g/L (20oC) 
Methyl salicylate 0.7 g/L (30oC) 
Indole 3.56 g/L (25oC) 
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Solution 4: Starting stock 10 g/L 
Compound Solubility in water 
Ethanoic acid Miscible 
Propanoic acid Miscible 
Butanoic acid  Miscible 
Pentanoic acid 24 g/L (25oC) 
Hexanoic acid 11 g/L (20oC) 
 
In order to make the dilutions 10 mL of the stock solution (for example 10 g/L) was 
added to a 100 mL volumetric flask and then topped to the fill line with deionized water, 
to give a 10 fold dilution in this example 1 g/L. For the next dilution 10 mL of the 1 g/L 
was added to a 100 mL volumetric flask and this was also topped up to the fill line with 
deionized water. This process was repeated as many times as required by the testing.  
Solution 1 concentrations analysed were: 10 g/L, 1 g/L, 0.1 g/L, 0.01 g/L, 0.001 g/L, 
0.0001 g/L, 0.00001 g/L, 0.000001 g/L. 
Solution 2 concentrations analysed were: 1 g/L, 0.1 g/L, 0.01 g/L, 0.001 g/L, 0.0001 
g/L, 0.00001 g/L, 0.000001 g/L, 0.0000001 g/L 
Solution 3 concentrations analysed were: 0.1 g/L, 0.01 g/L, 0.001 g/L, 0.0001 g/L, 
0.00001 g/L, 0.000001 g/L, 0.0000001 g/L 
Solution 4 concentrations analysed were: 10 g/L, 1 g/L, 0.1 g/L, 0.01 g/L. 
For sampling, 3 mL of a solution was removed to a headspace vial (PTFE/ silicone 
septa 10 mL Supelco, Sigma Aldrich), and the headspace was sampled with a 
polydimethylsiloxane/carboxen PDMS-CAR solid phase micro-extraction (SPME) 
portable field sampling fibre (Supelco, Sigma Aldrich Company Ltd.) for two minutes 
at ambient temp (21-25oC) without stirring. The fibre was then inserted into the GC-
MS port at 220oC constant temperature and left for the first three minutes of each run 
to fully desorb the analyte. 
Each mixture of organic compounds was run from most dilute to most concentrated to 
avoid carry over from the SPME fibre and/or column between samples. Where 
necessary blank runs were also used to further mitigate this issue. The above method 
was repeated three times for each of the four groups of organic compounds. This 
phase of experimentation took place over a four month period with the response of 
both the mass spectral analyser and sensor being tested with a control standard 
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solution (1% w/v solution of ethanol, methanol, propanol, butanol, and acetone) to 
ensure consistent performance of both detectors.  
 
CAS-number Compound Grade Supplier 
75-07-0 Acetaldehyde 99.5% Sigma-Aldrich 
67-64-1 Acetone 99.9% Fisher Scientific 
100-52-7 Benzaldehyde >99% Sigma-Aldrich 
100-51-6 Benzyl alcohol >99% Sigma-Aldrich 
123-72-8 Butanal 99.8% Sigma-Aldrich 
431-03-8 2,3-Butadione >99% Sigma-Aldrich 
71-36-3 Butanol >99% Sigma-Aldrich 
78-93-3 2-Butanone >99% Acros organics 
590-01-2 Butyl propanoate >99% Acros organics 
107-92-6 Butanoic acid >99% Sigma-Aldrich 
624-92-0 Dimethyl disulphide >99% Sigma-Aldrich 
64-19-7 Ethanoic acid 99.5% Sigma-Aldrich 
64-17-5 Ethanol 100% VWR chemicals 
105-54-4 Ethyl butanoate 99% Sigma-Aldrich 
141-78-6 Ethyl methanoate >97% Sigma-Aldrich 
105-37-3 Ethyl propanoate >99% Acros organics 
110-00-9 Furan >99% Sigma-Aldrich 
142-62-1 Hexanoic acid 99.5% Sigma-Aldrich 
120-72-9 Indole >99% Sigma-Aldrich 
67-56-1 Methanol >99.9% Sigma-Aldrich 
119-36-8 Methyl salicylate >99% Sigma-Aldrich 
88-72-2 2-Nitrotoluene >99% Sigma-Aldrich 
106-44-5 p-Cresol >99% Sigma-Aldrich 
109-52-4 Pentanoic (valeric) acid >99% Acros organics 
108-95-2 Phenol >99% Sigma-Aldrich 
123-38-6 Propanal >99% Acros organics 
79-09-4 Propanoic acid >99.5% Sigma-Aldrich 
71-23-8 Propanol >99.5% BDH chemicals 
109-97-7 Pyrrole >99% Acros organics 
Table 2.4 the grade and suppliers of compounds used to make the 29 stock standard solutions. 
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2.2.4 Stool samples 
Stool samples from healthy volunteers of diverse ethnic origins, gender and a mix of 
omnivore and vegetarian diets were collected (NHS Newcastle and North Tyneside 
research ethics committee reference 14/NE/0029). Three g were aliquoted into 20 mL 
headspace vials and stored in a freezer at -20oC. For sampling the vials were defrosted 
in a water bath set to 60oC for 30 minutes the SPME fibre was then added for 30 
minutes while the vial was maintained at 60oC.. 
2.2.5 Bacterial culture headspace analysis 
Two colonies of E. coli were picked from an overnight culture on an agar plate (Oxoid 
CM0003) and used to inoculate 5 mL of nutrient broth (Oxoid CM0067) in a sterile 
glass universal bottle. The broths were incubated overnight at 37oC. Absorbance was 
measured and colony forming units / mL (CFU/mL) was estimated using the Agilent 
online calculator (Agilent Genomics). Overnight cultures were diluted as appropriate 
to give between 105 CFU/mL and 106 CFU/mL in four glass headspace vials with 5 mL 
nutrient broth (Oxoid CM0067). One was frozen at -20oC immediately with the others 
undergoing 2, 4- and 24-hours further incubation respectively before freezing. One mL 
of each sample was extracted prior to freezing for final absorbance measurements.  
Prior to analysis vials were defrosted in a water bath set to 60oC for 30 minutes before 
the SPME fibre (as used for both the stool and standards) was inserted for 30 minutes 
sample adsorption time, as for the stool samples the vial was maintained at 60oC for 
the duration of the sampling.  
2.2.6 Analysis 
The same signal threshold of three times the noise was used for both the GC-MS 
chromatograms and the resistance trace from the sensor. The NIST library (version 
2.2, 2014) was used for peak identification. Due to the unreliable nature of siloxane 
and terpene identification these were recorded by family (siloxane or terpene 
respectively). All responses were searched manually and in order to be classed as 
NIST matched response, a minimum threshold of 800 match and reverse match was 
used, in cases where the threshold was not achieved the peak was characterised as 
unknown; similarly cases in which a peak appeared on the sensor trace that was not 
visible on the total ion chromatogram the peak noted as unidentified mass 
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spectrometer (unidentified MS), similarly responses on the sensor system that could 
not be NIST matched by the mass spectral analyser were noted as unidentified sensor 
system (unidentified SS). The standard solutions were considered undetectable when 
sufficiently diluted such that the signal threshold was no longer met. 
To analyse the sensor data the change in resistance from the base of the peak to the 
top of the peak was calculated for each response. Since the sensor output forms one 
continuous trace containing multiple GC-MS runs a marker was set as each GC-MS 
injection took place; this marker could then be used a T=0 minutes point to synchronise 
the chromatogram and sensor responses. 
In order to mimic the process of analysing an unknown gas mixture LOD optimisation 
techniques such as searching the chromatogram for individual product masses and/or 
running a single ion monitoring (SIM) MS method was not undertaken. Similarly, 
analysis of the MOS sensor trace as a function of Δ resistance/Δ time (ΔR/ΔT) was 
not used for data analysis; as this allows the data to be viewed as a function of the 
slope. ΔR/ΔT is a display function only and does not enhance the detection capabilities 
of the sensor. However, ΔR/ΔT allows changes in the gradient of a response recovery 
to become apparent; these changes in gradient can be small responses that would 
otherwise go unnoticed.  
  
2.3.0 Results and discussion 
2.3.1 Results of the analysis of standard solutions 
The 450oC sensor operating temperature was derived experimentally. At 450oC the 
water to ethanol response ratio was four times greater than when operated at 350oC 
which gave a response ratio of close to one. 
Of the 29 chemical standards investigated, 25 have been found on the breath of 
healthy humans, and three others have been found as volatiles emitted from the 
human body from other sources such as faeces, urine, and saliva [149]. Figure 2.11 
shows the full comparison of mode average LODs for all 29 VOCs, Figure 2.12 shows 
the data for each repeat. The MOS sensor showed greater LOD for 17 compounds 
including significantly improved sensitivity for butanol, 2-butanone and indole. The 
mass spectrometer only showed increased sensitivity for two compounds, methanol 
and butanal. The mass spectrometer and the MOS sensor exhibited the same 
sensitivity for the remaining nine compounds. The MOS sensor comprised two metal 
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oxides, tin oxide and zinc oxide both of which on their own are well known to be 
capable of sensing a wide range of VOCs. Previous work shows there are advantages 
in using a mixed system for enhanced detection of a range of VOCs [147,148].  
Table 2.5 shows indicative headspace concentration values based on Henry’s law 
constants; to give some indication as to the range of concentrations being detected 
above the solutions. Both the mass spectral analyser and MOS sensor show a wide 
dynamic range from low part per billion to part per million. Calculating an accurate 
headspace concentration is problematic as the headspace is pre-concentrated onto 
an SPME fibre thus the quantity absorbed will be subject to the selectivity of the fibre. 
Moreover, in a complex solution such as those analysed it is possible that Henry’s law 
will not be fully applicable due to inter compound interactions, although the solutions 
are extremely dilute. It should also be noted that as the solutions being used have 
factor of ten difference, the actual LOD would likely be at a value between the two 
solutions.  
 
CAS-number Compound 
Vapour 
concentration 
(ppb)  
Solution 
concentration (g/L)                         
75-07-0 Acetaldehyde 16215 1.00x10-02 
67-64-1 Acetone 57 1.00x10-04 
100-52-7 Benzaldehyde 242 1.00x10-03 
100-51-6 Benzyl alcohol 1027 1.00x1000 
123-72-8 Butanal 159 1.00x10-04 
431-03-8 2,3-Butadione 204 1.00x10-03 
71-36-3 Butanol 11 1.00x10-04 
78-93-3 2-Butanone 69 1.00x10-04 
590-01-2 Butyl propanoate 0.01 1.00x10-05 
107-92-6 Butanoic acid 5973 1.00x1000 
624-92-0 Dimethyl disulphide 115 1.00x10-05 
64-19-7 Ethanoic acid 3028 1.00x1000 
64-17-5 Ethanol 109 1.00x10-03 
105-54-4 ethyl butanoate 179 1.00x10
-04 
141-78-6 Ethyl methanoate 329 1.00x10
-04 
105-37-3 Ethyl propanoate 169 1.00x10-04 
110-00-9 Furan 8162 1.00x10-04 
142-62-1 Hexanoic acid 6149 1.00x1000 
120-72-9 Indole 1187 1.00x10-01 
67-56-1 Methanol 1419 1.00x10-02 
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CAS-number Compound 
Vapour 
concentration 
(ppb)  
Solution 
concentration (g/L)                         
119-36-8 Methyl salicylate 59 1.00x10-02 
88-72-2 2-Nitrotoluene 4289 1.00x10
-02 
106-44-5 p-Cresol 711 1.00x10-01 
109-52-4 Pentanoic (valeric) acid 4451 1.00x1000 
108-95-2 Phenol 366 1.00x10-01 
123-38-6 Propanal 1324 1.00x10-03 
79-09-4 Propanoic acid 2177 1.00x1000 
71-23-8 Propanol 119 1.00x10-03 
109-97-7 Pyrrole 230 1.00x10-03 
Table 2.5 our concentrations in ppb for corresponding solution concentration to give indicative values 
for limits of detection; all concentrations calculated using Henry’s law constants taken from Sander, 
Rolf. "Compilation of Henry's law constants (version 4.0) for water as solvent." Atmospheric Chemistry 
& Physics 15, no. 8 (2015). 
While the sensor showed high sensitivity to a wide range of analytes it unexpectedly 
elicited zero responses to siloxanes. Siloxanes were observed in many of the GC-MS 
chromatograms in this work these are a common GC contaminant often coming from 
the injection septum, sample vial septum, SPME fibre, column bleed or indeed the 
sample itself, as they are widely used in biomedical and cosmetic applications [150]. 
Siloxanes are relatively large, stable molecules yet they are volatile. While they are 
readily ionised in the mass spectral analyser the literature shows no instances where 
they are oxidised/ catalytically broken down, by metal oxides. Any reaction that may 
occur at the sensor surface is too slight to produce a sensor response. For analysis of 
biologically derived VOCs this is an advantage, as unwanted contaminant responses 
would reduce the ability of the sensor to recover and may obscure analyte responses. 
Additionally, if applying these resistance traces to algorithms in order to differentiate 
them into clinically relevant groups, siloxanes will interject false information into the 
equation. The lack of sensitivity of the MOS sensor to column bleed compounds such 
as the siloxanes means that at higher retention times the sensor has a more stable 
baseline and thus the potential to detect lower levels of "target" compounds in this 
region e.g. 3-methyl indole.  
A mean RT delay of six seconds across the chromatogram was observed between the 
mass spectrometer and MOS sensor with a standard deviation ±2 seconds; these RT 
differences are constant across the duration of the sample time. Using butanol as an 
example the highest concentration (10 g/L) RT for the MS was 14.10 and the lowest 
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concentration (0.0001 g/L) was 14.06. The sensor recorded RTs of 14.14 and 14.15 
respectively. These RT drifts are typical across the whole range of tested standards 
for both the MS and sensor. 
After responding to a VOC, the sensor tends to return to its previous oxygen surface 
state equilibrium and the resistance can take time to recover to the previous baseline 
value. During this recovery, which is enhanced by the purge gas, another compound 
can cause a sensor response which means that the size of the response is often very 
different between the MS and MOS. The helium carrier gas of the GC-MS can have a 
detrimental effect on sensor response over time as the oxygen species are depleted; 
this effect is countered by using air as a purge gas which allows the oxygen to be 
continuously replenished. In cases of very large responses the recovery can be 
sufficiently slow that the next compound appears only as a change of gradient and not 
a peak response; in these cases, viewing the resistance as ΔR/ΔT can help the 
resolution of responses from closely eluting compounds. In instances of the true co-
elution of two or more compounds this function would have limited utility as there is no 
change in the slope visible. A mass spectral analyser might be able to separate 
compounds based on product ions within the total ion chromatogram although this is 
not always the case. In contrast to the sensor, the mass spectral analyser will produce 
a response as long as the product ions are being detected and will cease when the 
ions are no longer detected thus the recovery time is typically shorter meaning the MS 
has superior peak resolution.  
An important point to reiterate is that the mass spectrometer was not run optimally in 
terms of maximum sensitivity (e.g. not SIM mode) but it was run using the same 
parameters as would be applied for the analysis of an unknown sample for example.  
The metal oxide sensor could also be run using parameters which increased 
sensitivity (column positioned closer to sensor) but which resulted in a loss of peak 
resolution (recovery time increased). Therefore, the sensor was optimised by altering 
the column position and carrier gas, purge gas flow rates to produce maximum 
sensitivity but appropriate separation/resolution for the compounds of interest. The 
directionality of the carrier gas stream exiting the column and its close proximity to the 
sensor ensures efficient transit of the analytes to the surface and minimal dilution by 
the purge gas. Thus, the purge gas flow rate was selected based upon providing a 
balance between maximal recovery between responses without sacrificing sensitivity. 
Low purge gas flow increased the level of noise which was disadvantageous when 
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analysing complex samples. The chamber flushing rate was also selected so that a 
high concentration of analyte presented at the exhaust and around the seals of the 
sensor chamber gave no sensor response. This was an important consideration to 
ensure the sensor baseline was not altered by environmental volatiles.  
The chamber was originally made from aluminium as it was easy to manufacture 
various iterations of the chamber design. We attempted to minimise all plastic within 
the chamber which might outgas additional compounds or adsorb compounds. On 
testing the current chamber with the standards, we did not get baseline issues with the 
sensor indicating that outgassing compounds were minimised. The directional 
transport of analytes to the sensor surface and efficient removal via the purge gas 
meant that we did not have issues with carryover or contamination. If issues had been 
identified then we may have considered other sensor chamber materials, or inert 
surface treatment of the current chamber. In terms of chamber size, it is possible that 
different designs or a smaller size may further optimise performance. We intend to 
continue to develop the current system which has gone through a number of iterations 
to reach its current state of development.  
Over the four-month testing period a slight change of ≤ 5% in the sensitivity per month 
was observed. During the test period, slight increases in sensitivity were observed for 
some compounds (butanol, propanol, acetone) and others slightly decreased (ethanol, 
methanol). Overall the sensor system gave good stability in terms of response to 
standard analytes at a known and relevant concentration. Baseline stability was also 
high with no significant drop during the testing period.  
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Figure 2.11 the limit of detection concentration of standard chemicals in deionised water, comparing a single quadrupole mass spectrometer with the mixed metal oxide 
(SnO2 and ZnO) sensor, plotted on a log scale using the mode average. 
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Figure 2.12 comparison of the detection limits for all the compounds used in standard solutions for the MS and sensor, plotted on a log scale for all repeats
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2.3.2 Stool Samples 
Across the 12 stool samples 84 compounds were detected, those which have a 
corresponding chemical standard from the standard solution experiments are shown 
in Table 2.6 along with the retention times. The remaining NIST matched compounds 
are shown in Table 2.7. On at least one occasion across the sample set each 
compound had a sensor response with a matching RT. Table 2.8 shows which 
compounds were detected in which sample and if they were detected by the mass 
spectral analyser, the MOS sensor or both. Very few of the terpenes seen could 
accurately be NIST matched thus they were denoted simply as terpenes however they 
were still included as NIST matched responses provided they met the thresholds 
described in the method. Siloxanes are known common contaminants and so were not 
included as NIST matched compounds.  
CAS- 
number 
Compound 
MS RT 
(mins) 
Sensor RT 
(mins) 
Chemical standard 
RT MS (mins) 
Chemical standard 
RT Sensor (mins) 
75-07-0 Acetaldehyde 8.93 8.98 8.94 9.08 
64-17-5 Ethanol 10.13 10.20 10.19 10.33 
67-64-1 Acetone 10.71 10.82 10.74 10.88 
71-23-8 Propanol 12.00 12.07 12.03 12.16 
123-72-8 Butanal 12.48 12.53 12.51 12.61 
431-03-8 2,3-Butadione 12.65 12.71 12.44 12.68 
78-93-3 2-Butanone 12.66 12.70 12.68 12.77 
64-19-7 Ethanoic acid 13.35 13.33 13.37 13.42 
71-36-3 Butanol 14.00 14.05 14.07 14.15 
105-37-3 Ethyl propanoate 14.42 14.45 14.43 14.54 
79-09-4 Propanoic acid 15.09 15.12 15.12 15.20 
624-92-0 Dimethyl disulphide 15.56 15.59 15.56 15.73 
105-54-4 Ethyl butanoate 16.09 16.14 16.10 16.19 
107-92-6 Butanoic acid 16.73 16.80 16.72 16.82 
590-01-2 Butyl propanoate 18.01 18.20 18.05 18.12 
109-52-4 Pentanoic acid 18.35 18.40 18.40 18.47 
108-95-2 Phenol 20.84 20.88 20.98 20.99 
106-44-5 p-Cresol 22.22 22.28 22.21 22.39 
120-72-9 Indole 26.92 27.04 26.90 27.17 
Table 2.6 the list of the compounds detected from the headspace of stool from healthy participants 
that have been matched to the standards used to assess the LOD of the mass analyser verses the 
MOS.
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CAS- 
number 
Compound MS RT 
(mins) 
Sensor 
RT (mins) 
    
74-93-1 Methanethiol 9.21 9.33 
75-18-3 Dimethyl sulphide 10.86 10.9 
79-20-9 Methyl ethanoate 11.07 11.14 
78-84-2 2-Methylpropanal 11.79 11.85 
141-78-6 Ethyl ethanoate 12.47 12.50 
554-12-1 Methyl propanoate 12.95 12.92 
78-83-1 2-Methyl-1-propanol 13.32 13.39 
7803-49-8 Hydroxylamine 13.37 13.42 
590-86-3 3-Methylbutanal 13.73 13.75 
96-17-3 2-Methylbutanal 13.89 13.90 
547-63-7 Methyl isobutyrate 13.95 13.94 
107-87-9 2-Pentanone 14.42 14.47 
563-80-4 3-Methyl 2-butanone 14.42 14.55 
24653-75-
6 
Mercaptoacetone 14.51 14.53 
109-60-4 Propyl ethanoate 14.52 14.55 
110-62-3 Pentanal 14.55 14.51 
623-42-7 Methyl butanoate 14.70 14.74 
97-62-1 Ethyl-2-methylpropanoate 15.29 15.45 
17220-38-
1 
Furazandiamine 15.40 15.39 
137-32-6 2-Methyl-1-butanol 15.42 15.45 
868-57-5 Methyl-2-methylbutanoate 15.71 15.99 
71-41-0 1-Pentanol 15.95 16.00 
106-36-5 Propyl propanoate 16.25 16.29 
591-78-6 2-Hexanone 16.36 16.37 
24552-04-
3 
3-Octanamine 16.36 N/D 
123-86-4 Butyl ethanoate 16.37 16.40 
66-25-1 Hexanal 16.49 16.52 
624-24-8 Methyl pentanoate 16.58 16.60 
540-42-1 2-Methylpropyl propanoate 16.78 16.98 
108-64-5 Ethyl 3-Methylbutanoate 17.05 17.07 
644-49-5 Propyl 2-methylpropanoate 17.08 17.05 
111-84-2 Nonane 17.42 N/D 
503-74-2 3-Methylbutanoic acid 17.66 17.70 
111-27-3 1-Hexanol 17.77 17.80 
116-53-0 2-Methylbutanoic acid 17.80 17.85 
105-66-8 Propyl butanoate 17.86 17.87 
110-43-0 2-Heptanone 18.16 18.18 
57-06-7 Allyl isothiocyanate 18.35 18.40 
106-70-7 Methyl hexanoate 18.35 18.39 
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CAS- 
number 
Compound MS RT 
(mins) 
Sensor 
RT (mins) 
79-31-2 2-methylpropanoic acid 18.37 18.46 
 
Terpene (1) 18.62 18.62 
557-00-6 Propyl 3-methylbutanoate 18.73 18.83 
539-90-2 2-Methylpropyl butanoate 18.83 18.83 
23747-45-
7 
S-Methyl 3-methylbutanethioate 18.92 18.96 
2179-60-4 Methyl propyl disulphide 19.00 19.03 
928-68-7 6-methyl-2-heptanone 19.28 19.27 
 
Terpene (2) 19.36 19.39 
109-21-7 Butyl butanoate 19.49 19.55 
2137-56-0 Pentyl pentanoate 19.51 19.55 
110-93-0 6-methyl 5-hepten-2-one 19.79 19.83 
 
Terpene (3) 19.93 19.89 
3658-80-8 Dimethyl trisulphide 20.02 20.04 
138-86-3 Limonene 20.21 20.24 
7341-17-5 2-ethyl-1-hexanethiol 20.48 20.52 
470-82-6 Eucalyptol 20.51 20.53 
22104-69-
4 
Methyl 2-heptenoate 21.07 21.13 
 
Terpene (4) 21.40 21.42 
3289-28-9 Ethyl cyclohexanecarboxylate 22.12 22.17 
98-89-5 Cyclohexanecarboxylic acid 22.60 22.70 
108-93-0 Cyclohexanol 23.18 23.24 
 
Terpene (5) 25.34 25.44 
 
Terpene (6) 26.33 26.37 
 
Terpene (7) 27.77 27.80 
 
Terpene (8) 28.60 28.63 
83-34-1 3-Methylindole 28.87 28.97 
Table 2.7 the list of NIST matched compounds detected in the headspace of 12 stool samples from 
healthy participants with MS and sensor RT.
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
CAS- number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
75-07-0 Acetaldehyde * * * * * * * * * * * * * * * * * * * * 
  
* * 
67-64-1 Acetone * 
 
* * * * * * * * * 
 
* 
 
* 
 
* * * * * * * * 
57-06-7 Allyl isothiocyanate 
          
* * 
      
* 
     
123-72-8 Butanal * * * * * * 
  
* * 
    
* * * * 
      
431-03-8 2,3-Butadione 
      
* * 
  
* * 
            
107-92-6 Butanoic acid * * * * * * * * * * * * 
  
* * * * * * * * * * 
71-36-3 Butanol * * * * * * * * * * * * * * * * 
    
* * * * 
78-93-3 2-Butanone 
  
* * * * * * * * * * * * 
          
109-21-7 Butyl butanoate * * * * * * * * 
        
* * 
  
* * 
  
123-86-4 Butyl ethanoate * * 
  
* * 
                  
590-01-2 Butyl propanoate * 
 
* * * 
 
* 
           
* 
 
* * * * 
98-89-5 Cyclohexanecarboxylic 
acid 
                  
* * * * 
  
108-93-0 Cyclohexanol 
                  
* * 
  
* * 
624-92-0 Dimethyl disulphide * * * * * * * * * * * * * * * * * * * * * * * * 
75-18-3 Dimethyl sulphide * * * * * * 
  
* 
 
* * * * * * * * 
      
3658-80-8 Dimethyl trisulphide * * * * * * * * * * * * * * * * * * * * * * * * 
64-19-7 Ethanoic acid * * * * * * 
  
* * 
    
* * 
  
* * * * * * 
64-17-5 Ethanol * * * * * * * * * * * * * * * * * * * * * * * * 
105-54-4 Ethyl butanoate * * * * * * * * 
    
* * * * 
  
* * * * * * 
3289-28-9 Ethyl 
cyclohexanecarboxylate 
* * 
               
* * * 
    
141-78-6 Ethyl ethanoate * * 
                
* * * * * * 
7341-17-5 2-Ethyl-1-hexanethiol * 
 
* * * * 
                  
108-64-5 Ethyl 3-methylbutanoate * 
 
* 
 
* * 
      
* * * * * * 
  
* * 
  
97-62-1 Ethyl-2-methylpropanoate * * 
  
* 
               
* 
 
* * 
105-37-3 Ethyl propanoate 
            
* 
     
* * * 
 
* * 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
CAS- number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
470-82-6 Eucalyptol 
      
* * 
                
17220-38-1 Furazandiamine 
                  
* * 
    
110-43-0 2-Heptanone 
  
* * * 
 
* * * * * * 
      
* * 
  
* 
 
66-25-1 Hexanal 
  
* * * * 
  
* * * * * * * * * * * * 
    
111-27-3 1-Hexanol 
    
* * * * 
                
591-78-6 2-Hexanone 
  
* * 
  
* * * * * * * * * * * * 
  
* * 
  
7803-49-8 Hydroxylamine 
  
* * 
              
* * 
    
120-72-9 Indole * * * * * * * * * * * * * * * * * * * * * * * * 
138-86-3 Limonene * * * 
 
* * * * * * 
  
* * * * * * * * * * * * 
24653-75-6 Mercaptoacetone * * * * * * * * 
      
* * 
        
74-93-1 Methanethiol * * * * * * * * * * * * * * * * * * * * 
    
96-17-3 2-Methylbutanal * * * * * * * * * * * * * * * * * * 
    
* * 
590-86-3 3-Methylbutanal * * * * * * * * * * * * * * * * * * * * 
  
* * 
623-42-7 Methyl butanoate * 
 
* * * 
 
* 
     
* 
 
* 
   
* * * * * * 
116-53-0 2-Methylbutanoic acid 
    
* * 
  
* * * * * * * * * * 
      
503-74-2 3-Methylbutanoic acid * * * * 
    
* 
 
* * * * * * * * * * * * * * 
137-32-6 2-methyl-1-butanol 
  
* * * * * * * * * * * * * * * * 
      
563-80-4 3-Methyl 2-butanone * * 
    
* 
       
* 
 
* * 
  
* * 
  
79-20-9 Methyl ethanoate * 
                 
* * * * * 
 
928-68-7 6-methyl-2-heptanone 
                  
* * 
    
22104-69-4 Methyl 2-heptenoate * * * * * * * 
                 
110-93-0 6-methyl 5-hepten-2-one * * * * * * * * * * * * * * * * * * * * * * * * 
106-70-7 Methyl hexanoate * * 
    
* * 
                
83-34-1 3-Methylindole 
  
* * * * * * 
  
* * * * 
  
* * 
      
547-63-7 Methyl isobutyrate 
                  
* * 
    
503-74-2 Methyl isopentanoic acid * 
                   
* 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
CAS- number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
868-57-5 Methyl-2-methylbutanoate 
      
* 
       
* * 
  
* * 
    
624-24-8 Methyl pentanoate * 
   
* 
 
* * 
          
* * * * 
  
554-12-1 Methyl propanoate * 
 
* * * * * * 
      
* * 
    
* * * * 
78-84-2 2-Methylpropanal * * * * * * * * * * * * * * * * * * * * 
    
79-31-2 2-Methylpropanoic acid 
                        
78-83-1 2-Methyl-1-propanol 
      
* * * * * * * * 
  
* * 
      
539-90-2 2-Methylpropyl butanoate * 
 
* 
 
* * 
      
* * 
      
* * 
  
540-42-1 2-Methylpropyl 
propanoate 
  
* * 
                    
2179-60-4 Methyl propyl disulphide 
            
* * 
          
111-84-2 Nonane 
  
* 
                     
24552-04-3 3-Octanamine 
                        
106-44-5 p-Cresol * * * * * * * * * * * * * * * * * * * * 
  
* * 
110-62-3 Pentanal 
            
* * 
          
109-52-4 Pentanoic acid 
  
* * * * 
  
* * 
  
* * * * 
  
* * * * * * 
71-41-0 1-Pentanol * * * * * * * * * * * * * * 
  
* * 
      
107-87-9 2-Pentanone 
  
* * * 
   
* * * 
             
2137-56-0 Pentyl pentanoate 
                  
* * 
  
* * 
108-95-2 Phenol * * * * * * * * 
          
* * * * * * 
79-09-4 Propanoic acid * * * * * * * * * * * * * * * * * * * * * * * * 
71-23-8 Propanol * * * * * * * * * * * * * * * * * 
 
* * * * * * 
105-66-8 Propyl butanoate * * * 
 
* 
 
* * 
    
* * * * * * * * * * * * 
109-60-4 Propyl ethanoate 
          
* * 
      
* * * * * 
 
644-49-5 Propyl 2-
methylpropanoate 
  
* * * * 
            
* * 
    
557-00-6 Propyl 3-methylbutanoate * 
 
* 
 
* 
             
* * * * 
  
106-36-5 Propyl propanoate * 
 
* * * 
   
* * 
  
* 
 
* * 
  
* * * * * * 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
CAS- number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
 
Siloxane (1) * 
 
* 
   
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
     
 
Siloxane (2) * 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
   
* 
 
* 
 
* 
 
* 
 
 
Siloxane (3) * 
       
* 
 
* 
       
* 
   
* 
 
23747-45-7 Methyl 3-
methylbutanethioate 
      
* * 
  
* * 
            
 
Terpene (1) * * * * 
  
* * * * * * * * 
  
* * 
      
 
Terpene (2) * * 
    
* * * * * * 
  
* 
   
* * 
    
 
Terpene (3) * * * * 
  
* * * * * 
     
* 
 
* * 
    
 
Terpene (4) * * * * * * * * 
    
* * 
      
* * 
  
 
Terpene (5) * * * * * * * * * * 
        
* * * * 
  
 
Terpene (6) 
    
* * 
    
* * 
            
 
Terpene (7) * * * * * * * * * * 
      
* * 
      
 
Terpene (8) 
  
* * 
    
* * * * 
    
* * 
  
* * 
  
 
Unknown MS/SS (1) * * * * * * 
  
* * * * * * * * * * * * 
  
* * 
 
Unknown MS/SS (2) * * * * * * * * * * 
    
* * * * * * 
  
* * 
 
Unknown MS/SS (3) * * * * 
     
* 
     
* * * * * 
    
 
Unknown MS/SS (4) * * 
  
* 
           
* * 
  
* * 
  
 
Unknown MS/SS (5) * * * * * * 
         
* 
     
* 
  
 
Unknown MS/SS (6) 
          
* * 
            
 
Unknown MS/SS (7) 
         
* * * 
    
* * 
 
* 
    
 Unknown SS (1)        *  *      *      *  * 
 
Unknown SS (2) 
                     
* 
  
 
Unknown SS (3) 
             
* 
          
 
Unknown SS (4) 
                     
* 
  
 
Unknown SS (5) 
           
* 
 
* 
          
 
Unknown SS (6) 
                     
* 
  
 
Unknown SS (7) 
                     
* 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 Sample 11 Sample 12 
CAS- number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
 
Unknown SS (8) 
               
* 
        
 
Unknown SS (9) 
                     
* 
  
 
Unknown SS (10) 
                       
* 
 
Unknown SS (11) 
           
* 
 
* 
          
 
Unknown SS (12) 
                     
* 
  
 
Unknown SS (13) 
             
* 
   
* 
  
* * 
 
* 
 
Unknown SS (14) 
  
* * 
   
* 
 
* 
 
* 
 
* 
  
* * 
      
 
Unknown SS (16) 
  
* * 
   
* 
   
* 
 
* 
          
 
Unknown SS (17) 
       
* 
                
 
Unknown SS (18) 
           
* 
            
 Table 2.8 data from individual stool samples including all responses (*) that met the signal to noise threshold criteria from both the mass spectral analyser (MS) and the MOS 
Sensor (SS). 
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Figure 2.13 chart showing the number of times each compound was detected in the headspace of 12 stool samples collected from healthy participants on both the mass 
spectral analyser and the metal oxide sensor, sampled with SPME fibre.  
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Table 2.9 shows the total number of responses detected by both detectors across all 
the samples, as previously mentioned the MOS sensor provides a resistance trace 
and so the identification of compounds causing resistance responses is based on the 
RTs from the mass spectral analyser. There was a mean difference between the 
standards and the sample of 2.5 (±3 seconds) for the mass spectral analyser and 5 
(±2 seconds) for the MOS sensor. Figure 2.14 shows an example of how the 
resistance trace compares to the chromatogram with several compounds marked. It is 
notable that the size of responses do not necessarily correlate across the two 
detectors. Over the course of our experiments the sensor has shown a consistently 
longer RT versus the mass spectral analyser. This could be in part because the sensor 
takes more time to reach the peak value from which we derive the RT. Moreover, 
between repeats of the same sample including standards there will be slight variation 
in the RT. Although we have made efforts to minimise differences there may also be 
slight variation in the column lengths between the swafer, and MS, sensor detectors. 
There may also be differences in temperature profiles across these transfer lines as 
one exits the GC oven. These combined factors could explain both the difference in 
RT and the consistency of the difference between sensor and MS. 
Table 2.9 shows a breakdown of the total number of responses detected on both the 
mass spectral analyser and MOS sensor from all 12 stool samples. Table 2.8 shows 
the raw data for each of the 12 stool samples, the total number of times each 
compound was detected are shown in Figure 2.13; in total 25 more NIST matched 
responses were detected on the mass spectral analyser. In most cases this is due to 
the resistance responses being lost in the recovery of the previous peak. When the 
resistance trace is viewed as a function of R/T  these responses are clearly visible 
on all but four occasions. Across the 12 samples the mass spectral analyser was 
unable to identify via the NIST library 41 responses at the defined threshold; these 
unidentified MS peaks were detected on the MOS sensor. However, the MOS sensor 
detected 43 additional responses across the 12 samples that did not appear three 
times above the noise on the chromatogram or had no peak at the matching RT. The 
mass spectral analyser detected 27 siloxanes across the 12 samples, no responses 
were detected on the MOS sensor at the matching RT. The majority of the unidentified 
responses from the MOS sensor traces appear during the last ten minutes of the 
sample run. Of the 85 detected compounds one (nonane) did not have a 
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corresponding resistance response. Due to the high number of carbons, stability, and 
lack of oxygen species compounds like nonane (and many other alkanes) are difficult 
to catalytically break down. The superior LOD of the sensor will account for many of 
the additional peaks; low concentrations in the samples will mean that the mass 
spectral analyser response will drop to a level indistinguishable from the noise, or 
disappear altogether.  
Several papers have utilized both GC-FID and GC-MOS systems, Mildner-Szkudlarz 
and Jelen, 2008 reported similar capabilities for the detection of olive oil impurities 
[143]. García-González and Aparicio, 2010 conclude that their MOS sensor array is 
very useful in the analysis of food aroma but had not yet reached the same 
performance as that of an FID [122]. FID is also far less expensive than mass 
spectrometry with a cost more in line with that of an E-nose or single MOS sensor 
system. That said the MOS sensor employed in this work would be considerably less 
expensive than an FID. However, an FID system is incapable of providing the 
qualitative data provided by the mass spectral analyser. It is this qualitative data that 
can provide detail about the biochemistry and possible biomarkers when utilised for 
clinical applications. Therefore, we wanted to benchmark our sensor system against 
a gold standard MS technique to investigate the range of compounds detected 
particularly when dealing with unknown samples.     
Table 2.9 also shows the mean number of responses per sample for both the mass 
spectral analyser and the MOS sensor. In general, the performance of both detectors 
is very similar though the MOS sensor exhibits twice as many unidentified responses 
than the MS; this is a benefit of the enhanced sensitivity of the MOS sensor and this 
coupled with the lack of response to siloxanes may have benefits in the correct 
classification of samples into groups (e.g. disease from non-disease). 
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MS 
complete 
set 
MOS 
Sensor 
complete 
set *  
MS mean per 
chromatogram 
MOS Sensor mean 
per 
chromatogram * 
NIST matched responses 488 463 44.5 (±7.9) 42.5 (±8.3) 
Unidentified responses 41 84 3.4 (±1.6) 7.0 (±2) 
Siloxanes 27 0 2.3 (±1.0) 0.0 
Total responses** 529 547 47.9 (±9.5) 49.5 (±10.3) 
Table 2.9 the total number of responses from the mass spectral analyser and MOS sensor detected 
from 12 stool samples from healthy participants; and the mean responses per sample for both the 
mass spectral analyser and MOS sensor. *Sensor response with RT corresponding with a NIST 
matched compound. **Total responses not including siloxanes. 
 
 
 
Figure 2.14 chromatogram of a typical stool sample MOS sensor trace (top) with corresponding 
chromatogram (bottom), time in minutes. (a) Dimethyl sulphide MOS Sensor RT 10.78 MS RT 10.86 
minutes. (b) p-Cresol, MOS Sensor RT 22.23 MS RT 22.22 minutes. (c) Indole MOS Sensor RT 26.95 
MS RT 26.92 minutes. (d) MOS Sensor peak RT 27.81 minutes unidentified by MS. 
2.3.3 Bacterial headspace analysis 
Twenty-nine compounds were NIST matched using the defined analytical parameters 
as set out in the experimental analysis section. This is relatively few compared to the 
(d) 
(a) 
(b) 
(b) 
(a) (c) 
(c) 
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84 NIST matched compounds of the stool samples. Table 2.10 shows those that had 
been matched with a corresponding chemical standard in the standard solution 
experiments, the remaining compounds are shown in Table 2.11. All ten of the 
compounds shown in Table 2.10 have been mentioned previously in the literature; as 
shown in Table 2.12. There are 16 compounds detected in our experiments that were 
not previously reported. However, our method was not developed with a specific focus 
but more as a general method to test the abilities of the system. There was no attempt 
in this study to replicate the methods of the cited work in Table 2.12. Despite this, 
Table 2.10 shows that we are able to detect a number of key compounds, this leads 
us to believe that our system is not only able to detect a wide range of compounds, in 
terms of mass and functional groups, but also that there are multiple applications 
including bacterial VC analysis. Dichloromethane was present in four of the samples 
analysed, this is likely to be a contaminant however is included as a compound as it 
was clearly identifiable and interestingly produced no response from the MOS sensor. 
This is fortuitous as in many instances’ dichloromethane is used as a solvent and can 
produce responses capable of overloading mass spectrometer detectors which often 
requires the use of solvent delays.  
The difference in the MS and MOS sensor responses is shown clearly in Figure 2.15, 
which shows a GC-MS chromatogram and MOS sensor resistance trace (in R/T 
negative only) overlaid on each other. Figure 2.15 illustrates just how well the 
responses correlate and in general larger responses on the chromatogram will result 
in larger responses from the MOS sensor; though this is not always the case, for 
example indole (Figure 2.15).  
The mass spectral analyser standards had a mean difference of 3 seconds ±2 versus 
the bacterial samples. The sensor also had a mean of 3 seconds ±2 seconds 
difference between the standards and bacterial headspace. The mean difference 
between the mass spectral analyser and sensor for the bacterial headspace samples 
was 4.5 seconds ±2; these values are consistent with those calculated from the stool 
samples.   
CAS-
number 
Compound 
MS RT 
(mins) 
MOS 
Sensor RT 
(mins) 
Standard 
solution MS RT 
(mins) 
Standard 
solution sensor 
RT (mins) 
64-17-5 Ethanol 10.20 10.30 10.19 10.33 
67-64-1 Acetone 10.80 10.93 10.74 10.88 
71-23-8 Propanol 12.09 12.17 12.03 12.16 
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CAS-
number 
Compound 
MS RT 
(mins) 
MOS 
Sensor RT 
(mins) 
Standard 
solution MS RT 
(mins) 
Standard 
solution sensor 
RT (mins) 
431-03-8 2,3-Butadione 12.54 12.60 12.44 12.68 
78-93-3 2-Butanone 12.66 12.71 12.68 12.77 
71-36-3 Butanol 14.09 14.17 14.07 14.15 
624-92-0 Dimethyl disulphide 15.64 15.70 15.56 15.73 
100-52-7 Benzaldehyde 20.08 20.10 20.03 20.18 
106-44-5 p-Cresol 22.27 22.35 22.21 22.39 
120-72-9 Indole 26.98 27.07 26.90 27.17 
Table 2.10 the list of compounds detected on the GC-MSS certified with chemical standards from 
standard solution experiments detected from the headspace of 10 E. coli broth samples. 
CAS-
number 
Compound MS RT 
(mins) 
MOS 
Sensor 
RT 
(mins) 
75-09-2 Dichloromethane 11.37 N/D 
110-54-3 Hexane 11.88 11.95 
96-14-0 3-Methylpentane 11.90 12.05 
141-78-6 Ethyl ethanoate 12.69 12.73 
78-83-1 2-Methyl -1-propanol 13.41 13.47 
74-98-6 Propane 13.80 13.85 
590-86-3 3-Methyl -1-butanal 13.82 13.87 
123-51-3 3-Methyl -1-butanol 15.44 15.53 
109.97.7 Pyrrole 16.48 16.52 
 
Terpene 1 17.59 N/D 
123-32-0 2,5-Dimethylpyrazine 18.58 18.63 
 
Terpene 2 18.98 19.05 
109-21-7 Butyl butanoate 19.55 19.58 
110-93-0 6-Methyl-5-hepten-2-one 19.85 19.87 
 
Terpene 3 20.11 20.14 
 
Terpene 4 20.26 20.33 
 
Terpene 5 23.23 23.25 
107-91-5 2-Cyanoacetamide 23.62 23.68 
 
Terpene 6 26.54 26.62 
Table 2.11 the list of NIST matched compounds detected in the headspace of E. coli culture along 
with MS and sensor RT
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Figure 2.15 an example of an overlaid chromatogram from the GC-MS with a MOS sensor resistance 
trace in the ΔR/ΔT view (displaying only negative values).
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Reference Indole Dimethyl disulphide Ethanol Propanol 2,3-Butadione 2-Butanone Acetone Methanol Butanol Benzaldehyde 
Tait, E. et al. (2014) [151]  *          
Siripatrawan, U (2008) [152]  * * *        
Arnold, J.W (1998) [153]  *  * *       
Hettinga, K.A (2008) [154]      * *     
Hossain, K. Bojko, B. Pawliszyn, J (2013) [155]   *         
Storer, M. et al. (2011) [156]  * *     * *   
Allardyce, R. et al. (2006) [157]  * * * *       
Thorn, R. Reynolds, D. Greenman, J (2011) 
[158]  
*  *      *  
Allardyce, R. Hill, A. Murdoch, D (2006) [159]   * *    *    
Concina, I. et al. (2009) [160]    *        
Bunge, M. et al. (2008) [161]  *  *   * * * *  
Maddula, S. et al. (2009) [162]    *        
Zscheppank, C. et al. (2014) [163]  *     *   *  
Umber, B. et al. (2013) [164]   * * *       
Schulz, S. Dickschat, J  (2007) [165]  *          
Chippendale, T. Spanel, P. Smith, D (2011) 
[166]  
 * * *   * *   
Aathithan, S. et al. (2001) [167]    *        
Zhu, J. et al. (2010) [168]  *  *        
Boots, A. et al.  (2014) [169]  *   * *     * 
Yu, K. et al. (2000) [170]  * *        * 
 Table 2.12 compounds NIST matched in the headspace of E. coli from existing literature which were also NIST matched in our analysis (* = match).
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Table 2.13 shows that as with the stool samples the MOS sensor is able to detect 
more responses versus the mass spectral analyser. In this case the sensor detected 
69 additional peaks when compared to the MS. This constitutes a much larger % 
increase (41%) when comparing the two detectors than observed for the stool 
samples. This highlights the enhanced LOD of the sensor for a range of compounds. 
Although it should be noted that the bacterial broth headspace would be expected to 
have lower concentrations of compounds then the headspace of the stool 
 
MS 
complete 
set 
MOS Sensor 
complete set 
*  
MS mean per 
chromatogram 
MOS Sensor 
mean per 
chromatogram * 
NIST matched 
responses 
156 143 15.6 (±3.0) 14.3 (±3.3) 
Unidentified  11 93 1.1 (±0.9) 9.3 (±2.4) 
Siloxanes 57 0 5.7 (±1.7) 0.0 
Total 
responses** 
167 236 16.7 (±3.9) 23.6 (±5.7) 
Table 2.13 comparison of the total number of responses found from 10 E. coli samples grown in 
nutrient broth and the mean number of responses per sample/chromatogram. *Sensor response with 
RT corresponding with a NIST matched compound. **Total responses not including siloxanes 
Table 2.14 shows the breakdown of all responses detected per sample on both the 
mass spectral analyser and the MOS sensor; Figure 2.16 shows how many times each 
compound was detected across the ten samples on both detectors. In many cases the 
unknown responses from the MOS sensor trace do have a very small corresponding 
MS peak that was not above the noise threshold. Moreover, the bacterial samples 
produced lower relative abundances on the chromatogram across the whole 
chromatogram when compared to those from the stool samples. There were six 
compounds in Table 2.10 that were present in both stool and the bacterial headspace 
had a mean 80% smaller chromatographic peak area in bacteria versus stool.  
As with the stool sample analysis, the sensor detects additional responses consistently 
across each sample with a mean of 23.6 (±5.7) from the MOS sensor versus 16.7 
(±3.9) from the mass spectral analyser. The lower relative abundances from the 
bacterial samples are indicative of lower concentrations of compounds; despite this 
the MOS sensor shows clear superiority over the mass spectral analyser in terms of 
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responses detected. This enhanced sensitivity should allow for greater discriminatory 
abilities by detecting more points of differences between samples.   
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 
CAS-number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
67-64-1 Acetone * * * * * * * * * * * * * * * * * * * * 
100-52-7 Benzaldehyde 
    
* * * * * * 
    
* * * * * * 
431-03-8 2,3-Butadione 
        
* * * * * * * * * * 
  
71-36-3 Butanol 
  
* * * * * * * * * * * * 
  
* * * * 
78-93-3 2-Butanone * * * * * * * * * * * * * * * * * * 
  
109-21-7 Butyl butanoate 
        
* * * * * * * * * * * * 
107-91-5 2-Cyanoacetamide 
        
* * 
          
75-09-2 Dichloromethane 
  
* 
 
* 
 
* 
 
* 
         
* 
 
123-32-0 2,5-Dimethylpyrazine 
    
* * * * * * 
          
624-92-0 Dimethyl disulphide * * * * * * * * * * * * * * * * * * * * 
64-17-5 Ethanol * * * * * * * * * * * * * * * * * * * * 
141-78-6 Ethyl ethanoate 
                  
* * 
110-54-3 Hexane 
                  
* * 
120-72-9 Indole 
    
* * * * * * * * * * * 
 
* * * * 
590-86-3 3-Methyl -1-butanal 
    
* * 
  
* * * * * * * * * * * * 
123-51-3 3-Methyl -1-butanol * * * * * * * * * * * * * * 
  
* * * * 
110-93-0 6-Methyl-5-hepten-2-one 
        
* * 
  
* * * * * * 
  
96-14-0 3-Methylpentane * * * * * * * * 
            
78-83-1 2-Methyl -1-propanol 
  
* * * * 
    
* * * * * * * * 
  
106-44-5 p-Cresol 
        
* * * * * * * * * * 
  
74-98-6 Propane 
  
* * 
                
71-23-8 Propanol * * * * * * * * * * * * * * * * * * * * 
109.97.7 Pyrrole 
          
* * * * * * * * 
  
 
Siloxane (1) 
            
* 
 
* 
 
* 
   
 
Siloxane (2) 
            
* 
   
* 
   
 
Siloxane (3) * 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
   
 
Siloxane (4) * 
 
* 
   
* 
 
* 
 
* 
 
* 
   
* 
   
 
Siloxane (5) * 
 
* 
 
* 
 
* 
   
* 
 
* 
 
* 
 
* 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 
CAS-number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
 
Siloxane (6) 
    
* 
 
* 
             
 
Siloxane (7) 
      
* 
   
* 
         
 
Siloxane (8) 
                
* 
   
 
Siloxane (9) * 
 
* 
 
* 
 
* 
     
* 
 
* 
 
* 
 
* 
 
 
Siloxane (10) * 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
 
Terpene (1) 
          
* * 
    
* * 
  
 
Terpene (2) 
        
* * * * * * * * * * 
  
 
Terpene (3) 
            
* * 
      
 
Terpene (4) 
            
* * 
      
 
Terpene (5) 
            
* 
       
 
Terpene (6) 
            
* * * * * * * * 
 
Unknown MS/SS (1) 
         
* * * * * 
  
* * * * 
 
Unknown MS (2) * 
                   
 
Unknown MS/SS (3) 
     
* 
 
* 
          
* * 
 
Unknown MS/SS (4) * * 
     
* 
           
* 
 
Unknown MS/SS (5) 
 
* 
   
* 
  
* * * * * * * * * * 
  
 
Unknown SS (1) 
           
* 
   
* 
 
* 
  
 
Unknown SS (2) 
 
* 
   
* 
 
* 
 
* 
         
* 
 
Unknown SS (3) 
 
* 
 
* 
 
* 
   
* 
 
* 
 
* 
 
* 
   
* 
 
Unknown SS (4) 
 
* 
 
* 
     
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
Unknown SS (5) 
 
* 
           
* 
 
* 
   
* 
 
Unknown SS (6) 
     
* 
 
* 
 
* 
          
 
Unknown SS (7) 
     
* 
 
* 
            
 
Unknown SS (8) 
           
* 
        
 
Unknown SS (9) 
     
* 
   
* 
 
* 
 
* 
 
* 
 
* 
  
 
Unknown SS (10) 
     
* 
   
* 
 
* 
 
* 
 
* 
 
* 
 
* 
 
Unknown SS (11) 
     
* 
     
* 
 
* 
 
* 
   
* 
 
Unknown SS (12) 
     
* 
 
* 
   
* 
 
* 
     
* 
 
Unknown SS (13) 
               
* 
 
* 
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Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6 Sample 7 Sample 8 Sample 9 Sample 10 
CAS-number Compound MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS MS SS 
 
Unknown SS (14) 
 
* 
   
* 
   
* 
 
* 
        
 
Unknown SS (15) 
         
* 
 
* 
        
 
Unknown SS (16) 
         
* 
     
* 
 
* 
  
 
Unknown SS (17) 
 
* 
 
* 
 
* 
   
* 
          
 
Unknown SS (18) 
 
* 
 
* 
 
* 
     
* 
        
Table 2.14 data from individual bacterial headspace samples including all responses (*) 3 times the noise from both the mass spectral analyser (MS) and the MOS Sensor 
(SS) 
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Figure 2.16 chart showing the number of times each compound was detected in the headspace of 10 E.coli broth culture samples on both the mass spectral analyser and the 
metal oxide sensor, sampled with SPME. 
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2.4.0 Conclusions 
To summarise, we have developed a gas chromatography mass spectrometry sensor 
(GC-MSS) system which couples a metal oxide sensor with a standard quadrupole 
detector. This system has shown the ability to detect a broad range of compounds at 
trace concentrations with a variety of different functional groups and masses. 
Moreover, in many cases the MOS sensor has shown superior sensitivity over the 
mass spectral analyser, particularly when applied to challenging matrices such as the 
headspace of bacterial culture. Overall the sensor detected over 100 peaks that were 
not seen by the mass spectral analyser or were sub-threshold. This is borne out by 
the standard solutions work whereby the sensor system was found to give superior 
LOD to a range of standard compounds verses the mass spectral analyser. 
In testing to standard solutions, stool, and headspace samples we have demonstrated 
the potential for multiple applications of this combined GC-MS and sensor system. 
Although the response of MOS sensors is very fast, recovery, especially with high 
concentrations of VOCs, can be slow, which may obscure very small peaks which 
subsequently elute from the column. Although this may also happen with the MS, it 
does possess faster response and recovery than the sensor and thus better peak 
resolution. In previous work the same sensor has been operated continuously for 6 
months while assessing hundreds of stool samples for C. difficile infection and has 
retained its sensitivity when tested to certified gas standards [83]. 
Currently our system is set up for SPME pre-concentration however we plan to adapt 
this system to use automated thermal desorption (ATD). Despite the additional costs 
and time associated with ATD the increased sensitivity and efficient sample storage 
(particularly of breath) make it a very desirable technique. We believe that systems of 
this type which incorporate chromatographic separation with MOS or other sensitive 
sensor technology have great potential utility in analysing a range of samples including 
those that are medically derived. For stool and urine headspace this may be possible 
via direct headspace analysis, but for breath and other matrices then appropriate 
sample collection and pre-concentration may be required either in system or offline.  
The purpose of this work was to assess the range and relative detection limits of the 
sensor as a detector when compared to a standard mass analyser. The sensor 
showed equivalent or better performance to a broad range of chemical compounds 
whilst exhibiting selectivity against siloxanes and other common chromatographic 
contaminants such as chlorinated solvents. Therefore, the development of sensor 
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systems combined with chromatographic separation can be seen to have potential 
utility in developing instruments with applications in the medical field. However, in 
order for this to occur work has to continue in developing sensors with high sensitivity, 
selectivity (if disease markers are known) and stability (baseline and response) as well 
as appropriate algorithms for deconvolution of “chromatographic” data and 
subsequent pattern classification.  
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Chapter 3: Gas Chromatography Mass Spectrometry (GC-
MS) Quantification of Metabolites in Stool Using 13C 
Labelled Compounds 
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The work in this chapter has been published in the journal Metabolites: - 
Gould O, de Lacy Costello B, Smart A, Jones P, Macmaster A, Ransley K, Ratcliffe 
N. Gas chromatography mass spectrometry (GC-MS) quantification of metabolites in 
stool using 13C labelled compounds. Metabolites. 2018 Oct 31;8(4):75.  
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3.1.0 Introduction 
Numerous studies have been conducted which present volatile compounds (VCs) as 
potential biomarkers for gastrointestinal (GI) disease states [53,171–173]. For 
instance, Garner et al. showed VCs were significantly different in infected patients with 
C. difficile, and C. jejuni compared to healthy participants [53]. Similarly, a pilot study 
suggested potential VC biomarkers of cholera [171]. Other work has suggested the 
VCs emitted from stool can have potential in the diagnosis of irritable bowel syndrome 
(IBS) and inflammatory bowel disease (IBD) [126,172,173]. Currently, GI diseases are 
commonly diagnosed invasively, via blood tests, endoscopy, and biopsy, while VC 
analysis of stools is non-invasive and is potentially more economical.  
However, if VCs are to have real clinical utility, it is crucial that the healthy state 
volatilome is better understood. The gut is known to contain a vast and dynamic 
population of bacteria, with an estimated 100 trillion bacteria comprised of ca. 1000 
species [174]. Currently, some 381 compounds have been identified from human 
stool, and this number may be unrepresentative considering over double this number 
of compounds have been identified in breath [25]. This discrepancy may simply be 
due to fewer studies attempting to identify compounds from stool rather than breath 
due to the increased complexity of sample gathering and difficulty in obtaining healthy 
stool samples. Determining the healthy gut volatilome is problematic as dietary 
alterations can both alter the composition of the microbiota and the metabolites 
produced [175]. For instance, Geypens et al. [176] investigated the effect of a high 
protein diet on VCs in stools, measuring the volatiles before and after a whey-protein 
supplemented diet in healthy volunteers. The study identified 120 VCs, ten of which 
appeared or increased after the protein-rich diet, particularly dimethyl trisulphide and 
short-chain fatty acids (SCFAs). Silvester et al. showed that high protein meals can 
also contribute to an increase in the production of N-nitroso compounds and ammonia 
by intestinal flora [177].  
Currently, the quantification of volatiles from biological samples are mostly restricted 
to real-time methods, such as selected ion flow tube mass spectrometry (SIFT-MS) 
[178]. However, the use of GC-MS in the quantification of volatile compounds has 
previously been reported using solid phase micro extraction (SPME) to sample latrine 
models [179]; ten VOCs were quantified, with butanoic acid being found in the highest 
concentration with a range of 1.4-46.2 µg/g, whereas dimethyl sulphide was measured 
in the lowest concentration range of 0.02–2.1 µg/g [179].  
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Walton et al. quantitatively analysed VCs in the faecal headspace before and after 
treatment from patients with Crohn’s disease (CD), ulcerative colitis (UC), and irritable 
bowel syndrome (IBS), and healthy controls. Following treatment, only propanoic acid 
ethyl ester remained significantly different across the groups [180]. Similarly, Baranska 
et al. used breath samples to differentiate IBS patients from healthy controls using GC 
time-of-flight mass spectrometry. This study suggests a set of 16 biomarkers that could 
be used to not only predict IBS, but also monitor its progression [75].  
Wang et al. analysed stool samples of autistic spectrum disorder (ASD) children and 
healthy, age-matched controls for short chain fatty acids, phenols, and ammonia. 
Those with ASD had higher concentrations of acids than the controls and higher faecal 
ammonia [181].  
De Preter et al. used purge and trap GC-MS analysis to quantify VCs in dried stool 
samples using calibration curves with diethyl sulphide, 2,6-dimethylphenol, and 2-
ethylbutyric acid used as internal standards. A total of 135 different VCs were reported 
with 22 compounds common to all volunteers. Butanoic acid was found in the highest 
concentration with a range of 5–500 mg/L and dimethyl sulphide was found in the 
lowest concentration with a range of 5–1000 µg/L [182]. 
GC-MS analysis of VOCs from the human body has typically provided qualitative data 
and limited work exists on the quantification of metabolites in human stool. However, 
a method has been developed based on using internal 13C labelled standards to 
calculate concentrations of key compounds in the solid stool sample and the 
headspace. This study used stool from participants of different nationalities and 
varying diets (vegetarian/omnivore) to assess the difference in VC composition. 
Knowing what constitutes a “healthy” profile across a range of geographic locations 
allows a better understanding of the deviations from this profile, which may be 
indicative of disease. No work appears to be published on VC analysis with pH alkaline 
alteration of stool. Altering the pH of stool to alkaline conditions was explored to allow 
quantification of some amine compounds. 
This study qualitatively identified compounds associated with stool samples from 
healthy volunteers and thus adds knowledge to the established human volatilome. 
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3.2.0. Materials and methods 
3.2.1 Instrumentation and separation methodology 
A Clarus 600 gas chromatograph (GC) and Clarus 600T mass spectrometer (MS) 
(Perkin Elmer, Buckinghamshire, U.K.) was used for all the experiments described.  
The GC used a 30 m × 0.25 mm SOLGEL-WAX 0.25 µm column (Trajan scientific 
Europe Ltd). The GC method started at 40 °C with a four-minute hold, then ramped at 
a rate of 8 °C per minute to 240 °C, with a final four minute hold, and a total run time 
of 33 minutes. The MS was set to scan m/z 29–450 with electron ionisation selected. 
The automated thermal desorption (ATD) unit was a Turbo matrix 350 (Perkin Elmer, 
Buckinghamshire, U.K.). TD tubes were filled with Tenax TA 26 mg and Sulficarb 68 
mg absorbents (Markes International Ltd, Llantrisant, U.K.). The valve was set to 215 
°C with a tube temperature of 315 °C. The transfer temperature was set to 300 °C with 
a trap rate of 99 °C/second; the trap low and high was set to −20 °C and 320 °C, 
respectively. The dry purge time was 5 min and the desorb time was 10 min with a 1.2 
mL/min column flow rate. The outlet split was 2 mL/min and the desorb was 180 
mL/min; the inlet split was 25 mL/min with a 50 mL/min dry purge. The heated purge 
temperature was 50 °C. 
3.2.2 Loading the thermal desorption (TD) tubes 
Thermal desorption (TD) tubes were loaded using an adapted single shot heated auto 
sampler from an SRI GC instrument. This has a temperature-controlled heating block. 
In the modified version, two needles pierce the headspace vial, one that allows the 
nitrogen purge gas (BOC UN1066 99.998%) to enter the vial, and the other, which is 
securely attached to the TD tube with brass fittings (Swagelok). The vials were 10 mL 
glass headspace vials with a screw top phenolic cap and PTFE/silicone septa 
(Supelco, Bellefonte, U.S.A.). The SRI GC instrument uses an EPC valve to control 
the purge gas flow, which was set to 80 mL/min and flowed through the headspace 
vial containing the sample (3 g stool). The purge gas is flowed through the vial and out 
through the TD tube for two minutes; the flow rate through the tube was checked each 
time using a Perkin Elmer PE 1000 flow meter (Perkin Elmer, Buckinghamshire, U.K.).  
One µL standards dissolved in methanol were injected onto the TD tube using a 1 µL 
syringe (SGE analytical science, Ringwood, Australia) (see standard solutions section 
for details on solutions used) and loading rig (Markes International Ltd, Llantrisant, 
U.K.). Following the injection, nitrogen gas (BOC UN1066 99.998%) was flowed 
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through the tube at 80 mL/min for 2 min to remove excess solvent prior to analysis. As 
with the stool samples flow was measured each time using a Perkin Elmer PE 1000 
flow meter (Perkin Elmer, Buckinghamshire, U.K.).  
Once the tube was loaded, it was added immediately to the ATD unit carousel and 
analysed within 30 min using the ATD-GC-MS. 
3.2.3 Standard Solutions 
Two solutions were used for this work. Table 3.15 shows solution 1, and 13C labelled 
compounds, which were used as internal standards in the samples and for the 
calibration curves (see Section 3.2.4 calibration curves). Table 3.16 shows solution 2, 
made of non-labelled compounds used for calibration curves. Both solutions were 
made up in methanol HPLC grade (Sigma Aldrich Company, Gillingham, U.K.) and 
stored at 4 °C.  
 
CAS number 
Compound 13C (purity) Supplier 
Volume/ mass (in 50 mL 
methanol) 
3881-06-9 Acetone 2-13C (99%) Sigma Aldrich Company 50µL/39.55 mg 
1329835-35-9 Ethyl butanoate 1-13C 
(>95%) 
Precursor supplier, Cambridge 
Isotope Laboratories Ltd 
50µL/43.25 mg 
136321-14-7 Dimethyl disulphide 13C2 
(99%) 
Cambridge Isotope Laboratories Ltd 50µL/53.0 mg 
1563-79-7 Ethanoic acid 1-13C (99%) Cambridge Isotope Laboratories Ltd 50µL/52.5 mg 
38765-83-2 Butanoic acid 1-13C (99%) Cambridge Isotope Laboratories Ltd 50µL/47.5 mg 
87994-84-1 3-Methylbutanoic acid 1-13C 
(99%) 
Cambridge Isotope Laboratories Ltd 50µL/46.25 mg 
NA Indole 2-13C (98%) Cambridge Isotope Laboratories Ltd 80 mg (solid) 
Table 3.15 solution 1: 13C labelled compounds used as internal standards, purity, suppliers, and 
masses used. 
 
CAS number Compound Supplier Volume/ mass (in 100 mL methanol*) 
75-18-3 Dimethyl sulphide Sigma Aldrich Company 100µL/84.6 mg 
67-64-1 Acetone Sigma Aldrich Company 100µL/79.1 mg 
7452-79-1 2-Methyl-butanoic acid, ethyl ester Sigma Aldrich Company 100µL/86.5 mg 
624-92-0 Dimethyl disulphide Sigma Aldrich Company 100µL/106.0 mg 
4312-99-6 1-Octen-3-one Sigma Aldrich Company 100µL/84.3 mg 
3658-80-8 Dimethyl trisulphide Sigma Aldrich Company 10 µL/15.97 mg (in75 mL methanol) 
 3391-86-4       1-Octen-3-ol Sigma Aldrich Company 100µL/84 mg 
107-92-6 Butanoic acid Sigma Aldrich Company 100µL/95.0 mg 
503-74-2 3-Methylbutanoic acid Sigma Aldrich Company 100µL/92.5 mg 
109-52-4 Pentanoic acid Sigma Aldrich Company 100µL/93.0 mg 
120-72-9 Indole Sigma Aldrich Company 80.5 mg (solid) 
83-34-1 3-Methylindole Sigma Aldrich Company 45 mg (solid) in 75 mL methanol 
Table 3.16 solution 2: compounds used for standards, purity, supplier, and volume/masses used. 
*Unless stated otherwise. 
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3.2.4 Calibration Curves 
Five mL of solution 1 was added to a 50 mL volumetric flask and topped to the fill line 
with methanol for a factor ten dilution. Five mL of this diluted solution was then placed 
into another 50 mL volumetric flask which was topped to the fill line with methanol 
which resulted in 100-fold dilution from the starting stock solution. Section 3.2.2 of 
loading TD tubes details how the solution was injected onto the tubes; 0.5 µL of the 
solutions 1 and 2, and the sequentially diluted solutions, were injected on to TD tubes. 
These were then analysed on the GC-MS, and the peak areas were recorded and 
noted for each compound. Calibration curves were created for each compound; none 
of the compounds in solution 1 or solution 2 yielded an r2 of less than 0.99 (see Figures 
3.17 and 3.18). Retention indices for all the standards were compared to that of the 
literature, and in all cases, the values obtained from our data matched the literature 
values. 
 
Figure 3.17 the three point calibration graphs generated from solution 1 which contains the 13C 
labelled compounds. 
 
R² = 0.9899
R² = 0.9998
R² = 0.9998
R² = 0.9971
R² = 0.9987
R² = 0.9986
R² = 0.9999
0
50
100
150
200
250
300
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
A
re
a 
u
n
d
er
 t
h
e 
cu
rv
e 
(a
rb
it
ra
ry
 u
n
it
s 
(x
1
0
6 )
)
mg/µL
13C Acetone
13C-Butanoic acid, ethyl
ester
13C-dimethyl disulphide
13C Acetic acid
13C butanoic acid
13C isovaleric acid
13C Indole
76 
 
 
Figure 3.18 the three-point calibrations curves generated from solution 2 which contains the chemical 
standard of the compounds quantified in stool. 
3.2.5 Sample Preparation  
Stool samples were collected from 38 healthy volunteers, age range of 18–60 years, 
with full ethical consent (research ethics committee reference 14/NE/0029); these 
were immediately refrigerated (4 °C) on arrival and processed in a microbiological 
safety cabinet within 4 h. Samples were initially collected in aluminium containers, L 
20 cm × W 11.5 cm × H 4 cm. Processing involved taking 6–8 aliquots weighing 3 g 
from each sample and placing them into 10mL headspace vials (Supelco), which were 
then frozen at −20 °C. The ethnic origin and the omnivore/ vegetarian status of the 
samples is shown in Table 3.17. 
 
Number of Participants Ethnic Origin Omnivore Vegetarian 
16 UK 8 8 
11 South America (Brazil, Mexico) 10 1 
3 Mainland Europe (Czech Republic, Latvia, and Spain) 1 2 
5 Asia (China, Vietnam, Iran) 4 1 
3 Africa (Maldives, Nigeria) 1 2 
Table 3.17 a breakdown of the participants by country of origin and omnivore/vegetarian status. 
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For analysis, the sample vial was removed from the freezer and immediately the screw 
cap was removed and a steel ball bearing (0.5 cm diameter, weighing approximately 
0.5 g) was added and the vial recapped. Next, 1 µL of solution 1 (see 3.2.3 standard 
solutions section) was injected through the septa using a 1 µL syringe (SGE analytical 
science). The vial was then inserted into the TD loading rig heating block at 30 °C for 
10 min, manually shaken for ca. 1 minute, and returned to the block. After a further 10 
min, the vial was shaken for a second time; then, it was returned to the block for a 
further 10 min, giving a total 30 min of heating time (see Section 3.2.2 loading TD 
tubes section for details). 
3.2.6 Trimethylamine Quantification in pH13 Stool Samples 
Trimethylamine solution standards were made separately. 25 mg of 13C 
trimethylamine (99% Cambridge Isotope Laboratories Ltd) was dissolved into 25 mL 
of methanol to give a final concentration of 1 mg/mL (most concentrated), and this 1 
mg/mL solution was sequentially diluted to 0.1 mg/mL and 0.01 mg/mL. 
Trimethylamine, 400 mg (25 wt% in water, Sigma Aldrich Company, Gillingham, U.K.) 
was dissolved in 100 mL methanol to give the same 1 mg/mL concentration, which 
was again used as the most concentrated standard. This was diluted 10-fold to give 
0.1 mg/mL and 0.01 mg/mL. These solutions were used to create calibration curves 
of the mass of compounds (x-axis) versus peak area recovered from the 
chromatogram (y-axis) (see calibration curves Section 3.2.4). 
The same sample processing took place as described in the sample preparation 
section above; however, in the case when the ball bearing was added to the sample 
on removal from the freezer, 5 mL of aqueous 0.1 M sodium hydroxide (Fisher 
Scientific, Loughborough, U.K.) was also pipetted into the sample. The pH of the stool 
samples was checked post analysis with indicator paper. A total of 15 stool samples 
were run using this method. 
3.2.7.0 Analysis 
3.2.7.1 Qualitative Analysis 
A signal threshold of three times the noise was set for all chromatograms. All peaks 
were searched manually using the NIST library (NIST 08). Compounds with a match 
and reverse match above 800 were identified. If the match and/or reverse match was 
under 800, then the peak was listed as unidentified. Terpene and siloxane compounds 
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were difficult to assign structures to and thus were listed under the chemical class 
name.  
3.2.7.2 Mass Calculations Using 13C Labelled Compounds 
Using solution 1, the following compounds were quantified: Dimethyl sulphide, 
acetone, butanoic acid ethyl ester, 2-methylbutanoic acid ethyl ester, dimethyl 
disulphide, 1-octen-3-one, dimethyl trisulphide, 1-octen-3-ol, ethanoic acid, butanoic 
acid, 3-methylbutanoic acid, pentanoic acid, indole, and 3-methylindole.  
To obtain the peak areas for each compound and the 13C equivalent we obtained a 
separate trace for the single ion of interest and obtained the peak area from this trace. 
For example, the primary m/z product for 3-methylbutanoic acid is 87 and 88 for the 
13C isotope. Knowing the mass of 13C compounds added to the sample we can 
calculate the proportion of 13C compound recovered from the headspace using the 
calibration graphs constructed. We can then use the ratio of 13C compound added to 
the sample versus the amount of 13C compound recovered from the headspace to 
correct the peak area of the compound being quantified and therefore, quantify the 
amount in the stool samples. To demonstrate the calculations the example of 3-
methylbutanoic acid will be used. Peak area units are marked as PAU. 
• The calibration curves (Figures 3.17 and 3.18) gave equations y=66.62x and 
y=74.58x for 13C 3-methylbutanoic acid and 3-methylbutanoic acid respectively.  
• Since 0.5 µL of solution 1 was used for the calibration curve but 1 µL of solution 
1 was added to the stool the first step was to calculate the theoretical peak area 
for 100% recovery of 13C 3-methylbutanoic acid from the sample. In this 
example 66.62 (slope of 13C 3-methylbutanoic acid) x 0.925 (mass (µg) in 1 µL 
solution 1) = 61.62 PAU. 
• 61.62 PAU is then divided by the PAU of 13C 3-methylbutanoic acid recovered 
from the sample; which in this case is 0.78 PAU so 61.62 PAU / 0.78 PAU = 
79; this value is the correction factor that allows the calculation of the amount 
of compound within the stool. 
• The correction factor is then multiplied by the peak area of the compound to be 
quantified from the sample, in this case the peak area of 3-methylbutanoic acid 
was 0.18 PAU, thus 79 x 0.18 PAU = 14.21 PAU.  
• So the peak area for the amount of 3-methylbutanoic acid contained in the stool 
is 14.21 PAU, this can then be used with the calibration curve for 3-
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methylbutanoic acid (y=74.58x) where y=peak area and x=mass of compound 
to solve for x so in our example x= 14.21 PAU/ 74.58= 0.19 µg 
• Finally, 0.19 µg is divided by the mass of stool (3 g) = 0.063 µg/g which we then 
convert to ng/g = 63.3 ng/g. 
  
3.2.7.3 Statistical analysis 
All statistical analysis was carried out using IBM SPSS statistics version 24. Basic 
descriptive statistics (median, interquartile range, and range of masses)) were carried 
out on the quantitative data. Each chromatogram was analysed manually to identify 
the chromatographic peaks and the peak areas which provided the qualitative data.   
The two largest groups of participants with different geographical origins were from 
the U.K. and South America, thus these groups were selected for comparison. 
Omnivore and vegetarian groups from the entire cohort of participants were also 
compared. To compare sample groups, the non-parametric test Mann Whitley U was 
carried out before a discriminant analysis using stepwise statistics (Wilks’ Lambda). 
Leave-one-out cross validation was used to calculate a ROC curve.   
The differences between samples (e.g., U.K. origin versus South American origin) 
have been discussed. Also discussed is the difference in chromatographic peaks both 
qualitatively and quantitatively for unmodified stool versus pH 13 stool.  
3.3.0 Results 
3.3.1 Qualitative data from unmodified stools 
Tables 3.18-3.29 show the raw qualitative data from all 38 samples; in total, 174 
distinct chromatographic peaks were recorded across these samples; the 
supplementary tables show these compounds separated into chemical class. The 
mean number of peaks above the noise threshold was 57 per sample with a range of 
36–72. Of the total number of chromatographic peaks, 32 could not be identified by 
the NIST library and 30 were identified as unspecified terpenes. Table 3.30 shows 
retention indices (RI) values calculated from the experimental data and compared 
where possible to literature values. All RIs for the unidentified and terpene compounds 
have also been calculated. Table 3.30 also highlights which compounds have been 
validated using standards.
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S1a)               
CAS Aldehydes  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
75-07-0 Acetaldehyde 2.16 169.44  230.78 72 53.08 166.03 97.55  91.36 81.08 260.13 82.12 
123-38-6 Propionaldehyde 2.43             
123-72-8 Butyraldehyde 3.10  12.26 4.52 24.8 10.74 9.49  4.47   10.25  
66-25-1 Hexanaldehyde 6.76 9.23 10.2 8.89 19.19 18.18 37.13 14.9 12.28  9.52 15.09 17.01 
100-52-7 Benzaldehyde 15.05 2.72 6.52 2.34 4.97 3.33 1.95 1.6  2.29 2.06 2.25  
55012-32-3 Isopropyl benzaldehyde 18.91          4.24   
 
S1b)               
CAS Aldehydes  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
75-07-0 Acetaldehyde 2.16 173.9 65.69 143.82 31.3 156.33 170.17 60.17 30.89 39.56 42.08 65.72 30.64 
123-38-6 Propionaldehyde 2.43       5.29      
123-72-8 Butyraldehyde 3.10   5.71   10.18 9.12 7.26   10.1 3.56 
66-25-1 Hexanaldehyde 6.76 12.85 105.43 8.35 9.07 63.28 39.54 4.58 8.77 6.63 8.6 2.86 3.15 
100-52-7 Benzaldehyde 15.05    1.22       2.06 1.29 
55012-32-3 Isopropyl benzaldehyde 18.91   2.39          
 
S1c)                 
CAS Aldehydes Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
75-07-0 Acetaldehyde 2.16 22.78 122.52 77.79 54.3 35.32 42.75 81.05  33.97 24.51  43.3 12.15 13.02 
123-38-6 Propionaldehyde 2.43    5.81   0.97 1.7  1.61 1.75 0.54  0.16 
123-72-8 Butyraldehyde 3.10  3.88     8.65 3.36 3.39  4.7 3.64 2.79 3.58 
66-25-1 Hexanaldehyde 6.76 15.61  6.98     5.35 5.24  16.45    
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S1c)                 
CAS Aldehydes Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
100-52-7 Benzaldehyde 15.05    1.92           
55012-32-3 Isopropyl benzaldehyde 18.91               
Table 3.18 sections a, b, and c aldehydes found in unmodified stool samples for all participants with retention time and chromatographic peak area.  
S2a)               
CAS Alcohols Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
64-17-5 Ethanol 3.91 54.64 163.04 244.98 113.15 95.58 129.81 88.27 74.59 61.08 150.72 291.37 925.93 
78-92-2 2-Butanol 5.64 22.04  19.74 21.55 29.81 24.51 16.18  14.08 44.64 16.93 12.31 
71-23-8 1-Propanol 5.92   87.79    44.53 132.26     
78-83-1 2-Methyl-1-propanol 7.27 11.68 13.1 25.51 24.08 41.83 21.15 14.48 22.89 7.71 15.85 37.54  
598-75-4 3-Methyl -2-butanol 7.80   4.64     4.87     
6032-29-7 2-Pentanol 7.83    7.2   3.1     3.97 
71-36-3 1-Butanol 8.29 5.44  55.42 72.25 45.08 21.47 21.97 208.89 6.06  100.22 466.05 
123-51-3 3-Methyl -1-butanol 9.51 18.33  13.04 32.73 43.3 24.12 11.86 23.5 20.74 21.16 43.48 17.77 
108-11-2 4-Methyl -2-pentanol 9.78             
71-41-0 1-Pentanol 10.35 10  16.52 28.77 36.72 11.49 13.57 56.66 5.03 9.53 19.39 78.22 
626-89-1 4-Methyl -1-pentanol 11.55 3.49 3.08 7.38 9.12   7.25 9.5   1.94  
543-49-7 2-Heptanol 11.59             
2313-61-3 4-Methyl -2-hexanol 11.66     3.38        
111-27-3 1-Hexanol 12.24    41.42 49.82   41.96  6.53 2.81 123.3 
123-96-6 2-Octanol 13.40     4.94        
3391-86-4 1-Octen-3-ol 13.90 14.42 15.78 6.37 11.98 2.03 1.69       
111-70-6 1-Heptanol 13.99    2.78 15.37        
104-76-7 2-Ethyl-1-hexanol 14.49             
111-87-5 1-Octanol 15.64     4.92        
15356-70-4 Cyclohexanol, 5methyl-2-(1-methylethyl)-,(1a,2b,5a) 16.90      8.01       
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S2b)               
CAS Alcohols Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
64-17-5 Ethanol 3.91 491.15 113.67 156.52   12.27 253.7 339.14 254.14 139.93 137.65 58.64 151.62 
78-92-2 2-Butanol 5.64 13.83 37.33 9.49 9.61 29.76 26.52 7.75 11.86 7.83 64.06 17.84 11.53 
71-23-8 1-Propanol 5.92           22.39           7.88 
78-83-1   1-Propanol,  7.27 11.54 9.14 13.78 5.55 11.31 54.5 86.4 20.77 10.26 27.88 11.98 44.08 
598-75-4 3-Methyl -2-butanol 7.80 1.27       4.44 2.52 1.24         4.87 
6032-29-7 2-Pentanol 7.83   11.2         2.35 4.69 1.98       
71-36-3 1-Butanol 8.29 61.48 12.91   55.51 12.25 1.68 132.28 147.5 46.15 28.17 8.71 72.26 
123-51-3 3-Methyl -1-butanol 9.51     3.26 6.26 20.27 34.86 32.49 23.46 14.55 18.03 22.28 53.67 
108-11-2 4-Methyl -2-pentanol 9.78   5.79                     
71-41-0 1-Pentanol 10.35 10.61 6.63 6.33 10.66     29.39           
626-89-1 4-Methyl-1-pentanol 11.55 4.35     3.01   6.93       0.94   2 
543-49-7 2-Heptanol 11.59                         
2313-61-3 4-Methyl -2-hexanol 11.66                       0.85 
111-27-3 1-Hexanol 12.24 8.31 5.9 2.69 11.12 3.43 3.82 1.83 2.22 5.53 0.87 1.42 1.34 
123-96-6 2-Octanol 13.40 0.6 1.26   0.35                 
3391-86-4 1-Octen-3--ol 13.90             0.36           
111-70-6 1-Heptanol 13.99   1.57             7.49 20.46     
104-76-7 2-Ethyl -1-hexanol 14.49                         
111-87-5 1-Octanol 15.64                         
15356-70-4 Cyclohexanol, 5methyl-2-(1-methylethyl)-,(1a,2b,5a) 16.90                         
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S2c)                 
CAS Alcohols  
Retention 
time (mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
64-17-5 Ethanol 3.91   200.44 96.72 
422.7
6 
292.3
6 
159.9
7 
100.6
9 
1052.
5 
165.1
7 
1479.78 
307.1
8 
286.7
5 
54.48 51.63 
78-92-2 2-Butanol 5.64 33.7 16.34     9.34   25.22 20.05 4.85   13.7 10.18     
71-23-8 1-Propanol 5.92       
320.3
2 
                    
78-83-1 2-Methyl-1-propanol, 7.27 27.48 37.51 9.11 4.46 41.82 5.77 73.17 19.88 5.75 17.65 8.98 11.93 3.77 9.47 
598-75-4 3-Methyl -2-butanol 7.80 28.73           4.95   1.06           
6032-29-
7 
2-Pentanol 7.83   2.17   47.17                     
71-36-3 1-Butanol 8.29 1106.38 40.2 9.3 5.03 20.55 6.73 
116.0
9 
307.8
1 
20.58 481.3 49.07 84.58 11.69 13.62 
123-51-3 3-Methyl -1-butanol 9.51 30.42 41.5 8.64 15.3 17.23 13.3 73.16 12.06 12.74 8.64 10.49 10.18 3.57 3.47 
108-11-2 4-Methyl -2-pentanol 9.78 4.49     24.19               2.18     
71-41-0 1-Pentanol 10.35 23.17     6.24 9.65 4.58 32.7 30.36 0.8 49.63 10.92 9.57 4.3 5.22 
626-89-1 4-Methyl -1-pentanol 11.55 15.49 0.73 3.68 0.87   1.49             0.59   
543-49-7 2-Heptanol 11.59         2.07                   
2313-61-
3 
4-Methyl -2-hexanol 11.66     0.46                       
111-27-3 1-Hexanol 12.24   9.8   1.88 6.26   26.29 2.55 0.9 1.77       4.38 
123-96-6 2-Octanol 13.40       5.06         0.74           
3391-86-
4 
1-Octen-3--ol 13.90 50.03 3.05 0.73                       
111-70-6 1-Heptanol 13.99     2.31                       
104-76-7 2-Ethyl -1-hexanol 14.49           5.39                 
111-87-5 1-Octanol 15.64   0.64                         
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S2c)                 
CAS Alcohols  
Retention 
time (mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
15356-
70-4 
Cyclohexanol, 5methyl-2-(1-
methylethyl)-,(1a,2b,5a) 
16.90   6.06                         
Table 3.19 sections a, b, and c alcohols found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
S3a)               
CAS Esters and thioesters Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
79-20-9 Ethanoic  acid, methyl ester 2.69 107.77 101.23 117.83 136.73 104.72 206.31 107.89 177.06 88.00 73.82 104.92  
141-78-6 Ethanoic acid ethyl ester 3.21   13.13   20.11 24.31 17.81   11.33 483.39 
105-37-3 Propanoic acid ethyl ester 4.28   18.47   31.27 38.51 26.72   7.5 368.55 
97-62-1 2-Methylpropanoic acid ethyl ester 4.44   4.85       1.4  36.65 
109-60-4 Ethanoic acid propyl ester 4.60            380.99 
623-42-7 Butanoic acid methyl ester 4.79 11.88 9.6 133.9 48.71 10.79 287.95 252.51 268.02  7.24 34 776.39 
868-57-5 2-Methylbutanoic acid methyl ester 5.28   12.78   14.28 16.27 15.87     
556-24-1 3-Methylbutanoic acid methyl ester 5.49        20.05    13.51 
105-54-4 Butanoic acid ethyl ester  5.87             
106-36-5 Propanoic acid propyl ester 6.04       18.72 66.2    269.37 
7452-79-1 2-Methylbutanoic acid ethyl ester 6.21   4.19 7.57  11.56 10.9      
123-86-4 Ethanoic  acid butyl ester 6.61        36.17    214.65 
624-24-8 Pentanoic acid methyl ester 6.87   20.52 11.51 4.83 52.98 41.21 62.74   13.26 106.62 
105-66-8 Butanoic acid propyl ester 7.64   11.58 3.69 4.03 20.92 32.52 34.72   4.29 1205.79 
539-82-2 Pentanoic acid ethyl ester 7.92   6.98   14.37 19.25 17.26    425.37 
590-01-2 Propanoic acid butyl ester 8.06 77.7  13.23 20.74 16.6 10.96 31.24 50.47 25.32 56.09 1.97 205.3 
97-87-0 Propanoic acid 2-methylbutyl ester 8.18            10 
539-90-2 Butanoic acid 2-methylpropyl ester 8.45      10.19 9.16 5.29  30.82  20.77 
628-63-7 Ethanoic  acid pentyl ester 8.68             
123-92-2 Ethanoic acid 3-methylbutanyl ester 8.75        6.02  4.00  27.47 
106-70-7 Hexanoic acid methyl ester 9.01    15.44 6.28  21.85 25.74  0.88  293.84 
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S3a)               
CAS Esters and thioesters Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
109-21-7 Butanoic acid butyl ester 9.68   5.45 3.25  8.18 7.27 13.29   2.07 877.59 
141-06-0 Pentanoic acid propyl ester 9.73       7.66 10.11     
123-66-0 Hexanoic acid ethyl ester 9.99       4.93 10.3    1089.71 
624-54-4 Propanoic acid pentyl ester 10.12        4.53     
109-19-3 3 -Methylbutanoic acid butyl ester  10.29        7.41     
106-27-4 Butanoic acid 3-methylbutyl ester  10.60            14.59 
142-92-7 Ethanoic  acid hexyl ester 10.73            38.28 
106-73-0 Heptanoic acid methyl ester 11.02    7.86   4.03 5.8    20.31 
591-68-4 Pentanoic acid butyl ester  11.50             
5870-93-9 Butanoic acid heptyl ester 11.51             
626-77-7 Hexanoic acid propyl ester 11.63            438.07 
106-30-9 Heptanoic acid ethyl ester 11.88             
4630-82-4 Cyclohexane carboxylic acid methyl ester 12.71        21.93    12.22 
111-11-5 Octanoic acid methyl ester 12.82             
626-82-4 Hexanoic acid  butyl ester 13.30            149.2 
 
S3b)               
CAS Esters and thioesters  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
79-20-9 Ethanoic  acid methyl ester 2.69 118.44 130 72.01 118.43 124.64 86.24 109.89 155.81 64.69 103.66 54.19 53.44 
141-78-6 Ethanoic acid ethyl ester 3.21 124.04 2.6   138.53   23.95   15.17         
105-37-3 Propanoic acid ethyl ester 4.28 105.99   7.63 152.64 7.6 50.66   13 4.86     9.48 
97-62-1 2-Methylpropanoic acid ethyl ester 4.44 22.33     66.71   30.57   4.51 38.36 16.98   2.35 
109-60-4 Ethanoic acid propyl ester 4.60 66.09     56.77 223.64     70.46     44.68 5.2 
623-42-7 Butanoic acid methyl ester 4.79 104.48 25.53 11.77 248.03 40.94 17.27 16.92   21.62 45.44 7.9 8.67 
868-57-5 2-Methylbutanoic acid methyl ester 5.28 3.77     23.62   23.76   2.73       1.7 
556-24-1 3-Methylbutanoic acid methyl ester 5.49 11.54   16.09 68.49 37.21 27.56 8.34 8.26 11.34   64.57 26.41 
105-54-4 Butanoic acid ethyl ester  5.87 519.8   171.54 630.87   426.27 463.79 141.16   120.9     
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S3b)               
CAS Esters and thioesters  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
106-36-5 Propanoic acid propyl ester 6.04 22.66     15.18                 
7452-79-1 2-Methylbutanoic acid ethyl ester 6.21 9.82 4.8   47.99   22.48 6.87 3.74 1.58     2.78 
123-86-4 Ethanoic  acid butyl ester 6.61 14.5   0.93 22.03       6.2         
624-24-8 Pentanoic acid methyl ester 6.87 18.01 5.43 4.84 41.96 21.58 2             
105-66-8 Butanoic acid propyl ester 7.64 49.85   2.4 20.98   50.3   8.19 7.79   2.32   
539-82-2 Pentanoic acid ethyl ester 7.92 58.21   2.49 93.66   51.21 1.55 2.87 4.63   89.42 3.57 
590-01-2 Propanoic acid butyl ester 8.06 9.91   16.35 19.29   2.53     5.07 7.68 16.4   
97-87-0 Propanoic acid 2-methyl butyl ester 8.18     11.58   11.47 8.79             
539-90-2 Butanoic acid 2-methylpropyl ester 8.45   4.81 1.1 9.24   57.99             
628-63-7 Aethanoic  acid pentyl ester 8.68                         
123-92-2 Ethanoic acid 3-methyl butanyl ester 8.75 1.44     3.03 18.62 1.93   0.71 4.23 1.1 4.04 1.47 
106-70-7 Hexanoic acid methyl ester 9.01 14.52 5.54 1.43 2.49     4.32 7.74   1.36   22.93 
109-21-7 Butanoic acid butyl ester 9.68 18.3     9.62 2.32 17.78 2.56 4.17   1.45   2.92 
141-06-0 Pentanoic acid propyl ester 9.73 8       1.45 16.69           1.67 
123-66-0 Hexanoic acid ethyl ester 9.99 42.59     70.59 0.68 1.74     1.77   0.79   
624-54-4 Propanoic acid pentyl ester 10.12 1.22 38.46 1.46     4.07         7.56   
109-19-3 3- Methylbutanoic acid butyl ester  10.29         10.09 18.27   21.9 10.56 10.36 4.38 26.15 
106-27-4 Butanoic acid 3-methylbutyl ester  10.60 1.39       3.01           6.72   
142-92-7 Ethanoic  acid hexyl ester 10.73 0.92     1.55 0.99 0.98     1.11 0.91 2.4   
106-73-0 Heptanoic acid methyl ester 11.02 3.2   2.4 4.47                 
591-68-4 Pentanoic acid butyl ester  11.50                         
5870-93-9 Butanoic acid heptyl ester 11.51                         
626-77-7 Hexanoic acid propyl ester 11.63 5.72 4.29   2.59 0.73               
106-30-9 Heptanoic acid ethyl ester 11.88 3.78     2.66 30.09 17.84 30.75 20.37 6.8 9.82 50.34 71.99 
4630-82-4 Cyclohexane carboxylic acid methyl ester 12.71         1.02           0.42   
111-11-5 Octanoic acid methyl ester 12.82                         
626-82-4 Hexanoic acid, butyl ester 13.30 1.35   2.15 1.28 0.4             0.39 
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S3c)                 
CAS Esters  and thioesters 
Retention time 
(mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
79-20-9 Ethanoic  acid, methyl ester 2.69 506.42 
216.7
4 
75.0
2 
120.8
3 
79.7
5 
129.0
5 
129.6
8 
242.88 203.39 
556.9
4 
4.12 69.11 
11.8
5 
18.1
4 
141-78-6 Ethanoic acid ethyl ester 3.21   13.79   93.82 2.96   11.35 229.27 26.4   2.42 2.02 0.7 0.84 
105-37-3 Propanoic acid ethyl ester 4.28       
449.6
7 
    11.76 81.22 48.23 
833.2
5 
46.6
1 
3.07 2.89 1.7 
97-62-1 2-Methyl propanoic acid ethyl ester 4.44 49.1     15.19     78.57 5.26             
109-60-4 Ethanoic acid propyl ester 4.60       17.25       80.21 54.21 
482.5
3 
    5.19   
623-42-7 Butanoic acid methyl ester 4.79   8.32 5.46 84.59 
38.5
6 
11.42 204 597.33 
335.20
8 
2314.
9 
17.1
2 
58.6 9.25 7.53 
868-57-5 2-Methyl butanoic acid methyl ester 5.28       31.96     12.26   4.83     1.25 
51.3
6 
  
556-24-1 3-Methyl butanoic acid methyl ester 5.49 13.25 19.77               16.16         
105-54-4 Butanoic acid ethyl ester  5.87   
164.1
5 
          
1075.9
2 
287.35     
198.3
5 
    
106-36-5 Propanoic acid propyl ester 6.04   2.8             68.87           
7452-79-
1 
2-Methyl butanoic acid ethyl ester 6.21 472.99   2.5 19.33     2.12   4.92           
123-86-4 Ethanoic  acid butyl ester 6.61 435.4     4.98       30.89   
277.5
8 
        
624-24-8 Pentanoic acid methyl ester 6.87 67.82 3.09 1.7 5.6 8.43 5.75 29.36 61.61 24.68 332.4 
49.4
5 
11.04     
105-66-8 Butanoic acid propyl ester 7.64 
1043.2
3 
  1.46 25.92 1.12   21.4 94.32 39.03 
136.0
7 
1.68 4.41 2.38   
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S3c)                 
CAS Esters  and thioesters 
Retention time 
(mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
539-82-2 Pentanoic acid ethyl ester 7.92   6.21 1.55 3.35     2.91 59.3 2.94 
788.3
1 
  1.89 1.04   
590-01-2 Propanoic acid butyl ester 8.06 361.95 15.37   12.49     7.61     
208.2
5 
  2.07 0.95 0.74 
97-87-0 Propanoic acid 2-methylbutyl ester 8.18       4.88                     
539-90-2 Butanoic acid 2-methylpropyl ester 8.45     0.85       7.83     67.33         
628-63-7 Aethanoic  acid pentyl ester 8.68             3.24     19.12         
123-92-2 Ethanoic acid 3-methyl butanyl ester 8.75 8.39   3.17 2.91                     
106-70-7 Hexanoic acid methyl ester 9.01       2.98 7.81 1.33 29.21 1.24   5.36       3.1 
109-21-7 Butanoic acid butyl ester 9.68   2.55   17.29     18.27 55.87 4.81 
715.4
1 
  2.03 1.25 0.78 
141-06-0 Pentanoic acid propyl ester 9.73     0.43                       
123-66-0 Hexanoic acid ethyl ester 9.99 8.2   0.47       2.31     19.14     0.46 0.44 
624-54-4 Propanoic acid pentyl ester 10.12 2.53     0.47     1.18   3.59 9.77         
109-19-3 3- Methyl butanoic acid butyl ester  10.29 14.78 18.36 4.82 2.53         4.57       1.25   
106-27-4 Butanoic acid 3-methylbutyl ester  10.60             4.9     7.82         
142-92-7 Ethanoic  acid hexyl ester 10.73 3.57     14.43     1.55     2.76         
106-73-0 Heptanoic acid methyl ester 11.02             8.64             0.73 
591-68-4 Pentanoic acid butyl ester  11.50                   78.93         
5870-93-
9 
Butanoic acid heptyl ester 11.51             10.84 7.5             
626-77-7 Hexanoic acid propyl ester 11.63 3.03 2.14                         
106-30-9 Heptanoic acid ethyl ester 11.88 57.61 27.71 10.9 1.23             1.04       
4630-82-
4 
Cyclohexane carboxylic acid methyl 
ester 
12.71 3.29     1.29         12.16           
111-11-5 Octanoic acid methyl ester 12.82           2.21                 
89 
 
S3c)                 
CAS Esters  and thioesters 
Retention time 
(mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
626-82-4 Hexanoic acid, butyl ester 13.30     0.2       6.12     2.65         
 Table 3.20 section a, b, and c esters and thioesters found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
 
S4a)               
CAS Ketones  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
67-64-1 Acetone 2.61 148.03 187.16 184.56 179.32 193.52 404.75 363.6 146.87 162.02 170.04 202.18 210.3 
78-93-3 2-Butanone 3.37  546.72           
563-80-4 3-Methyl 2-butanone  4.56             
107-87-9 2-Pentanone 4.61  37.44  198.34 58.79 141.58 108.36 117.22  29.05 42.67  
431-03-8 2,3-Butanedione 4.61   47.06          
108-10-1 Methyl isobutyl ketone 5.19    27.36         
591-78-6 2-Hexanone 5.21      12.93       
565-61-7 3-Methyl 2-pentanone  5.37    12.83     5.82    
600-14-6 2,3- Pentanedione 6.33           19.55  
105-42-0 4-Methyl 2-hexanone  8.84             
110-43-0 2-Heptanone 8.91   3.94 17.39 26.59 4.68 8.23 1.96 4.03 3.86 2.35  
110-93-0 6-Methyl -5-hepten-2-one  11.94 68.91 98.65 43.13 37.69 15.41 101.06 9.14 4.33 52.48 12.54 43.31 100.71 
 
S4b)               
CAS Ketones  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
67-64-1 Acetone 2.61 206.65 340.64 25.04 55.52 533.55 186.84 109.9 95.74 154.69 148.61 466.96 151.9 
78-93-3 2-Butanone 3.37                         
563-80-4 3-Methyl 2-butanone  4.56                         
107-87-9 2-Pentanone 4.61   557.96       27.73 26.39           
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S4b)               
CAS Ketones  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
431-03-8 2,3-Butanedione 4.61                         
108-10-1 Methyl isobutyl ketone 5.19 7.02 20.15         6.1           
591-78-6 2-Hexanone 5.21         3.29     2.65 3.4 5.38     
565-61-7 3-Methyl -2-pentanone  5.37   15.59         9.35   5.04 6.85     
600-14-6 2,3- Pentanedione 6.33 7.47   10.75     6.9   11.51 2.21   5.59   
105-42-0 4-Methyl- 2-hexanone  8.84                         
110-43-0 2-Heptanone 8.91 5.63 23.09   2.53 11.61   0.98 1.59 2.83   3.91   
110-93-0 6-Methyl -5-hepten-2-one  11.94 0.78 13 7.47 3.2   1.57 0.86           
 
S4c)                 
CAS Ketones  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
67-64-1 Acetone 2.61 211.47 240.61 78.31 43.06 73.78 356.22 286.22 103.38 56.55 110.4 340.88 185.94 37.79 20.18 
78-93-3 2-Butanone 3.37                             
563-80-4 3-Methyl -2-butanone  4.56                           2.89 
107-87-9 2-Pentanone 4.61   48.74 85.84                       
431-03-8 2,3-Butanedione 4.61         6.95 17.86                 
108-10-1 Methyl isobutyl ketone 5.19     2.54 4.53         5.31           
591-78-6 2-Hexanone 5.21 14.19                           
565-61-7 3-Methyl -2-pentanone  5.37 24.08                     1.46     
600-14-6 2,3,- Pentanedione 6.33 65.04 9.48         2.04   2.22           
105-42-0 4-Methyl -2-hexanone  8.84         1.58 0.99 3.91 1.47 2.69   1       
110-43-0 2-Heptanone 8.91 15.36 2.32 0.99                       
110-93-0 6-Methyl -5-hepten-2-one  11.94 3.27       1.54     1.81   2.17         
Table 3.21 section a, b, and c ketones found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
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S5a)               
CAS Acids  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
64-19-7 Ethanoic acid 14.11 36.5 49.85 39.26 84.42 29.61 27.56 29.65 184.72 83.28 60.75 56.5 61.11 
79-09-4 Propanoic acid 15.42        116.3 44.51 20.4 13.88 27.17 
79-31-2 2-Methylpropanoic acid 15.93 1.99 1.48 2.26 2.96 1.84 2.46 9.25 63.54 21.57 10.37 6.5 12.15 
107-92-6 Butanoic acid 16.82 17.25 13.78 18.45 46.21 18.42 12.8 25.93 322.75 133.6 60.27 44.23 78.16 
503-74-2 3-Methylbutanoic acid 17.33 8.63 10.39 11.6 10.3 10.31 10.46 19.8 110.89 39.97 18.27 17.16 32.86 
109-52-4 Pentanoic acid 18.40 2.19  4.54   4.04 14.06 89.51  12.82 13.84 20.04 
142-62-1 Hexanoic acid  19.77             
111-14-8 Heptanoic acid  21.23            3.71 
98-89-5 Cyclohexanecarboxylic acid 22.89        9.94     
65-85-0 Benzoic acid 27.00    25.97         
 
S5b)               
CAS Acids  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
64-19-7 Ethanoic acid 14.11 56.46 120.09 5.05 68.57  52.97 20.96 15.61   31.51 20.94 
79-09-4 Propanoic acid 15.42 20.73 34.6 8.38  8.3 15.66 4.93 2.89 1.61 3.98 3.22 3.44 
79-31-2 2-Methylpropanoic acid 15.93 9.67 11.61 3.24 11.81 6.15 12.07 3.41 2.14 0.75 2.29 1.26 2.11 
107-92-6 Butanoic acid 16.82 71.31 99.34 29.87 85.42 40.99 57.1 16.49 9.48 4.36 12.36 10.47 13.74 
503-74-2 3-Methylbutanoic acid 17.33 19.9 23.13 7.08 20.46 12.43 22.91 6.66 4.53  4.43 3 4 
109-52-4 Pentanoic acid 18.40 15.51 12.86 2.96 11.14 6.92 11.14 4.74 1.93  2.47 1.86  
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S5b)               
CAS Acids  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
142-62-1 Hexanoic acid  19.77             
111-14-8 Heptanoic acid  21.23     0.91        
98-89-5 Cyclohexanecarboxylic acid 22.89             
65-85-0 Benzoic acid 27.00             
 
S5c)                 
CAS Acids  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
64-19-7 Ethanoic acid 14.11  53.75  10.72 20.82 26.06 230.18 101.34 8.05 179.82 87.46 24.03 12.41 14.98 
79-09-4 Propanoic acid 15.42  12.27 14.99 3.32  5.56 94.61 30.23 30.4 74.44 32.75 5.37 2.67 3.09 
79-31-2 2-Methylpropanoic acid 15.93 92.22 3.49    2.81 71.8 21.83 16.47 30.53 15.91 2.84 2.24 1.59 
107-92-6 Butanoic acid 16.82 637.09 48.91 18.02 11.88 13.49 23 364.97 116.71 102.47 274.48 135.55 25.23 12.58 16.38 
503-74-2 3-Methylbutanoic acid 17.33 162.97 9.08    5.74 133.1 45.8 30.86 41.62 22.97 5.53 2.56 5.54 
109-52-4 Pentanoic acid 18.40  5.77   5.12 3.35 64.32 28.85 16.77 37.22 22.59 7.38 2.75 2.3 
142-62-1 Hexanoic acid  19.77       2.16 12.38 6.69 17.93 7.8  1.72  
111-14-8 Heptanoic acid  21.23   2.66    4.32        
98-89-5 Cyclohexanecarboxylic acid 22.89   1.43            
65-85-0 Benzoic acid 27.00               
Table 3.22 sections a, b, and c acid found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
S6a)               
CAS Nitrogen containing compounds  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
75-05-8 Acetonitrile 5.10 5.42 13.59 9.33      10.6 9.69 17.7  
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-2-aminobenzoate 15.63  12.59  1.18         
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S6a)               
CAS Nitrogen containing compounds  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
120-72-9 Indole 26.78 22.53 26.36 14.06 12.37 14.87 13.82 39.7 3.13     
83-34-1 3-Methylindole 27.27 16.84 27.74 19.94 12.67 20.08 7.09  0.5     
 
S6b)               
CAS Nitrogen containing compounds  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
75-05-8 Acetonitrile 5.10 5.01  12.58  3.55  3.85 3.7 5.9 4.44 9.5 2.89 
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-2-aminobenzoate 15.63  1.82  1.98         
120-72-9 Indole 26.78     17.61 40.36 18.46 6.19 5.89 6.72 5.88 8.99 
83-34-1 3-Methylindole 27.27     11.87 13.09 9.63 3.35 15.19 3.98 7.81 7.62 
 
S6c)                 
CAS 
Nitrogen containing 
compounds  
Retention 
time 
(mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
75-05-8 Acetonitrile 5.10  12.72 4.43 3.94 4.44 5.72 6.37 3.06   7.52 2   
7149-26-
0 
1,6-Octadien-3-ol, 3,7-
dimethyl-2-
aminobenzoate 
15.63   1.68            
120-72-9 Indole 26.78 20.56 31.73 7.11 12.9 71 14.5 21.78 19.25  13.5 9.8 18.1   
83-34-1 3-Methylindole 27.27 10.89 12.14 3.77 3.14 3.16 6.62 5.7 12.42       
Table 3.23 sections a, b, and c nitrogen containing compounds found in unmodified stool samples for all participants with retention time and chromatographic 
peak area. 
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S7a)               
CAS Sulphur compounds  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
75-18-3 Dimethyl sulphide 2.30 203.39 56.77 16.53  23.15 45.02 223.11 203.39 374.49 42.98 281.73 106.79 
624-92-0 Dimethyl disuphide 6.52 231.45 325.68 86.61 197.58 195.1 259.84 213.6 178.59 200.21 168.97 834.04 188.52 
5925-75-7 S-Methyl propanethioate  7.45 42.57 20.19 6.1 1.22 9.1 13.4  2 0.79 36.37   
23747-45-7 S-Methyl 3-methylbutanethioate 9.69             
2179-60-4 Methyl propyl disulphide 9.87 3.4  1.94  3.87   0.93   2.59  
1618-26-4 2,4-Dithiapentane 10.60           7.07  
57-06-7 Allyl isothiocyanate 12.32    13.45     6.97  5.42  
3658-80-8 Dimethyl trisulphide 12.65 9.41 17.77 4.59 9.3 9.92 9.62 14.5  3.81 2.17 52.99  
 
S7b)               
CAS Sulphur compounds  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
75-18-3 Dimethyl sulphide 2.30 16.7 17.12  55.47 24.21 238.77 37.98 44.42 19.91 165.05  32.7 
624-92-0 Dimethyl disulphide 6.52 296.83 516.85 224.59 362.51 166.39 566.67 484.93 200.35 212.21 237.7 200.09 604.71 
5925-75-7 S-Methyl propanethioate 7.45   5.73 10.85       13.79  
23747-45-7 S-Methyl 3-methylbutanethioate 9.69             
2179-60-4 Methyl propyl disulphide 9.87 1.58 2.99           
1618-26-4 2,4-Dithiapentane 10.60       0.54      
57-06-7 Allyl isothiocyanate 12.32 0.55 2.01  0.7  2.3 1.8     0.89 
3658-80-8 Dimethyl trisulfide 12.65 20.62 20.93 3 15.81 5.99 39.63 24.67 1.82 4.67 10.05 2.82 2.69 
 
S7c)                 
CAS Sulphur compounds  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
75-18-3 Dimethyl sulphide 2.30 8.79 282.86 20.75 28.7 57.14 81.34 34.74 137.39  46.26 65.97 129.46 350.25 18.64 
624-92-0 Dimethyl disuphide 6.52 491.65 412.1 23.49 197.74 488.56 183.41 762.2 267.79 117.79 136.73 464.7 496.07 196.26 71.58 
5925-75-7 S-Methyl propanethioate 7.45     1.45          
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S7c)                 
CAS Sulphur compounds  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
23747-45-7 S-Methyl 3-methylbutanethioate 9.69     3.57  18.2 2.08   1.8 1.6   
2179-60-4 Methyl propyl disulphide 9.87  3.02   4.78 1.34 1.77  0.84    0.51  
1618-26-4 2,4-Dithiapentane 10.60  1.13             
57-06-7 Allyl isothiocyanate 12.32 13.61 1.24  1.23           
3658-80-8 Dimethyl trisulfide 12.65 63.43 19.61 13.68 13.54 43.15 4.32 62.39 27.27  2.94 36.14 39.72 11.54 4.25 
Table 3.24 sections a, b, and c sulphur containing compounds found in unmodified stool samples for all participants with retention time and chromatographic 
peak area. 
S8a)               
CAS Miscellaneous Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
75-09-2 Dichloromethane 3.78 82.96 144.14 46.62      92.1    
1073-91-2 1,2,4,5- Tetroxane, 3,3,6,6-tetramethyl 4.63 18.86        13.29    
 
S8b)               
CAS Miscellaneous Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
75-09-2 Dichloromethane  3.78 73.89  77.16  227.47 92.56 68.45 151.42  117.81 148.9 95.33 
1073-91-2 1,2,4,5- Tetroxane, 3,3,6,6-tetramethyl 4.63   33.38          
 
S8c)                 
CAS Miscellaneous Retention time (mins) 25 26 27 28 3029 30 31 32 33 34 35 36 37 38 
75-09-2 Dichloromethane  3.78 97.01 92.4 107.9 55.36 44.6 130.81 83.48  44.97  95.41 84.58 31.43 20.89 
1073-91-2 1,2,4,5- Tetroxane, 3,3,6,6-tetramethyl 4.63            22.79   
Table 3.25 sections a, b, and c uncategorised compound found in unmodified stool samples for all participants with retention time and chromatographic peak 
area. 
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S9a)               
CAS Aromatic compounds  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-2-aminobenzoate 15.63  12.59  1.18         
140-67-0 Estragole 17.32             
108-95-2 Phenol 21.84 10.65 12.26 20.53 21.72 9.4 10.36 13.1 16.14 11.66 10.85 14.11 12.48 
106-44-5 4-Methylphenol 22.76 49.39 76.34 67.8 40.56 81.97 97.82 79.73 52.38 63.66 37.6 61.66 72.45 
120-72-9 Indole 26.78 22.53 26.36 14.06 12.37 14.87 13.82 39.7 3.13     
83-34-1 3-Methyl indole 27.27 16.84 27.74 19.94 12.67 20.08 7.09  0.5     
 
S9b)               
CAS Aromatic compounds  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-,2-aminobenzoate 15.63  1.82  1.98         
140-67-0 Estragole 17.32    4.39     2.38    
108-95-2 Phenol 21.84 5.33 5.27 4.94 5.18 4.2 5.79 6.03 3.94 3.39  15.67 10.76 
106-44-5 4-Methylphenol 22.76 84.54 97.97 112.53 55.98 47.26 144.16 102.33 72.75 65.4 97.56 91.74 114.85 
120-72-9 Indole 26.78     17.61 40.36 18.46 6.19 5.89 6.72 5.88 8.99 
83-34-1 3-Methylindole 27.27 
    
11.87 13.09 9.63 3.35 15.19 3.98 7.81 7.62 
 
S9c)                 
CAS Aromatic compounds  
Retention 
time (mins) 
25 26 27 28 29 30 31 32 33 34 35 36 37 38 
7149-26-
0 
1,6-Octadien-3-ol, 3,7-
dimethyl-,2-aminobenzoate 
15.63   1.68            
140-67-0 Estragole 17.32 
              
108-95-2 Phenol 
21.84 22.65 4.8 8.49 7.39 12.26 8.46 5.98 5.92 14.57 11.32 4.98 4.94 2.12 1.72 
106-44-5 4-Methylphenol 22.76 179.67 250.49 60.76 42.3 39.49 
 155.92 54.74 15.67 13.52 32.45 22.78 5.48 3.89 
120-72-9 Indole 26.78 20.56 31.73 7.11 12.9 71 14.5 21.78 19.25 
 13.5 9.8 18.1   
83-34-1 3-Methylindole 27.27 10.89 12.14 3.77 3.14 3.16 6.62 5.7 12.42 
      
 Table 3.26 sections a, b, and c aromatic compounds found in unmodified stool samples for all participants with retention time and chromatographic peak 
area. 
97 
 
S10a)              
Siloxanes  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Siloxane (1) 4.31    19.99         
Siloxane (2) 13.03  10.44 4.62  5.28 3.64 4.06 8.42 3.48 2.89 3.97  
Siloxane (3) 15.32 4.81 5.16 4.57 5.4 6.49 3.88 5.51  2.03 1.94 2.34  
 
S10b)              
Siloxanes  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
Siloxane (1) 4.31             
Siloxane (2) 13.03 1.48 2.94  4.09 1.62 2.61 2.43 0.92  2.89 1.97 1.31 
Siloxane (3) 15.32    1.08         
 
S10c)                
Siloxanes  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
Siloxane (1) 4.31               
Siloxane (2) 13.03 20.89 2.66 29.28   1.38 7.13 11.49 7.12 2.57  2.38 1.46  
Siloxane (3) 15.32 18.68   2.87           
Table 3.27 sections a, b, and c siloxanes found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
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S11a)              
Terpenes  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Terpene (1) 3.12 18.15        11.49 10.61  
 
Terpene (2) 4.13            
 
Terpene (3) 5.30            
 
Terpene (4) 5.52 60.25 187.79 27.85 21.87 44.69 27.29 28.09  18.77 113.72  
 
Terpene (5) 5.78            
 
Terpene (6) 6.39     8.39    12.39 4.15  
 
Terpene (7) 7.13 69.38 35.86 10.72 14.75 134.4 17.7 11.42 7.53 14.13 262.89  16.46 
Terpene (8) 7.37            
 
Terpene (9) 8.16     27.09 4.43 8.42 6.65  4.37 6.97 
 
Terpene (10) 8.42 13.47 531.5   10.12      1.8 
 
Terpene (11) 8.47         7   
 
Terpene (12) 9.16 81.61 15555.7 33.19 13.06 21.47 243.65 26.07 60.62 21.39 79.09 9.22 6.75 
Terpene (13) 9.34 6.68    4.89 5.8   4.38 9.65  
 
Terpene (14) 9.92            
 
Terpene (15) 10.16 27.03 11.71 22.36 6.54 79.37 5.37 2.21  4.1 114.69 1.24 
 
Terpene (16) 10.38  14.73          
 
Terpene (17) 10.63 13.3 42.15 14.48 3.27 32.28 10.11 3.14 1.9 3.27 132.89  
 
Terpene (18) 10.95  14.7   16.42       
 
Terpene (19) 13.69  63.44        0.8  
 
Terpene (20) 13.73   7.17         
 
Terpene (21) 14.56     2.07       
 
Terpene (22) 14.73  40.71 0.66  3.45 1.33 0.71   2.58  
 
Terpene (23) 15.47  4.6 4.52 7.8 3.62 3.41      
 
Terpene (24) 16.16 3.9           
 
Terpene (25) 16.35 15.42 27.56 3.8 5.09 27.95 7.87 6.64 1.87 4.79 29.53 3.31 
 
Terpene (26) 17.99     1.97       
 
Terpene (27) 18.12         6.66   
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S11a)              
Terpenes  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Terpene (28) 18.22 1.53           
 
Terpene (29) 20.71  33.18 7.86      10.91 6.86  
 
Terpene (29) 23.86  2.27 1.21 3.21    1.1   0.91 
 
Terpene (30) 24.64 
   
14.18 6.41  
      
 
S11b)              
Terpenes  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
Terpene (1) 3.12   34.48          
Terpene (2) 4.13             
Terpene (3) 5.30             
Terpene (4) 5.52  17.42           
Terpene (5) 5.78     106.26   126.39 67.9  97.28 150.86 
Terpene (6) 6.39             
Terpene (7) 7.13  60.76 11.9 171.24 30.42      38.37  
Terpene (8) 7.37             
Terpene (9) 8.16 1.37  4.62 9.99 66.92        
Terpene (10) 8.42 3.26  1.99 3.49 4.07        
Terpene (11) 8.47     0.79 13.37  0.49     
Terpene (12) 9.16 6.94  6.44 42.26 36.39 3.51  2.7 28.21  57.74  
Terpene (13) 9.34   2.05 3.63 1.1 0.88  3.74   3.24 2.59 
Terpene (14) 9.92             
Terpene (15) 10.16    84.68         
Terpene (16) 10.38     2.15       2.23 
Terpene (17) 10.63  21.08 1.22 28.48         
Terpene (18) 10.95  4.67   4.22 2.32 0.95     1.48 
Terpene (19) 13.69     39.61      0.39  
Terpene (20) 13.73             
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S11b)              
Terpenes  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
Terpene (21) 14.56         1.1    
Terpene (22) 14.73   1.3 1.07 2.85      1.25  
Terpene (23) 15.47    25.27         
Terpene (24) 16.16             
Terpene (25) 16.35 1.84 3.8 10.77 4.62 3.19 2.81 1.44  0.99   1.28 
Terpene (26) 17.99             
Terpene (27) 18.12  3.22 4.81     0.45     
Terpene (28) 18.22  28.78 2.73         2.63 
Terpene (29) 20.71             
Terpene (29) 23.86             
Terpene (30) 24.64             
 
S11c)                
Terpenes  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
Terpene (1) 3.12               
Terpene (2) 4.13     4.25          
Terpene (3) 5.30      1.57  3.19  14.17  1.02   
Terpene (4) 5.52   7.23  12.62 27.49  21.48 14.43      
Terpene (5) 5.78   47.1   103.61         
Terpene (6) 6.39     5.39 7.25    18.53     
Terpene (7) 7.13 16.09 3.39 2.91 1.52 3.59 4.83  17.83 5.59 2.12  3.23 1.38  
Terpene (8) 7.37      2.65  4.2 3.91 2.65     
Terpene (9) 8.16 16.58    4.72 2.54  45.33 14.67    3.74  
Terpene (10) 8.42     2.84 0.75   2.91    0.76  
Terpene (11) 8.47  8.03      2.01       
Terpene (12) 9.16 53.23 4.56 6.7  10.97 26.35 2.76 23.68 7.94 287.27 1.34 4.17 5.28 0.74 
Terpene (13) 9.34 1.2 2   22.72 2.67  2.05 1.38 13.76     
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S11c)                
Terpenes  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
Terpene (14) 9.92     3.84   1.18       
Terpene (15) 10.16     1.67 5.04       0.48  
Terpene (16) 10.38 43.96              
Terpene (17) 10.63     6.12 1.89   2.49      
Terpene (18) 10.95 2.49 2.5  3.15  2.97     2.55    
Terpene (19) 13.69    3.97      0.72     
Terpene (20) 13.73               
Terpene (21) 14.56  2.5 0.77            
Terpene (22) 14.73  1.17             
Terpene (23) 15.47   4.76  7.02          
Terpene (24) 16.16               
Terpene (25) 16.35 3.85 4.7  5.37 4.53 7.08  2.37 1.75   2   
Terpene (26) 17.99               
Terpene (27) 18.12 100.88     1.56         
Terpene (28) 18.22   1.77            
Terpene (29) 20.71  26.1  5.52 13.81 17.34  0.89 1.07      
Terpene (29) 23.86          1.15     
Terpene (30) 24.64               
Table 3.28 sections a, b, and c terpenes found in unmodified stool samples for all participants with retention time and chromatographic peak area. 
S12a)              
Unidentified  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Unidentified (1) 3.46  954.93          1149.81 
Unidentified (2) 3.81    103.68   111.2 122.12  47.91 73.41  
Unidentified (3) 4.38             
Unidentified (4) 5.19   10.58  13.99        
Unidentified (5) 5.37   10.07  5.87     9.93   
Unidentified (6) 5.84 10.02 116.36 88.28 160.57       114.57  
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S12a)              
Unidentified  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Unidentified (7) 5.87     97.72 186.13 175.49 144.23  66.06   
Unidentified (8) 6.04             
Unidentified (9) 6.23        12.49    55.16 
Unidentified (10) 6.36 3.38 6.95  6.61    0.8     
Unidentified (11) 6.67             
Unidentified (12) 6.92  13.3           
Unidentified (13) 7.60 2.27 6.74           
Unidentified (14) 7.91 5.42         1.72 6.18  
Unidentified (15) 9.58       3.37      
Unidentified (16) 10.43           5.88  
Unidentified (17) 10.53             
Unidentified (18) 11.26 2.03      5.05 2.97   1.67  
Unidentified (19) 12.04           3.82  
Unidentified (20) 12.29             
Unidentified (21) 13.31        2.82     
Unidentified (22) 13.35       1.31      
Unidentified (21) 15.02        5.04    17.57 
Unidentified (22) 17.58     1.27        
Unidentified (23) 17.75     5.47     1.82 1.18  
Unidentified (24) 19.86             
Unidentified (25) 20.31 4.41 7.07 3.5  62.59        
Unidentified (26) 20.82        2.73     
Unidentified (27) 21.22      2.19 3.4 6.69 4.54 2.32   
Unidentified (28) 21.56      2.62 2.2 3.18 2.22    
Unidentified (29) 21.99 13.55 7.47           
Unidentified (30) 25.61      8.1       
Unidentified (31) 25.88 12.58 10.95 10.14  5.53        
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S12a)              
Unidentified  Retention time (mins) 1 2 3 4 5 6 7 8 9 10 11 12 
Unidentified (32) 26.97     18.77 7.7       
 
S12b)              
Unidentified  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
Unidentified (1) 3.46             
Unidentified (2) 3.81  85.19   97.28    151.12    
Unidentified (3) 4.38             
Unidentified (4) 5.19     7.92   4.68  11.4 14.33  
Unidentified (5) 5.37 11.82            
Unidentified (6) 5.84  74.7           
Unidentified (7) 5.87             
Unidentified (8) 6.04             
Unidentified (9) 6.23             
Unidentified (10) 6.36  12.36  2.82         
Unidentified (11) 6.67      9.8 4.9 9.34 4.53  24.08 14.01 
Unidentified (12) 6.92             
Unidentified (13) 7.60       5.83     5.34 
Unidentified (14) 7.91             
Unidentified (15) 9.58            1.07 
Unidentified (16) 10.43 2.11 2.64 6.62 1.89  2.14 3.02 1.47 1.28 1.79 1.83  
Unidentified (17) 10.53      6.09  0.79    1.19 
Unidentified (18) 11.26 0.48 1.19  0.97  1.14       
Unidentified (19) 12.04 1.36 0.77  1.58         
Unidentified (20) 12.29             
Unidentified (21) 13.31             
Unidentified (22) 13.35 1.17            
Unidentified (21) 15.02  1.35 3.12   2.41 1.2 0.64  0.8   
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S12b)              
Unidentified  Retention time (mins) 13 14 15 16 17 18 19 20 21 22 23 24 
Unidentified (22) 17.58             
Unidentified (23) 17.75   2.49          
Unidentified (24) 19.86             
Unidentified (25) 20.31      1.2       
Unidentified (26) 20.82    1.88     23.07 23.97   
Unidentified (27) 21.22 1.47 1.34           
Unidentified (28) 21.56             
Unidentified (29) 21.99             
Unidentified (30) 25.61             
Unidentified (31) 25.88             
Unidentified (32) 26.97           6.64  
 
S12c)                
Unidentified  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
Unidentified (1) 3.46               
Unidentified (2) 3.81               
Unidentified (3) 4.38       2.33        
Unidentified (4) 5.19               
Unidentified (5) 5.37   2.76      2.76      
Unidentified (6) 5.84     138.32  206.48    237.85   21.89 
Unidentified (7) 5.87               
Unidentified (8) 6.04          7023.54     
Unidentified (9) 6.23               
Unidentified (10) 6.36               
Unidentified (11) 6.67  10.06    2.14 11.77   7.02  2.7   
Unidentified (12) 6.92               
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S12c)                
Unidentified  Retention time (mins) 25 26 27 28 29 30 31 32 33 34 35 36 37 38 
Unidentified (13) 7.60  2.27    4.42         
Unidentified (14) 7.91 365.96    0.86       0.78   
Unidentified (15) 9.58 419.43              
Unidentified (16) 10.43 3.52  5.45        2    
Unidentified (17) 10.53 12.84   1.44    6.49       
Unidentified (18) 11.26 1.41   0.26   3.89       0.5 
Unidentified (19) 12.04             0.5  
Unidentified (20) 12.29     1.86          
Unidentified (21) 13.31     0.53          
Unidentified (22) 13.35 13.55    0.62   5.1       
Unidentified (21) 15.02 16.88      3.1        
Unidentified (22) 17.58   9.13  2.08          
Unidentified (23) 17.75   0.51            
Unidentified (24) 19.86              1.22 
Unidentified (25) 20.31      3.88         
Unidentified (26) 20.82   8.81            
Unidentified (27) 21.22               
Unidentified (28) 21.56   3.96            
Unidentified (29) 21.99               
Unidentified (30) 25.61   0.31         1.72   
Unidentified (31) 25.88   2.02            
Unidentified (32) 26.97    0.51           
Table 3.29 sections a, b, and c unidentified compounds found in unmodified stool samples for all participants, with retention time and chromatographic peak 
area. 
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
75-07-0 Acetaldehyde 2.16 788     
123-38-6 Propionaldehyde 2.43 804 801    
123-72-8 Butyraldehyde 3.1 882 878    
66-25-1 Hexanaldehyde 6.76 1087 1080    
100-52-7 Benzaldehyde 15.05 1513 1528    
55012-32-3 Isopropyl benzaldehyde (cuminaldehyde) 18.91 1782  1784.1   
64-17-5 Ethanol 3.91 938 932    
78-92-2 2-Butanol 5.64 1027 1035    
71-23-8 1-Propanol 5.92 1043 1052    
78-83-1 2-Methyl-1-propanol 7.27 1112  1089.3*   
6032-29-7 2-Pentanol 7.83 1137 1142    
71-36-3 1-Butanol 8.29 1157 1152    
123-51-3 3-Methyl -1-butanol 9.51 1203 1215    
108-11-2 4-Methyl -2-pentanol 9.78 1218     
71-41-0 1-Pentanol 10.35 1248 1256    
626-89-1 4-Methyl -1-pentanol 11.55 1306     
543-49-7 2-Heptanol 11.59 1308  1315.3   
2313-61-3 4-Methyl -2-hexanol 11.66 1313     
111-27-3 1-Hexanol 12.24 1346 1354    
123-96-6 2-Octanol 13.4 1409     
3391-86-4 1-Octen-3-ol 13.9 1442 1456   yes 
111-70-6 1-Heptanol 13.99 1448 1460    
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
104-76-7 2-Ethyl-1-hexanol 14.49 1479 1492    
111-87-5 1-Octanol 15.64 1552 1561    
15356-70-4 Cyclohexanol, 5methyl-2-(1-methylethyl)-,(1a,2b,5a) 16.9 1631  1630.4   
        
79-20-9 Ethanoic acid, methyl ester 2.69 846 828    
141-78-6 Ethanoic acid ethyl ester 3.21 890 893    
105-37-3 Propanoic acid ethyl ester 4.28 958     
97-62-1 2-Methylpropanoic acid ethyl ester 4.44 966 960    
109-60-4 Ethanoic acid propyl ester 4.6 974 976    
623-42-7 Butanoic acid methyl ester 4.79 982 982    
868-57-5 2-Methylbutanoic acid methyl ester 5.28 1003     
556-24-1 3-Methylbutanoic acid methyl ester 5.49 1017 1024    
105-54-4 Butanoic acid ethyl ester 5.87 1040 1040    
106-36-5 Propanoic acid propyl ester 6.04 1050 1056    
7452-79-1 2-Methylbutanoic acid ethyl ester 6.21 1060     
123-86-4 Ethanoic acid butyl ester 6.61 1080 1077    
624-24-8 Pentanoic acid methyl ester 6.87 1093 1087    
105-66-8 Butanoic acid propyl ester 7.64 1129 1123    
539-82-2 Pentanoic acid ethyl ester 7.92 1141 1138    
590-01-2 Propanoic acid butyl ester 8.06 1147     
97-87-0 Propanoic acid 2-methylbutyl ester 8.18 1152 1154    
539-90-2 Butanoic acid 2-methylpropyl ester 8.45 1163 1152    
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
628-63-7 Aethanoic  acid pentyl ester 8.68 1172 1180    
123-92-2 Ethanoic acid 3-methylbutanyl ester 8.75 1175 1125    
106-70-7 Hexanoic acid methyl ester 9.01 1184 1190    
109-21-7 Butanoic acid butyl ester 9.68 1212 1223    
141-06-0 Pentanoic acid propyl ester 9.73 1215   1233 Peng et al..  
123-66-0 Hexanoic acid ethyl ester 9.99 1229 1238    
624-54-4 Propanoic acid pentyl ester 10.12 1236 1239    
109-19-3 3 -Methylbutanoic acid butyl ester 10.29 1244     
106-27-4 Butanoic acid 3-methylbutyl ester 10.6 1260 1267    
142-92-7 Ethanoic acid hexyl ester 10.73 1266 1269    
106-73-0 Heptanoic acid methyl ester 11.02 1280 1288    
591-68-4 Pentanoic acid butyl ester 11.5 1303     
5870-93-9 Butanoic acid heptyl ester 11.51 1304     
626-77-7 Hexanoic acid propyl ester 11.63 1311 1324    
106-30-9 Heptanoic acid ethyl ester 11.88 1325 1331    
4630-82-4 Cyclohexane carboxylic acid methyl ester 12.71 1371     
111-11-5 Octanoic acid methyl ester 12.82 1377 1387    
626-82-4 Hexanoic acid butyl ester 13.3 1403 1420    
108-64-5 3-Methylbutanoic acid ethyl ester 6.48 1074     
5870-93-9 Butanoic acid heptyl ester 11.51 1304     
3289-28-9 Cyclohexanecarboxylic acid ethyl ester 13.42 1411     
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
67-64-1 Acetone 2.61 814 814   yes 
78-93-3 2-Butanone 3.37 901 901    
563-80-4 3-Methyl 2-butanone 4.56 972     
107-87-9 2-Pentanone 4.61 974 980    
431-03-8 2,3-Butanedione 4.61 974 986    
108-10-1 Methyl isobutyl ketone 5.19 998 1008    
591-78-6 2-Hexanone 5.21 999     
565-61-7 3-Methyl 2-pentanone 5.37 1009     
600-14-6 2,3- Pentanedione 6.33 1066 1071    
105-42-0 4-Methyl 2-hexanone 8.84 1178     
110-43-0 2-Heptanone 8.91 1180 1185    
110-93-0 6-Methyl -5-hepten-2-one 11.94 1329 1340    
        
107-92-6 Butanoic acid 16.82 1626 1630   yes 
109-52-4 Pentanoic acid 18.4 1737    yes 
142-62-1 Hexanoic acid 19.77 1854     
503-74-2 3-Methylbutanoic acid 17.33 1659    yes 
64-19-7 Ethanoic acid 14.11 1455 1480    
65-85-0 Benzoic acid 27 2266     
79-09-4 Propanoic acid 15.42 1538 1554    
79-31-2 2-Methylpropanoic acid 15.93 1570     
111-14-8 Heptanoic acid 21.23 1972     
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
98-89-5 Cyclohexanecarboxylic acid 22.89 2081     
        
75-50-3 Trimethylamine 1.95 775    yes 
124-40-3 Dimethylamine 3.19 889     
75-05-8 Acetonitrile 5.1 995     
926-64-7 Acetonitrile (dimethylamino) 10.02 1230   1243 (Pub Chem)  
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-2-aminobenzoate 15.63 1551     
120-72-9 Indole 26.78 2253    yes 
83-34-1 3-Methylindole 27.27 2282    yes 
        
75-18-3 Dimethyl sulphide 2.3 795    yes 
624-92-0 Dimethyl disuphide 6.52 1076 1075   yes 
5925-75-7 S-Methyl propanethioate 7.45 1121     
23747-45-7 S-Methyl 3-methylbutanethioate 9.69 1213     
2179-60-4 Methyl propyl disulphide 9.87 1223     
1618-26-4 2,4-Dithiapentane 10.6 1260   1260 (Shluter et al.)  
57-06-7 Allyl isothiocyanate 12.32 1350 1372    
3658-80-8 Dimethyl trisulphide 12.65 1368 1383 1376.2  yes 
        
75-09-2 Dichloromethane 3.78 930     
1073-91-2 1,2,4,5- Tetroxane, 3,3,6,6-tetramethyl 4.63 975     
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
7149-26-0 1,6-Octadien-3-ol, 3,7-dimethyl-2-aminobenzoate 15.63 1551     
140-67-0 Estragole 17.32 1658     
108-95-2 Phenol 21.84 1959     
106-44-5 4-Methylphenol 22.76 2014     
120-72-9 Indole 26.78 2253    yes 
83-34-1 3-Methyl indole 27.27 2282    yes 
        
 Terpene (1) 3.12 884     
 Terpene (2) 4.13 950     
 Terpene (3) 5.3 1005     
 Terpene (4) 5.52 1019     
 Terpene (5) 5.78 1035     
 Terpene (6) 6.39 1069     
 Terpene (7) 7.13 1105     
 Terpene (8) 7.37 1117     
 Terpene (9) 8.16 1151     
 Terpene (10) 8.42 1162     
 Terpene (11) 8.47 1164     
 Terpene (12) 9.16 1190     
 Terpene (13) 9.34 1196     
 Terpene (14) 9.92 1225     
 Terpene (15) 10.16 1238     
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
 Terpene (16) 10.38 1249     
 Terpene (17) 10.63 1261     
 Terpene (18) 10.95 1277     
 Terpene (19) 13.69 1428     
 Terpene (20) 13.73 1431     
 Terpene (21) 14.56 1483     
 Terpene (22) 14.73 1493     
 Terpene (23) 15.47 1541     
 Terpene (24) 16.16 1584     
 Terpene (25) 16.35 1595     
 Terpene (26) 17.99 1700     
 Terpene (27) 18.12 1712     
 Terpene (28) 18.22 1721     
 Terpene (29) 20.71 1929     
 Terpene (29) 23.86 2079     
 Terpene (30) 24.64 2125     
        
 Unidentified (1) 3.46 908     
 Unidentified (2) 3.81 931     
 Unidentified (3) 4.38 963     
 Unidentified (4) 5.19 998     
 Unidentified (5) 5.37 1009     
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CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
 Unidentified (6) 5.84 1039     
 Unidentified (7) 5.87 1040     
 Unidentified (8) 6.04 1050     
 Unidentified (9) 6.23 1061     
 Unidentified (10) 6.36 1068     
 Unidentified (11) 6.67 1083     
 Unidentified (12) 6.92 1095     
 Unidentified (13) 7.6 1127     
 Unidentified (14) 7.91 1141     
 Unidentified (15) 9.58 1207     
 Unidentified (16) 10.43 1252     
 Unidentified (17) 10.53 1257     
 Unidentified (18) 11.26 1291     
 Unidentified (19) 12.04 1334     
 Unidentified (20) 12.29 1349     
 Unidentified (21) 13.31 1403     
 Unidentified (22) 13.35 1406     
 Unidentified (21) 15.02 1512     
 Unidentified (22) 17.58 1675     
 Unidentified (23) 17.75 1685     
 Unidentified (24) 19.86 1861     
 Unidentified (25) 20.31 1896     
114 
 
CAS Compound name 
RT 
(mins) 
RI exp 
(KI) 
RI lit [A]   
(F. Bianchi et al.. 
2007) 
RI lit [B] 
(V.I. Babushok et al.. 
2011) 
RI lit other source 
[Ref] 
Confirmed by 
Standard 
 Unidentified (26) 20.82 1938     
 Unidentified (27) 21.22 1971     
 Unidentified (28) 21.56 1998     
 Unidentified (29) 21.99 2010     
 Unidentified (30) 25.61 2183     
 Unidentified (31) 25.88 2199     
 Unidentified (32) 26.97 2264     
        
Table 3.30 shows the retention indices calculated from the experimental data and where possible compared to available literature retention indices for PEG 
based polar columns. [A] F. Bianchi et al. J. Sep. Sci. 2007, 30, 563-572 [B] V.I. Babushok et al. J. Phys. Chem. Ref. Data, Vol. 40, No. 4, 2011, 043101-1, 
C.T.Peng et al.., J. Chromatogr., 1991, 586, 1, 85-112, S. Schlüter et al.., J. Agric. Food Chem., 1999, 47, 12, 5146-5150 
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3.3.2 Quantitative data from unaltered stools 
Table 3.31 shows the mean and standard deviation for each compound in nanograms 
per gram of stool for all samples. The raw data for each individual sample can be found 
in Table 3.32 Table 3.31 also shows the mean concentration (ng/g) and standard 
deviation for each compound separated by samples of UK and South American origin, 
as these were the two largest groups. 
 Origin 
Number of 
Samples 
Number of Times 
Detected 
Median 
(ng/g) 
Inter. Range 
(ng/g) 
Range 
(ng/g) 
 
Dimethyl sulphide 
CAS 75-18-3 
Total 38 37 1682 4999 25–25626  
UK 16 16 1058 4124 26–8637  
South 
America 
11 10 1644 3719 621– 8079  
Acetone 
CAS 67-64-1 
Total 38 38 1874 925 442– 3005  
UK 16 16 1227 743 442– 2521  
South 
America 
11 11 1768 641 819– 2377  
Ethyl butanoate 
CAS 105-54-4 
Total 38 21 290 1097 39–2468  
UK 16 14 152 287 39–2468  
South 
America 
11 3 393 355 118–828  
Ethyl 2-
methylbutanoate 
CAS 7452-79-1 
Total 38 12 13 10 0.34–180  
UK 16 10 11 11 0.3–180  
South 
America 
11 2 26 17 9–42  
Dimethyl disulphide 
CAS 624-92-0 
Total 38 38 513 890 35–1302  
UK 16 16 228 282 48–864  
South 
America 
11 11 374 755 36–1313  
1-Octen-3-one 
CAS 4312-99-6 
Total 38 1 12 0 12  
UK 16 1 12 0 12  
South 
America 
11 0 0 0 
Not 
detected 
 
Dimethyl trisulphide 
CAS 3658-80-8 
Total 38 38 105 289 10–409  
UK 16 16 61 95 10–253  
South 
America 
11 11 143 168 13–364  
1-Octen-3-ol 
CAS 3391-86-4 
Total 38 13 3 33 0.4–58  
UK 16 10 8 30 1–58  
South 
America 
11 3 1 1 0.4–2  
Ethanoic acid 
CAS 64-19-7 
Total 38 38 9455 2519 672–12963  
UK 16 16 7849 2889 672–11343  
South 
America 
11 11 9250 1253 
7968–
12963 
 
Butanoic acid 
CAS 107-92-6 
Total 38 38 8200 4661 
2493–
11553 
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UK 16 16 6673 3592 2493–8376  
South 
America 
11 11 8633 855 7043–9953  
3-Methylbutanoic acid 
CAS 503-74-2 
Total 38 36 3878 3807 63–8262  
UK 16 16 1033 1824 64–3602  
South 
America 
11 10 4785 4097 220–6885  
Pentanoic acid  
CAS 109-52-4 
Total 38 37 4516 5149 88–21886  
UK 16 16 1437 2345 88–5970  
South 
America 
11 11 6712 5896 946–21886  
Indole 
CAS 120-72-9 
Total 38 38 4495 2076 290–5477  
UK 16 16 3079 924 1508–4309  
South 
America 
11 11 4232 847 3286–5477  
3-Methyl-1H-indole 
CAS 83-34-1 
Total 38 38 1062 654 37–3483  
UK 16 16 1146 1092 425–3054  
South 
America 
11 11 1485 558 636–3483  
Trimethylamine 
CAS 75-50-3 
Total 15 15 161 108 40–920.5  
Table 3.31 the mean concentration (ng/g) and standard deviation for compounds quantified from the 
stool of healthy participants using GC-MS. The mean concentration (ng/g) and S.D. of each 
compound from the UK and South American participants has also been compared.
117 
 
 
Sample Diet Origin Dimethyl 
Sulphide 
Acetone Butanoic 
acid, ethyl 
ester 
2-Methyl-
butanoic acid, 
ethyl 
Dimethyl 
disulphide 
1-
Octen-
3-one 
Dimethyl 
Trisulphide 
1-
Octen-
3-ol 
Ethanoic 
acid 
Butanoic 
acid 
3-
Methylbutanoic 
acid 
Pentanoic 
acid 
Indole 3-
methyl 
indole 
Trimethyl 
amine 
1 Veg UK 5238.15 598.82 0 0 148.61 11.88 43.95 35.07 4297.67 2492.6 63.56 88.3 2213.48 626.3 180.94 
2 Meat UK 916.89 1478.2 40.47 0 285.53 0 89.11 58.2 4989.53 2681.27 642.62 816.26 2342.28 830.68 132.49 
3 Veg UK 1328.85 1844.24 175.28 13.47 222.07 0 76.82 26.05 6193.06 2785.31 826.22 1113.08 2862.26 726.45 304.47 
4 Veg UK 153.99 1098.05 39.28 0.34 118.12 0 52.36 38.05 9030 4103.38 1074.09 1760.06 1508.71 670.22   
5 Veg UK 502.9 1539.91 39.33 0.84 233.34 0 68.58 12.27 6953.33 4177.96 422.29 734.63 1862.04 1040.24 163.22 
6 Meat UK 669.77 2222.98 311.08 16.6 245.71 0 53.77 3.03 672 3328.19 991.47 1010.12 2500.71 585.03   
7 Meat UK 8088.71 2198.58 339.64 18.1 295.84 0 119.51 2.37 6087.5 5548.11 2295.07 2380.76 2910.77 425.42 920.5 
8 Meat UK 5408.83 869.02 264.7 8.14 75.94 0 30.22 2.7 9146.98 7427.16 3602.64 5970.98 3318.1 677.29   
9 Veg UK 8636.56 1356.9 0 0 91.31 0 19.23 0 11343.44 8228.25 406.55 558.75 4309.01 1251.73   
10 Veg UK 1199.38 1494.35 43.41 4.66 48.47 0 10.83 0 8830 7700.68 372.04 565.21 3278.59 1629.85   
11 Meat UK 4368.62 697.32 129.1 8.29 863.74 0 253.34 1.08 7236.49 6463.85 1927.86 2984.45 3247.19 3054   
12 Veg UK 91.42 442.04 1659.32 0 52.95 0 22.66 0 8685.19 7331.51 2224.45 3531.9 2698.7 2185.55   
13 Veg UK 565.56 874.6 1166.05 0 590.75 0 183.08 1.83 7007.78 7496.09 2506.21 4943.48 3577.83 1529.18   
14 Meat UK 341.06 2520.59 69.78 15.41 725.96 0 135.15 0 10337.8 8376.46 366.05 730.37 4127.2 1457.4   
15 Meat UK 25.8 1049.61 53.49 0 62.03 0 10.15 0 9133.87 6881.94 1707.53 2708.97 3961.73 2583.96   
16 Meat UK 2055.58 1086.78 2468.23 179.98 755.98 0 141.86 0 8462.22 7518.38 2386.87 3360.7 3320.22 2180.09   
17 Meat South America 746.73 2376.78 0 0 315.09 0 62.65 0.42 9434.78 9009.96 3084.57 4667.99 4313.84 1485.49 175.92 
18 Meat South America 6961.49 819.28 828.15 42.43 1012.95 0 315.66 0 9154.69 9363.66 0 6012.64 4756.23 1472.41 185.18 
19 Meat South America 1333.53 1011.08 0 0 957.42 0 207.74 1.23 7967.65 8624.19 5645.87 21886 4443.32 2561.2   
20 Meat South America 1910.67 2048.95 0 0 373.75 0 199.6 0 8137.5 8632.79 575.85 946.12 3836.98 1085.39   
21 Meat South America 621.54 1369.21 0 0 145.66 0 30.67 0 10750 8153.84 220.33 3015.06 3286.3 1646.75   
22 Meat South America 5311.77 1440.22 0 0 355.64 0 91.73 0 9250 8547.05 5508.16 9259.46 3465.66 1162.92 5311.77 
23 Meat South America 0 1993.51 0 0 36.04 0 12.65 0 10519.44 8157.61 716.06 1117.26 4232.06 3483.23 351.83 
24 Meat South America 1376.92 1768.06 0 0 1302.92 0 241.31 0 9611.54 9050.63 6885.2 11172.57 3701.86 2103.59 104.16 
25 Meat South America 1294.29 1347.73 392.53 8.98 121.09 0 50.73 0 12963.32 7042.55 4838.42 6711.54 4677.54 1622.99 158.33 
26 Veg South America 8078.67 2000.63 0 0 712.09 0 142.55 2.22 8686.36 9953.48 5095.05 10216.02 5477.47 1479.56 39.88 
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Sample Diet Origin Dimethyl 
Sulphide 
Acetone Butanoic 
acid, ethyl 
ester 
2-Methyl-
butanoic acid, 
ethyl 
Dimethyl 
disulphide 
1-
Octen-
3-one 
Dimethyl 
Trisulphide 
1-
Octen-
3-ol 
Ethanoic 
acid 
Butanoic 
acid 
3-
Methylbutanoic 
acid 
Pentanoic 
acid 
Indole 3-
methyl 
indole 
Trimethyl 
amine 
27 Veg Africa 611.89 1370.4 0 0 619.84 0 162.57 0 9590 9784.61 1836.05 2015.14 4776.4 1389.45   
28 Meat Asia 613.44 453.09 1770.12 0 98.52 0 36.1 0 9975 8838.37 0 0 5050.3 956.18   
29 Veg Africa 2704.33 2287.17 0 0 227.25 0 33.37 0 9203.51 9344.76 5220.03 6311.4 4543.73 2267.31   
30 Meat Europe 1532.28 785.92 0 0 963.02 0 319.58 0 7670.83 4368.24 8262.24 13774.4 5070.29 790.31   
31 Meat Africa 579.1 2156.48 0 0 1137.74 0 409.57 0 9670.6 7391.69 4914.36 4364.38 4714.12 1085.59   
32 Meat Africa 5747.89 1747.46 2333.28 0 828.49 0 286.25 0 9475.73 9324.14 3606.73 3163.39 4117.27 774.76   
33 Veg Asia 124.57 957.07 290.43 0 37.16 0 15.66 0 9763.67 8923.94 3558.52 3050.35 4586.6 686.74   
34 Meat Asia 1546.13 1845.72 859.88 0 35.01 0 14.89 0 9982.29 8872.95 4098.55 5810.87 4605 403.99 545.95 
35 Meat Asia 2070.65 3005.62 0 0 1189.27 0 362.32 0 9984.12 9632.85 4149.28 5829.42 4782.7 993.61   
36 Meat South America 4157.13 1998.93 118.41 0 1084.08 0 364.48 0 8937.71 9604.83 4732.02 7429.37 3725.53 636.13   
37 Veg Europe 25626.1 1101.97 0 0 1058.28 0 199.02 0 12233.44 10448.77 3041.42 3295.83 289.94 37.25 55.35 
38 Veg Europe 3689.88 1028.97 0 0 809.81 0 162.32 0 11374.26 11552.97 5821.2 5532.56 4770.44 717.13 119.94 
Table 3.32 raw data of concentrations of a range of stool compounds, in ng/g, calculated by adding 13 C labelled internal standards to stool samples and analysing the 
headspace using automated thermal desorption gas chromatography mass spectrometry.
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3.3.3 UK samples versus South American samples 
Mann Whitney U tests revealed six compounds to be significantly different between 
UK and South American samples, and these are shown in Table 3.33. 
 
Compound Sig. 
Ethyl butanoate 0.023 
1-Octen-3-ol 0.034 
Ethanoic acid 0.011 
Butanoic acid 0.000 
Pentanoic acid 0.001 
Indole 0.000 
Table 3.33 statistical analyses showing significant differences (95% significance level) for six 
compounds using Mann Whitney U tests to determine differences in the quantities of compounds 
measured in stool from UK and South American participants. 
Discriminant analysis using stepwise statistics (Wilks’ Lambda) calculated butanoic 
acid and ethyl butanoate as being the two significant grouping variables.  
Figure 3.19 shows a plot of the discriminant scores versus country of origin. There is 
a clear difference between the groups, with the South American sample set having a 
smaller range of scores versus the UK samples. This demonstrates that, with the 
exception of the outliers, the two means are very well separated. Figure 3.20 shows 
the resultant receiver operator curve (ROC) from the calculated discriminant scores; 
the area under the curve was 0.937 with a standard error of 0.044. This shows close 
to perfect separation of the U.K. and South American samples based on differences 
in the concentration of butanoic acid and ethyl butanoate. These two compounds alone 
can predict group membership. Figures 3.21 and 3.22 show the box plots for the 
masses of ethyl butanoate and butanoic acid respectively. Butanoic acid provides the 
better separation of the of UK and South American samples as a single variable (see 
Figure 3.22) however, the addition of ethyl butanoate into the model adds an extra 
level of differentiation (as in Figure 3.19). Figure 3.21 shows that the majority of 
samples fall into a relatively narrow band with only 5 outliers from the whole sample 
set. Figure 3.22 shows that in the South American samples the level of butanoic acid 
has a small range at a higher average versus the UK samples which have a wider 
range with a significantly lower average mass.  
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Figure 3.19 discriminant scores’ box plots showing the differentiation between UK and South 
American stool samples (Wilks’ Lambda analysis showed butanoic acid and ethyl butanoate to be the 
significant grouping variables). 
 
Figure 3.20 ROC curve based on leave-one-out cross validation discriminant scores, using butanoic 
acid and ethyl butanoate for different UK and South American stool samples. 
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Figure 3.21 box plot of ethyl butanoate ng/g for UK versus South American participants 
 
Figure 3.22 box plot of butanoic acid ng/g for UK versus South American participants 
3.3.4 Omnivore versus vegetarian 
The same series of statistical tests were carried out comparing vegetarians and 
omnivores; Table 3.34 shows the mean concentration (ng/g) and standard deviation 
for each compound. However, in this instance, there was no statistically significant 
differences in those compounds analysed. Discriminant analysis using stepwise 
statistics (Wilks’ Lambda) calculated that the most significantly different compound 
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was dimethyl trisulphide with a p = 0.055. The discriminant scores for this compound 
measured in the omnivore and vegetarian groups are plotted in Figure 3.23. While the 
range of discriminant scores is wider for omnivore participants, the two groups 
completely overlap, illustrating the lack of any significant difference between the two 
groups. 
 Diet 
Number of 
Samples 
Number of Times 
Detected 
Median 
(ng/g) 
Inter. Range 
(ng/g) 
Range 
(ng/g) 
Dimethyl sulphide 
75-18-3 
Vegetarian 14 14 1264 4333 91–25626 
Omnivore 24 23 1532 3555 26–8089 
Acetone 
CAS 67-64-1 
Vegetarian 14 14 1229 553 442–2287 
Omnivore 24 24 1613 1036 453–3006 
Ethyl butanoate 
CAS 105-54-4 
Vegetarian 14 7 175 687 39–1659 
Omnivore 24 14 325 731 40–2468 
Ethyl 2-
methylbutanoate 
CAS 7452-79-1 
Vegetarian 14 4 3 6 0.3–13 
Omnivore 24 8 16 15 8–180 
Dimethyl disulphide 
CAS 624-92-0 
Vegetarian 14 14 225 225 37–1058 
Omnivore 24 24 365 365 35–1303 
1-Octen-3-one 
CAS 4312-99-6 
Vegetarian 14 1 12 12 12 
Omnivore 24 0 0 0 
Not 
detected 
Dimethyl trisulphide 
CAS 3658-80-8 
Vegetarian 14 14 60 60 11–199 
Omnivore 24 24 127 127 10–410 
1-Octen-3-ol 
CAS 3391-86-4 
Vegetarian 14 6 19 19 2–38 
Omnivore 24 7 2 2 0.4–58 
Ethanoic acid 
CAS 64-19-7 
Vegetarian 14 14 8930 2293 
4298–
12233 
Omnivore 24 24 9202 1882 672–12963 
Butanoic acid 
CAS 107-92-6 
Vegetarian 14 14 7964 4708 
2493–
11553 
Omnivore 24 24 8267 1905 2681–9633 
3-Methylbutanoic acid 
CAS 503-74-2 
Vegetarian 14 14 2030 2906 64–5821 
Omnivore 24 22 3344 3641 220–8262 
Pentanoic acid 
CAS 109-52-4 
Vegetarian 14 14 2533 3761 88–10216 
Omnivore 24 23 4364 3817 730–21886 
Indole 
CAS 120-72-9 
Vegetarian 14 14 3428 2241 290–5477 
Omnivore 24 24 4040 1303 2342–5070 
3-Methyl-1H-indole 
CAS 83-34-1 
Vegetarian 14 14 1146 822 37–2267 
Omnivore 24 24 1124 975 404–3483 
Table 3.34 the mean concentration (ng/g) and measured concentration range (ng/g) for each 
compound in the omnivore and vegetarian diet groups. 
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Figure 3.23 discriminant scores’ box plots showing a lack of differentiation of stool samples from 
vegetarian and omnivore volunteers. 
 
3.3.5 Qualitative data from alkaline (pH13) stools 
A total of 15 stool samples were analysed after the addition of sodium hydroxide to 
alter the pH to 13. A total of 133 chromatographic peaks were recorded across the 15 
samples with a mean of 43 peaks per chromatogram: with the lowest number of peaks 
being 29 and the highest 53. Of the total number of peaks, 16 were unidentified and 
43 were categorised as terpenes. Table 3.35– 3.45 shows the qualitative data 
separated by chemical class. 
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CAS Nitrogen containing compounds  RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
75-50-3 Trimethylamine 1.95 8.26 7.76 31.95 11.95 7.42 8.39 4.19 18.21 40.65 40.01 97.26 5.65   1.59 
124-40-3 Dimethylamine 3.19      9.51 215.77   314.32   86.69   
75-05-8 Acetonitrile 5.1 16.55 10.99  15.94 17.05 13.13  21.01 13.99 8.53 12.68 8.51 5.47 16.82 21.23 
926-64-7 Acetonitrile (dimethylamino) 10.02 6.41 51.86   7.94 22.61 32.54 4.41 23.03   13.57 8.64 21.88 13.52 
120-72-9 Indole 26.78 58.63  31.28  62.31 39.9 23.14 11.88 39.84 30.13 46.36 15.01 56.04   
83-34-1 3-Methylindole 27.27      26.31  30.13 3.66   23.48    
Table 3.35 nitrogen containing compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and 
chromatographic peak area. 
CAS Aldehydes RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
75-07-0 Acetaldehyde 2.16 12.37 2.08 4.31 31.59 2.23 10.56 1.84 2.45  19.32 9.04 5.36 36.89 5.16 5.1 
123-72-8 Butyraldehyde 3.1 25.28    17 1.85     8.34  3.65 1.89  
66-25-1 Hexanaldehyde 6.76 5.29               
Table 3.36 aldehyde compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
CAS Sulphides RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
75-18-3 Dimethyl sulphide 2.3 110.78 32.67 17.83 104.6 4.69 243.23 102.33  16.1 73.12 115.65 3.39 34.36 332.31 12.93 
624-92-0 Dimethyl disuphide 6.52 41.24    50.8 148.71 21.35 4.85 51.92 83.43 46.39 14.18   46.16 
23747-45-7 S-methyl 3-methylbutanethioate 9.69     3.1           
Table 3.37 sulphide compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
CAS Ketones RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
67-64-1 Acetone 2.61 80.3 200.02 179.45 174.92 434.16 69.08 46.68 314.15 117.53 234.79 82.31 59.39 105.27 196.82 55.35 
107-87-9 2-pentanone 4.61  27.89 48.5  133.37   32.29   13.75   19.26  
591-78-6 2-hexanone 6.75     28.63   14.89        
105-42-0 4-Methyl 2-hexanone  8.84    3.73 14.3           
110-43-0 2-Heptanone 8.91        3.19        
111-13-7 2-Octanone 10.91   14.42             
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110-93-0 6-Methyl 5-hepten-2-one  11.94 58.17 64.95 9.81 2.93 9.01 7.72 3.28 17.36 67.41 32.06 9.16 10.43 3.52 3.78 52.32 
Table 3.38 ketone compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
CAS Esters RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
79-20-9 Ethanoic acid, methyl ester 2.69 67.5 117.34 74.36 72.72 84.96 56.36 70.26 52.96 58.36  78.99 85.11 394.92 48.61 61.7 
141-78-6 Ethanoic acid ethyl ester 3.21    40.51 99.29       12.32    
105-37-3 Propanoic acid ethyl ester 4.28      39.5    448.29  26.95 886.65   
97-62-1 Propanoic acid, 2-methyl- ethyl ester 4.44      27.03    53.51   39.29   
109-60-4 Ethanoic acid propyl ester 4.6    62.1      200.57   319.61   
623-42-7 Butanoic acid methyl ester 4.79    223.7  87.46 17.03 5.14 5.03 778.65 2.21 115.95 1265.08   
868-57-5 2-Methylbutanoic acid methyl ester 5.28    20.92  24.95    19.76  16.28 4.18   
556-24-1 3-Methylbutanoic acid methyl ester 5.49    27.8            
105-54-4 Butanoic acid methyl ester  5.87    42.67  208.41 51.57  55.49 2199.01  78.62    
106-36-5 Propanoic acid propyl ester 6.04          23.62  8.07 268.18   
7452-79-1 2-Methylbutanoic acid ethyl ester 6.21    26.14  25.14 6.42   62.44  7.04 25.28   
108-64-5 3-Methylbutanoic acid ethyl ester 6.48  13.13 30.12 110         51.64 50.48  
123-86-4 Ethanoic acid butyl ester 6.61          127.97   182.48   
624-24-8 Pentanoic acid methyl ester 6.87    32.36  25.41      14.08 135.44   
105-66-8 Butanoic acid propyl ester 7.64    89.12  45.96 7.95  5.63 560.89  9.22 578.32   
539-82-2 Pentanoic acid ethyl ester 7.92          52.24  5.65 593.2   
590-01-2 Propanoic acid butyl ester 8.06             134.41   
97-87-0 Propanoic acid 2-methyl butyl ester 8.18             2.28   
539-90-2 Butanoic acid 2-methylpropyl ester 8.45      11.43 1.78         
628-63-7 Ethanoic acid pentyl ester 8.68             13.76   
123-92-2 Ethanoic acid 3-methyl butanyl ester 8.75                
106-70-7 Hexanoic acid methyl ester 9.01    6.03            
109-21-7 Butanoic acid butyl ester 9.68    26.75  26.14 5.78   306.99  3.26 178.47   
141-06-0 Pentanoic acid propyl ester 9.73         5.67      1.28 
123-66-0 Hexanoic acid ethyl ester 9.99    11.1       49.67     
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109-19-3 3- Methylbutanoic acid butyl ester 10.29   10.69       33.21    4.74  
591-68-4 Pentanoic acid butyl ester  11.5      2.51    11.79      
5870-93-9 Butanoic acid heptyl ester 11.51             15.71   
4630-82-4 Cyclohexanecarboxylic acid methyl ester 12.65          33.8      
3289-28-9 Cyclohexanecarboxylic acid ethyl ester 13.42          44.71      
Table 3.39 ester compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
CAS Alcohols RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
64-17-5 Ethanol 3.91    128.5  161.7  122.42  74.94 222.59 217.58 1184.95   
78-92-2 2-Butanol 5.64     13.61           
73-23-8 1-Propanol 5.92             3777.17  206.89 
78-83-1 2-Methyl -1-propanol 7.27      19.44 14.18  20.11   7.69 15.82   
1572-93-6 3-Methyl-2-butanol 7.78         2.06   1.81    
6032-29-7 2-Pentanol 7.83    3.93            
71-36-3 1-Butanol 8.29      29.81 24.73  32.63 320.62 6.55 19.73 438.54 5.74 10.95 
137-32-6 2-Methyl-1-butanol 9.51 5.18   14.19 13.4 11.57 9.12 7.94 22.76 12.4 9.53 5.48  10.37 9.62 
71-41-0 1-Pentanol 10.35    13.3 9.36 10.46 8.03  14.41   6.98    
626-89-1 4-Methyl-1-pentanol 11.51         1.49       
Table 3.40 alcohols found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic peak area. 
CAS Acids RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
79-31-2 2-Methylpropanoic acid 6.7      4.68          
64-19-7 Ethanoic acid 14.11 26.14  19.23 31.94 15.4 19 18.72  12.84 16.95  20.32 36.52 20.27 23.15 
107-92-6 Butanoic acid 16.82 18.14 13.15  24.67         34.47 10.52  
Table 3.41 acids found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic peak area. 
CAS Aromatic compounds RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
7149-26-0 
1,6-Octadien-3-ol, 3,7-  
dimethyl-,2-aminobenzoate 
15.63             52.57   
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108-95-2 Phenol 21.84 6.32 7.81 6.18 5.94 8.59 7.38 19.75 5.15 9.6 9.98 10.15 5.66 6.85 5.38 4.77 
106-44-5 4-Methylphenol 22.76 59.39 70.1 100.66 60.66 120.73 69.62 76.09 83.48 113.1 35.04 34.77 49.98 30.72 40.6 44.75 
120-72-9 Indole 26.78 58.63  31.28  62.31 39.9 23.14 11.88 39.84 30.13 46.36 15.01 56.04   
83-34-1 3-Methylindole 27.27      26.31  30.13 3.66   23.48    
Table 3.42 aromatic compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
Siloxanes RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
Siloxane (1) 4.31 23.43 33.97 17.49 110.4 24.75   15.45 31.05  11.31   12.6  
Siloxane (2) 6.83     5.38     16.75      
Siloxane (3) 7.58   3.72  1.97         2.78  
Siloxane (4) 10.53        5.21     13.13   
Siloxane (5) 13.03           5.63     
Siloxane (6) 13.13 9.95 7.58 3.97 3 5.61 2.94 2.32 2.98 10.19 2.29  5.07  3.18 2.34 
Siloxane (7) 15.32 8.53            9.16   
Table 3.43 siloxane compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
Terpenes RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
Terpene (1) 3.02         29.63   6.39    
Terpene (2) 5.3   5.08   46.18   1.12       
Terpene (3) 5.52 78.67 332.62 68.07  46.87   67.66 39.98 68.77 28.22 31.64 49.67 13.5  
Terpene (4) 5.59 22.2      21.66   16.54  11.15    
Terpene (5) 5.78 10.31 64.32 20.43  46.26   16.12   32.03   26.52  
Terpene (6) 6.39  10.4 19.85     8.51   10.2  29.68   
Terpene (7) 6.87 6.57               
Terpene (8) 7.13 61.47 61.46 145.04 10.19 56.33 7.64  22.71  112.28 17.89 24.61 12.1 10.33  
Terpene (9) 7.37 45.91 32.57 11.38 8.62 1.23 6.1  8.66  32.81   15.76  18.15 
Terpene (10) 7.4        11.42    7.58    
Terpene (11) 7.86     155.85 55.22 3.02 1.26 3.18  1.78     
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Terpene (12) 7.99 72.26 72.86 24.83    2.18 34.55 5.4 179.23 4.52 15.04  2.89  
Terpene (13) 8.16  68.87 67.35  7.81 1.56 14.58 15.06 1.21 17.75 14.04   30.04 12.98 
Terpene (14) 8.37        3.6        
Terpene (15) 8.42 2.1 698.76   39.18       5.84 510.92 3.02  
Terpene (16) 8.47           1.27     
Terpene (17) 8.69 3.27 6.79      4.23  83.44      
Terpene (18) 8.88   21.35       3.81 3.07 1.29  3.78  
Terpene (19) 9.16 74.57  64.69 21.49 64.24 10.9 3.57 28.66 31.28 470.09 5.61 21.22 1328.47 39.74 57.75 
Terpene (20) 9.34 7.38 1486.21 7.54  2.88 1.12  5.5 2.77 5.39 3.76 1.95 50.39   
Terpene (21) 9.92             47.96   
Terpene (22) 10.16 11 18.56 99.67    0.26 7.45  105.84  28.74 136.34  5.77 
Terpene (23) 10.38 5.71       3.8   4.3     
Terpene (24) 10.51 14.65  71 11.78 14.21 12.55 10.09  10.03 45.09 8.68   4.64 7.23 
Terpene (25) 10.6        11.55    28.98    
Terpene (26) 10.63  70.69              
Terpene (27) 10.83  25.54              
Terpene (28) 10.95  17.05   4.81           
Terpene (29) 12.21   9.89 4.84 3.82 3.69    3.08 3.42   1.4 4.8 
Terpene (30) 12.53  4.4  4.88         24.63   
Terpene (31) 12.92  10.4              
Terpene (32) 13.69  24.13 1.13             
Terpene (33) 14.73   2.13           5.32  
Terpene (34) 15.47    7.93 14.08 5.27 6.54    12.65   6.84 5.59 
Terpene (35) 16.35 14.94 23.15 18.19  5.74 4.67  8.71  10.84 4.41 4.21  18.77  
Terpene (36) 17.46  4.93 3.72  3.89 3.85    3.67 3.56 4.61  4.19 5.81 
Terpene (37) 17.99   1.67             
Terpene (38) 18.12   2.42             
Terpene (39) 18.22   3.12             
Terpene (40) 19.58  12.23              
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Terpene (41) 20.71 40.4 39.44 22.93 39.12 45.63 29.39 26.86 23.71 22.01 25.07 5.19 17.4 39.5 33.56 26.66 
Terpene (42) 23.86  3.14 1.88 1.05  1.46 1.5  3.03 1.61    2.8  
Terpene (43) 24.64  0.75 0.64 0.58  0.69 0.55 0.72 0.92 0.65  0.74  1.13  
Table 3.44 terpene compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
Unidentified  RT (mins) 1 2 5 7 17 18 22 23 24 25 26 32 34 37 38 
Unidentified (1) 4.56 8.29     10.18 9.11  24.2   19.73    
Unidentified (2) 6.08        0.82        
Unidentified (3) 6.23               2.29 
Unidentified (4) 6.67   13.68      28.6       
Unidentified (5) 7.55 2.5               
Unidentified (6) 7.6           2.46     
Unidentified (7) 8.39         2.3       
Unidentified (8) 9.58   14.62          13.56   
Unidentified (9) 11.53    2.02            
Unidentified (10) 12.29              3.63  
Unidentified (11) 14.25           13.69     
Unidentified (12) 15.49            4.91    
Unidentified (13) 16.84   9.66  11.58 12.11 13.6 8.33 12.44 13.74 8.37 12.35   13.09 
Unidentified (14) 17.38    7.93    2.84     9.72   
Unidentified (15) 18.38  3.88  9.29 2.78 8.64 8.27   7.29 2.1   2.14 6.53 
Unidentified (16) 19.86       0.8         
Table 3.45 identified compounds found in stool samples adjusted to pH 13 with sodium hydroxide for 15 participants with retention time and chromatographic 
peak area. 
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3.3.6 Quantitative data from alkaline (pH13) stools 
Figure 3.24 shows the comparison between chromatograms of unaltered stool (Figure 
3.24a) and the same sample with 5 mL of 0.1M sodium hydroxide added (Figure 
3.24b). As expected, the region containing the majority of the short chain fatty acids 
(retention time 7–18 min) has both less chromatographic peaks and smaller peak 
areas when the sodium hydroxide is added. However, Figures 3.24 and 3.25 show 
that when sodium hydroxide is added to make the stool alkali the trimethylamine can 
be detected. In the unmodified stool (Figure 3.24a) there is no 58 m/z peak at the 1.94-
minute retention time, which is indicative of trimethylamine. The peak with a retention 
of 1.91 in Figure 3.24 does not have any clear matches in the NIST library. This peak 
is no longer visible when only the 58 m/z for trimethylamine is displayed as shown in 
the section of the chromatogram displayed in Figure 3.25a. Whereas the identical 
section of the chromatogram for the pH altered stool gives a peak at the earlier 
retention time with a library match for trimethylamine (Figure 3.25b).  
 
 
Figure 3.24 a) Chromatogram produced from unmodified stool sample spiked with 13C labelled 
internal standards (solution 1) b) chromatogram produced from another aliquot of the sample with 
5mL of 0.1M aqueous sodium hydroxide added in addition to 13C labelled trimethylamine. 
 
 
a) 
b) 
Unaltered 
pH 13 
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Figure 3.25 a) the same sample as Figure 3.22a with only m/z 58 ions displayed vs. time. The peak 
at retention time 2.62 min was identified as acetone b) the same sample as Figure 3.22b (the pH 
altered stool) with only m/z 58 ions displayed vs. time. The peak at retention time 1.94 min was 
identified by the NIST library as trimethylamine, and the peak at retention time 2.58 min as acetone. 
3.4.0 Discussion 
It is considered that some diseases could be linked to the microbiome [183]. There is 
a lack of knowledge of gut chemistry, due in part to the complexity of the stool mixture. 
Recently, hundreds of new compounds have been identified in the gut mainly due to 
the VC analyses in headspace studies, and much of this work is of a qualitative nature 
[66,173]. We have developed a method for quantifying key compounds from stool 
samples, which minimizes chemical alterations to the stool using 13C isotope labelled 
internal standards. It quantifies headspace concentrations and accounts for dissolved 
stool concentrations by comparing the distribution and relative recovery of isotope 
labelled compounds from the headspace above stool.  
We have also devised a method to quantify trimethylamine in stool by using isotope 
13C labelled trimethylamine in conjunction with elevating the pH to 13. Although 
addition of base to stool samples is not common, Wang et al. also added sodium 
hydroxide to stool prior to the sample being centrifuged and filtered to measure lactic 
acid and short chain fatty acids (SCFAs) with high-performance liquid chromatography 
[184]. However, in the Wang et al. study, no healthy participants were used, and all 
the participants were premature infants. This study also differs from our study as only 
a) 
b) 
Acetone 
Acetone 
Trimethylamine 
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1 mL of 10 mmol/L sodium hydroxide was added along with 5 mmol/L of crotonic acid, 
with no mention as to the effect these additions had on the pH.  
Walton et al. used TD-GC-MS, a similar method to that reported here, to analyse the 
headspace of stool samples. They found levels of acetone that were 142 ng/L whereas 
butanoic acid was 33 ng/L, 3-methylbutanoic acid was 7 ng/L, and Indole was 9 ng/L. 
Measuring the headspace concentration underestimates the level of free acid and 
other compounds, such as indole, in the stool, due to the relatively low concentrations 
portioning into the headspace. To determine the differences in quantification of the 
headspace concentrations versus the in-stool concentrations, headspace 
quantification was done on a subset of samples (16 UK samples). Although the levels 
of acetone, dimethyl sulphide, and other lower molecular weight, less water soluble, 
and lower boiling point compounds were equivalent to the values measured during the 
quantitation studies for the same samples (Table 3.16 and Table 3.35, UK 
participants), much lower amounts of acids and indole were determined if just pure 
headspace concentrations were measured (Table 3.46). Thus, the method we devised 
considered the headspace concentration vs. dissolved concentration, by dissolving a 
known 13C isotope with similar chemical properties into the stool and measuring 
headspace concentrations, but correcting for lower than expected recovery and 
applying this same correction factor to the levels detected (peak areas) of the non-
isotope labelled naturally occurring compounds.  
As mentioned, fatty acids and indole concentrations in stool are disproportionately 
underestimated if just the headspace concentration is considered. The devised 
method does rely on distributing the 13C labelled compound throughout the stool 
sample. 
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Compound 2 6 7 8 11 14 15 16 Mean omnivore 1 3 4 5 9 10 12 13 Mean vegetarian 
Trimethylamine ND ND ND ND ND 2.6 ND ND 2.6 ND ND ND ND ND ND ND ND ND 
Dimethyl Sulphide 213.6 400.0 1786.2 850.4 3922.0 50.5 34.9 827.1 1010.6 2159.0 229.1 28.0 178.6 2423.1 260.2 314.5 621.3 776.7 
Acetone 290.4 2384.9 3771.6 1666.2 602.6 2149.0 72.6 145.2 1385.3 842.2 2029.2 410.2 1847.7 838.5 254.1 653.4 700.6 947.0 
Propanethiol 9.5 ND ND 23.8 ND 33.3 ND ND 22.2 ND ND ND ND 7.6 ND ND ND 7.6 
Pantanal ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ethyl-2-methyl butanoate ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Dimethyl disulphide 365.0 206.0 223.7 164.8 1106.7 129.5 64.8 688.8 368.7 288.5 482.7 14.1 223.7 88.3 306.1 100.1 370.9 234.3 
1-Octen-3-one ND ND ND ND ND ND ND ND ND ND 2.4 1.3 ND ND ND ND 2.8 2.1 
Dimethyl trisulphide 94.7 78.9 98.6 68.7 560.3 51.3 5.5 284.1 155.3 75.0 161.8 5.5 56.0 20.5 75.0 39.5 94.7 66.0 
1-Octen-3-ol ND ND ND ND 0.2 ND ND ND 0.2 0.2 ND ND ND ND ND ND 0.2 0.2 
Butanoic acid 88.1 363.5 82.6 170.7 269.8 19.8 66.1 253.3 164.2 27.5 82.6 44.1 38.5 25.9 38.5 1921.9 126.7 288.2 
3-Methylbutanoic acid 23.0 140.4 25.5 70.2 44.7 3.8 22.3 51.1 47.6 5.7 23.6 10.9 6.4 7.0 6.4 197.9 25.5 35.4 
Pentanoic acid 12.8 98.9 19.1 59.4 36.4 ND 9.6 44.7 40.1 3.2 14.7 6.4 6.4 3.8 4.5 217.0 17.9 34.2 
Indole 6.6 22.9 14.8 46.5 9.6 13.3 7.4 11.1 16.5 31.0 14.0 1.5 22.1 11.1 5.2 25.8 11.8 15.3 
3-Methyl indole 9.8 11.5 5.7 29.5 57.4 4.9 32.0 13.1 20.5 11.5 12.3 16.4 24.6 19.7 18.0 8.2 11.5 15.3 
Table 3.46 quantities of compounds determined from the headspace of healthy stool samples from the U.K. omnivore and vegetarian samples. Quantities 
were calculated by collecting a known volume of headspace on TD tubes and using calibration curves of standards spiked onto the same TD tubes at 
different concentrations to calculate concentration in ng/g of stool. N.D. =not detected 
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Extensive method development was undertaken using standard mixtures containing 
18 compounds previously identified in stool to optimise the chromatography method 
and automated thermal desorption (ATD) tube loading. Prior to this, a number of 
different solvents had been used for the standard mixture and methanol was selected 
due to its compatibility with a wide range of compounds, ease of removal from ATD 
tubes when loading calibration standards, and minimal solvent peak, which did not 
interfere with the compounds of interest in unmodified stool. 
The method relies on correcting recovered values based on the 13C standard recovery. 
This gives a more realistic quantitation for the amount of certain compounds in stool. 
However, if the naturally occurring compounds of interest are below the limit of 
detection for the headspace analysis method, then there is no way to apply the 
correction to ascertain the actual concentration of the compound in stool. Therefore, 
a solvent extraction method, which does not rely on working close to the limit of 
detection, may have enabled quantitation of the full range of samples. Prior to 
developing the headspace-based method reported here, a solvent extraction method 
had been developed for quantifying selected compounds in stool. However, it proved 
difficult to obtain a reliable solvent extraction method that enabled simultaneous 
quantitation of the compounds of interest, which span a broad range of chemical 
classes.  
Wang et al. utilized a vacuum distillation process to isolate the short chain fatty acids 
(SCFAs) in stool [181]. These studies identified higher levels of SCFA than the method 
reported here, with levels in the high µg/g range compared to this study where values 
were in the low µg/g range. Wang et al. obtained median values of 3705 µg/g for 
ethanoic acid, 1756 µg/g for butanoic acid, and 285 µg/g for 3-methylbutanoic acid. 
These values are higher than those reported here due to the methodology used, 
whereby both the free acid and anionic forms would be extracted and analysed.  
De Preter et al. freeze dried their stool samples before they were salted with sodium 
sulphate and acidified with sulphuric acid [182]. Acidification of stool samples is a 
reasonably common technique as detailed in a comprehensive review of SCFA 
analysis via GC and other methods [185]. Their reported values for the SCFAS 
measured (ethanoic acid, butanoic acid, and 3-methylbutanoic acid) were in the high 
µg/g range in agreement with the studies of Wang et al. detailed above [181]. 
Interestingly, de Preter also quantified dimethyl sulphide and found levels of 0–402 
ng/g whereas this study identified DMS at a mean concentration of 3058 ng/g with a 
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range of 26–25626 ng/g. So, there is fairly good agreement between the two different 
analysis methods for quantifying volatile sulphur compounds, and this is because the 
alteration of the chemistry does not affect the quantification of sulphides in the same 
way as SCFAs. De Preter also quantified indole and found levels ranging from 24 µg/g 
to 44 µg/g whereas this study found mean values of 3 µg/g. Therefore, there is fairly 
good agreement that can be explained by the different effects altering the stool 
chemistry has on quantifying indole vs. quantifying SCFAs. 
As mentioned, by the action of acidifying stool, both the free acid and the previously 
anionic form is measured. However, in the gut, the acid exists as free acid, but also 
more so in the anionic form [186] (with the counter cation being H+, metal cations, and, 
to a lesser extent, ammonium ions). Our contention is that quantification of the free 
SCFA concentration in addition to the total SCFA concentration is important to know 
in a study of the gut chemistry. The amount of free acid will dictate the amount of acid 
detectable in the headspace and thus the amount available for potential diagnostic 
purposes [187].  
Preliminary work on the basification of stool was reported. The unmodified stools 
yielded a mean of 174 peaks across 38 samples with a mean of 57 per sample (range 
36–73). The addition of the sodium hydroxide reduced both values significantly to 133 
and 43 (range 29–53), respectively. Moreover, as demonstrated in Figure 3.24a and 
3.24b, after the first 10–12 min, the frequency and size of the chromatographic peaks 
notably reduces. By making the stool alkali, we have shown that it is possible to not 
only detect, but also quantify, trimethylamine, which is likely to be a result of the 
conversion of protonated trimethylamine to trimethylamine in the high pH conditions. 
Figure 3.25b shows a clear peak with an RT of 1.94 after the sodium hydroxide is 
added, which is identified by the NIST library with a match and reverse-match at 999 
and 992, respectively. Figure 3.25a shows the same sample with unmodified stool in 
which the 1.94-minute peak is barely visible. Lin et al. found that in their latrine models, 
the amine smell became more prominent as the pH increased to 9 [179]. They also 
found that trimethylamine could not be detected from their field samples, and this could 
be due to the presence of acids in the sample protonating the amine compounds [177], 
resulting in a lack of free trimethylamine within the samples. Simenhoff et al. 
suggested that secondary and tertiary amines were in high levels on the breath of 
patients with end stage renal disease [188]; a finding that was also supported by Davis, 
Spanel, and Smith [189]. Moreover, ammonia has been associated with hepatic 
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encephalopathy [190]. Thus, improving amine detection techniques could have clinical 
utility in the future. While we were unable to quantify any other amine compounds in 
this instance, we are confident that with further method development we should be 
able to quantify more amine compounds. We were able to identify methylamine in one 
of the stools modified to pH 13, and this peak eluted as a shoulder to the methanol 
solvent peak; this is suggestive that methylamine may be in other samples but co-
elutes with the solvent peak. Thus, developing the method further to reduce or 
eliminate this solvent peak, for instance, by increasing the tube collection purge time 
to drive off more methanol, may reveal more amine compounds. Table 3.47 shows the 
differences in the number of compounds detected for each chemical class between 
the unaltered and alkaline stool samples. There were fewer compounds detected 
across all the chemical classes, with the exception of nitrogen containing compounds, 
in the alkaline stool; not surprisingly, the largest percentage decrease in the number 
of compounds came from the acids with a 70% decrease. The least change came from 
the esters, which only decreased by 17% following pH alteration. As expected, the 
only class of compounds that showed an increase in numbers were the nitrogen 
containing compounds. 1,6-Octadien-3-ol-3,7-dimethyl-2-aminobenzoate was 
detected in the unmodified stool but was not detected in the alkaline stool. 
Trimethylamine, dimethylamine, and acetonitrile (dimethylamino) were detected in the 
alkaline stool, but not in the unmodified stool. Acetonitrile, indole, and 3-methyl indole 
were seen in both unmodified and pH modified stool. 
Chemical Family Unmodified pH Modified 
Percentage 
change 
(Unmodified to 
pH13 Modified) 
Aldehydes 6 3 -50% 
Esters and thioesters 36 30 -17% 
Ketones 12 7 -42% 
Alcohols 20 11 -45% 
Acids 10 3 -70% 
Nitrogen containing 4 6 +50% 
Sulphides 8 3 -63% 
Aromatic compounds 6 5 -29% 
Miscellaneous 2 0 -100% 
Terpenes 30 22 -40% 
Unidentified 32 16 -50% 
Table 3.47 comparison of compounds found across different classes of chemicals in unmodified stool 
and the stool modified to pH 13. 
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The origins of a majority of the esters could arise from reactions between the alcohols 
and acids reported here. A homologous series of alcohols from ethanol to octanol was 
found, and from ethanoic acid to heptanoic acid, in agreement with previous work 
[191], and their reaction would produce many straight chain esters. Branched chain 
esters can similarly be explained by a reaction of, for example, 3-methylbutanoic acid 
with alcohols. Interestingly, a large number of methyl esters (nine in total) were found 
although no free methanol was observed. It may be that that the body, or bacterial 
enzymes, particularly “trap” methanol as esters, reduce the methanol’s toxic effects 
on cells.   
The statistical tests on the gathered data showed that five compounds were in 
significantly different quantities in stool gathered from UK and South American 
participants; significantly, these participants were temporarily living in the UK with little 
exposure to a UK diet due to the short duration of their time in the UK. Moreover, using 
one cross validation, we were able build an example model using butanoic acid and 
ethyl butanoate to differentiate UK and South American samples; albeit, this was 
based on a small dataset. However, there was very little overlap between the two 
groups. In many clinical studies, there is little attention paid to the ‘healthy’ participants; 
however, developing a comprehensive understanding of how healthy samples can 
differ from population to population could be significant in the development of VC 
based diagnostics. For example, a stool volatile based diagnostic test that has high 
accuracy in the UK may not exhibit the same accuracy in a South American population. 
The results presented here do seem to suggest that further work is required to assess 
the difference in volatile profiles of healthy participants of different geographical 
origins.  
A 2010 study compared the microbiota of children from Burkina Faso with children 
from the European Union (EU) [192]. This team suggested that there was a significant 
difference in the composition of gut microbiota between the two groups; they proposed 
the increased sugar, animal fats, and general calorie dense foods as the reason for 
this difference [192]. A difference in microbiota composition will inevitably lead to 
differences in the faecal volatilome. Similarly, a research team from China assessed 
the gut microbiota of 314 healthy participants of different geographical origins within 
China. This group was also able to determine differences in the composition of gut 
microbiota from these geographical origin groups; interestingly, this study was unable 
to determine any difference as a result of lifestyle. However, importantly, the team 
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state they did not process the necessary dietary information to make any inferences 
on the role diet plays in the formation of microbiota [193]. A 2006 study examined the 
gut microbiota of four different European countries; in this instance, very few 
differences were noted as a result of country of origin, however, this study suggested 
that other factors, such as age and gender, conferred significant differences [194]. 
Taken together, there is sufficient evidence to say that there are a number of variables 
that can influence the gut microbiota and, in turn, the associated volatilome.  
Comparing the quantities of the compounds in omnivore samples versus vegetarian 
samples revealed no significant differences between the two groups, as evidenced by 
the discriminant scores plot shown in Figure 3.19. There have been numerous 
publications that suggest why this might be the case, for instance, Kabeerdoss et al. 
compared the microbiota of female southern Indian omnivores and vegetarians. This 
groups found that, with the exception of Clostridium cluster XIVa and some butanoate 
producing bacteria, which were more prevalent in omnivores, the groups were very 
similar [195]. While our results showed no significant difference due to the large 
standard deviations, the butanoic acid, ethyl butanoate, and ethyl 2-methylbutanoate 
were all higher in the omnivore group versus the vegetarian group. Van Faassen et al. 
demonstrated that while stool mass and frequency was higher in vegetarians versus 
omnivores, the pH of the stool was not significantly different; this was attributed to both 
vegetarians and omnivores having similar calcium intake [196]. In a recent 2015 study, 
Ferrocino et al. assessed the gut microbiota of 153 healthy participants from five 
different regions of Italy. This group also found that significant differences in gut 
microbiota could be attributed to region of origin rather than dietary habits 
(vegetarian/omnivore) [197]. 
A 2014 review of the healthy human volatilome found 381 distinct compounds from 
human stool [191]. Overall, we were able to identify 106 distinct compounds; 
moreover, we have tentatively identified additional compounds that have not 
previously been reported in the literature from stool samples of healthy participants 
(see Table 3.48). However, 3-Methyl-2-butanone has previously been reported in the 
urine samples of healthy individuals [197]. The compound, 2,4-dithiapentane, has 
been associated with white truffles [198] and truffle oil [199], and is likely to be directly 
derived from diet. Cyclohexanol, 5-methyl-2-(1-methylethyl)-,(1a,2b,5a) is a none 
verified isomer of menthol [200], and 4-isopropyl benzaldehyde is better known as a 
cuminaldehyde and both of these compounds are found in food [201]. Table 3.49 
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shows a further three compounds that were identified in the alkali treated stool 
samples that have not previously been reported in the current literature concerning 
volatile compounds emanating from stool of healthy individuals, but acetonitrile 
(dimethylamino) was identified in the headspace above stool of patients with C. difficile 
[53]. It is important to understand more about the volatilome if volatile compounds are 
going to prove useful in monitoring health. It may be particularly important to 
understand the gut derived volatilome both directly and indirectly due to the important 
role the microbiome plays in human health. Tables 3.48 and 3.49 show the retention 
indices for each compound calculated from the sample versus the literature values, in 
all cases where literature values exist or samples matched closely. Table 3.48 shows 
the RI values for all chromatographic peaks detected across all samples and 
compares those to the literature. In the vast majority of cases, our experimental value 
is in-line with those in the literature. Figures 3.26– 3.37 shows the mass spectra for 
each of the compounds in Tables 3.48 and 3.49. Trimethylamine was checked against 
the standards used for quantification. Future work will include verifying all of these 
compounds with chemical standards. 
 
CAS  Compound 
Retention 
Time (min) 
Retention 
Indices 
Sample 
Retention 
Indices 
Literature 
563-80-4 3-Methyl-2-butanone  4.56 972 970 [202]  
556-24-1 3-Methylbutanoic acid methyl ester  5.49 1017 1024 [203] 
97-87-0 Propanoic acid 2-methylbutyl ester  8.18 1152 1154 [203] 
539-90-2 Butanoic acid 2-methylpropyl ester  8.45 1158 1,152 [203] 
141-06-0 Pentanoic acid propyl ester  9.73 1215 
1,200–1233 
[204] 
1618-26-4 2,4-Dithiapentane  10.6 1260 1260 [205] 
2313-61-3 2-heptanol  11.66 1308 1315.3 [206] 
15356-70-4 
Cyclohexanol, 5methyl-2-(1-methylethyl)-
,(1a,2b,5a) (Menthol) 
16.9 1631 1630.4 [206] 
55012-32-3 4-Isopropyl benzaldehyde (cuminaldehyde) 18.91 1783 1781.4 [206] 
Table 3.48 details of 12 compounds identified from the headspace above stool samples from healthy 
individuals that have not been previously reported in the literature. Babushok, Linstrom, and 
Zenkevich reported the retention indices for 505 compounds frequently occurring in plant essential 
oils [206]. Bianchi et al.. evaluated the retention indices for 250 compounds based on a polar column 
similar to that used to carry out our work [203]. 
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CAS  Compound 
Retention 
Time (mins) 
Retention 
Indices Sample 
Retention 
Indices 
Literature 
75-50-3 Trimethylamine  1.95 - - 
108-64-5 
3-Methyl butanoic acid 
ethyl ester  
6.48 1074 1068 [204] 
926-64-7 
Acetonitrile 
(dimethylamino ) 
10.02 1230 1243 [207] 
Table 3.49 three compounds, previously unreported in the literature, identified from the headspace of 
alkaline treated stool samples.
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Compound 2 6 7 8 11 14 15 16 Mean omnivore 1 3 4 5 9 10 12 13 Mean vegetarian 
Trimethylamine ND ND ND ND ND 2.6 ND ND 2.6 ND ND ND ND ND ND ND ND ND 
Dimethyl Sulphide 213.6 400.0 1786.2 850.4 3922.0 50.5 34.9 827.1 1010.6 2159.0 229.1 28.0 178.6 2423.1 260.2 314.5 621.3 776.7 
Acetone 290.4 2384.9 3771.6 1666.2 602.6 2149.0 72.6 145.2 1385.3 842.2 2029.2 410.2 1847.7 838.5 254.1 653.4 700.6 947.0 
Propanethiol 9.5 ND ND 23.8 ND 33.3 ND ND 22.2 ND ND ND ND 7.6 ND ND ND 7.6 
Pantanal ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Ethyl-2-methyl butanoate ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 
Dimethyl disulphide 365.0 206.0 223.7 164.8 1106.7 129.5 64.8 688.8 368.7 288.5 482.7 14.1 223.7 88.3 306.1 100.1 370.9 234.3 
1-Octen-3-one ND ND ND ND ND ND ND ND ND ND 2.4 1.3 ND ND ND ND 2.8 2.1 
Dimethyl trisulphide 94.7 78.9 98.6 68.7 560.3 51.3 5.5 284.1 155.3 75.0 161.8 5.5 56.0 20.5 75.0 39.5 94.7 66.0 
1-Octen-3-ol ND ND ND ND 0.2 ND ND ND 0.2 0.2 ND ND ND ND ND ND 0.2 0.2 
Butanoic acid 88.1 363.5 82.6 170.7 269.8 19.8 66.1 253.3 164.2 27.5 82.6 44.1 38.5 25.9 38.5 1921.9 126.7 288.2 
3-Methylbutanoic acid 23.0 140.4 25.5 70.2 44.7 3.8 22.3 51.1 47.6 5.7 23.6 10.9 6.4 7.0 6.4 197.9 25.5 35.4 
Pentanoic acid 12.8 98.9 19.1 59.4 36.4 ND 9.6 44.7 40.1 3.2 14.7 6.4 6.4 3.8 4.5 217.0 17.9 34.2 
Indole 6.6 22.9 14.8 46.5 9.6 13.3 7.4 11.1 16.5 31.0 14.0 1.5 22.1 11.1 5.2 25.8 11.8 15.3 
3-Methyl indole 9.8 11.5 5.7 29.5 57.4 4.9 32.0 13.1 20.5 11.5 12.3 16.4 24.6 19.7 18.0 8.2 11.5 15.3 
Table 3.50 quantities of compounds determined from the headspace of healthy stool samples from the U.K. omnivore and vegetarian samples. Quantities 
were calculated by collecting a known volume of headspace on TD tubes and using calibration curves of standards spiked onto the same TD tubes at 
different concentrations to calculate concentration in ng/g of stool. N.D. =not detected 
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Figure 3.26 mass spectra for 3-methyl-2-
butanone 
Figure 3.27 mass spectra for 3-methyl 
butanoic acid methyl ester 
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Figure 3.29 mass spectra for 
butanoic acid 2-methylpropyl 
ester 
 
Figure 3.28 mass spectra for 
propanoic acid 2-methylbutyl ester 
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Figure 3.31 mass spectra for 2,4-
dithiapentane 
 
 
Figure 3.30 mass spectra for pentanoic 
acid propyl ester 
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Figure 3.32 mass spectra for 
2-heptanol 
 
Figure 3.33 mass spectra for 
Cyclohexanol, 5 methyl-2-(1-methylethyl)-
,(1a,2b,5a) (Menthol) 
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Figure 3.34 mass spectra for 
4-isopropyl benzaldehyde 
(cuminaldehyde) 
 
Figure 3.35 mass spectra for 
trimethylamine 
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Figure 3.37 mass spectra for 
acetonitrile (dimethylamino) 
 
Figure 3.36 mass spectra for 3-
methylbutanoic acid ethyl ester 
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3.5.0 Conclusions 
We have presented a method for the analysis of stool samples whereby the addition 
of 13C compounds has allowed us to quantify a range of VOCs in stool: Dimethyl 
sulphide (26–2,5626 ng/g), acetone (442–3006 ng/g), ethyl butanoate (39–2468 
ng/g), ethyl 2-methylbutanoate (0.3–180 ng/g), dimethyl disulphide (35–1303 ng/g), 
1-octen-3-one (12 ng/g), dimethyl trisulphide (10–410 ng/g), 1-octen-3-ol (0.4–58 
ng/g), ethanoic acid (672–1,2963 ng/g), butanoic acid (2493–1,1553 ng/g), 3-
methylbutanoic acid (64–8262 ng/g), pentanoic acid (88–2,1886 ng/g), indole (290–
5477 ng/g), and 3-methyl indole (37–3483 ng/g). Moreover, by altering the pH of the 
stool to pH 13, in conjunction with the addition of 13C trimethylamine, we have also 
been able to detect and quantify trimethylamine for the first time (range 40–5312 
ng/g). We were able to gather stool samples from participants of different countries 
of origin, which allowed us to compare the quantities of compounds from samples of 
UK origin with those of South American origin. Using a Mann Whitney U test, five 
compounds, ethyl butanoate, 1-octen-3-ol, ethanoic acid, butanoic acid, pentanoic 
acid, and indole, were calculated to be significantly different between South 
American and UK samples. Wilks’ Lambda analysis showed that butanoic acid and 
ethyl butanoate could be used to differentiate the two groups. This has important 
implications for future studies looking to develop diagnostic tests based on VCs, 
especially where these diagnostics are not based on distinct markers of disease, but 
on changes in a number of VCs that are commonly observed in healthy individuals. 
This is because in order for diagnostic tests to be effective there must be a baseline 
range for which to compare the disease state to.  
Logic might dictate that the difference in diet would lead to changes in produced 
metabolites. However, our work shows no significant differences in metabolite 
quantities between omnivores and vegetarians were observed in this study, in 
agreement with previous studies. Additionally, we have been able to tentatively 
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identify 15 compounds that have not previously been reported from stool samples. 
This data adds to the understanding of the human volatilome. 
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Chapter 4: Selected ion flow tube mass spectrometry 
(SIFT-MS) assessment of the oxides of nitrogen produced 
by EDX 110 dressings. 
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4.1.0 Introduction 
In the United Kingdom in 2017, 3.7 million people were diagnosed or living with 
diabetes [208] and predictions suggest this value could reach five million by the year 
2025 [209]. A serious symptom of poorly managed diabetes is diabetic neuropathy 
which is estimated to cause foot ulcers in 25% of diabetics [210]. Complications of 
ulcers such as ischaemia, infection, and impaired angiogenesis are common to 
chronic wounds such as those seen in diabetic patients [211,212]. To aid the care of 
diabetic foot ulcers Edixomed Ltd. have developed a two-part dressing which 
consists of a cotton mesh layer (5 cm x 5 cm primary contact layer) soaked in sodium 
nitrite (NaNO2) (Figure 4.38 right) which contacts the wound. The secondary 
adhesive glycerol-based hydrogel layer 10 cm x 10 cm (Figure 4.38 left) is added 
over the mesh, this gel contains a carboxylic acid at an approximate pH 4. When 
combined (as in Figure 4.39) the NaNO2 soaks into the gel and reacts to produce 
nitric oxide (NO).  
NO is a mediator of vasodilation and is also implicated as having antimicrobial effects 
[212].  A stage 3 clinical trial carried out testing the Edixomed Ltd. EDX110 dressing 
compared the NO producing dressing versus optimal standard care pathway for 
diabetic foot ulcers. The current standard care pathway involves removal of dead 
cells and any debris followed by getting patients to keep pressure on the wound and 
controlling infections, this pathway can be found in more detail in Kruse and 
Edelman, 2006 [213]. Over the course of the study the EDX110 dressing showed a 
percentage area reduction in the wound of 88.6% versus 46.9% for the standard 
care pathway [214]. The dermal application of NO was shown in work by Oplander 
et al., 2011 to easily permeate through the epidermal barrier in significant quantities 
[215]. This clearly demonstrates that the presence of NO can enhance the healing 
process. While the role of NO in the healing pathway is somewhat understood the 
complete reactions of the EDX110 dressing particularly with regards to the 
production of nitrogen dioxide (NO2) and nitrous acid (HONO) is not yet fully 
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understood. We intend to address within this chapter using SIFT-MS to quantify in 
real-time NO, NO2, and HONO.  
Polyol based hydrogels have been reviewed [216] poly(vinyl alcohol) (PVA), is 
crossed linked with a polymer either by chemical reaction or physical reaction. Many 
polymers have been crosslinked with PVA including alginate, chitosan, starch, 
gelatine, and glucan to name some examples. Glycerol is to PVA/chitosan hydrogels 
to accelerate the healing process; Yang et al. tested this hydrogel and found that 
there was good biocompatibility and significant improvement in healing versus 
standard gauze; in a rat model after eight days the gauze had reduced the wound 
down to 45% of its starting size while the hydrogel had reduced the wound to 10% 
of the starting size [217].  
NO is a mediator of vasodilation and is also implicated as having antimicrobial effects 
[212]. NO is most commonly produced from the acidification of nitrite in the following 
reactions: 
NO2- + H+ → HONO 
2HONO ↔ N2O3 + H2O → NO + NO2 
3HONO → 2NO + NO3- + H+ + H2O 
Reactions from the acidification of nitrite to form nitric oxide [212]. 
Despite the benefits of NO to wound healing the presence of acid can cause extreme 
discomfort on a wound and the production of nitrogen dioxide (NO2) must also be 
considered as this is a toxic by-product of NO production. There has been work done 
that suggests that in high moisture environments the NO2 produced is transient due 
to the following reactions [218]: 
NO + NO2 + H2O → 2HONO 
2NO2 + H2O → HONO + HNO3 
Reactions showing the presence of water pushes the NO2 to the HONO side of the equation [218]. 
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The above reactions show that high humidity conditions can cause the NO2 to be 
more transient and highlights the importance of nitrous acid (HONO) as an 
intermediate in the reactions. 
 
Image redacted due to copyright permissions 
Figure 4.38 the 10 cm x 10 cm hydrogel pad (left) shown adhesive side up, and the 5 cm x 5 cm 
sodium nitrite soaked mesh (right) which holds approximately 140 mg of 1M sodium nitrite.  
 
Image redacted due to copyright permissions 
 
Figure 4.39 the EDX110 with the sodium nitrite approximately (140 mg 1 M) soaked layer applied to 
the centre of the adhesive hydrogel which contains a carboxylic acid at an approximate pH 4. 
The most common method for the quantification of the oxides of nitrogen (NOx) is 
chemiluminescence. This method operates on two different modes, total NOx 
compounds are detected by catalysing the breakdown of NO2 and the other 
intermediates to NO which is then reacted with O3; the light emitted from this reaction 
is detected and used to provide quantitative output. It is also possible to detect just 
the NO by bypassing the catalytic process and reacting directly with O3 since NO2 is 
more stable it will not be detected during this process [219]. While this method is 
considered reliable and cost effective it is not suitable for use on sampling the real-
time reactions such as acidified nitrite as it is unable to factor in the multiple 
intermediates produced in the reaction. SIFT-MS however, has been shown to be 
able to differentiate NO and NO2 using O2+ reagent ions and HONO and nitric acid 
(HNO3) by using the H3O+ reagent ion, while providing real time quantification [220]. 
The mechanism behind SIFT-MS is discussed in chapter 1 section 1.3.1 along with 
examples of its use in biomedical applications. This chapter presents a method for 
the quantitative analysis of the products of the acid nitrite reaction in real-time using 
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SIFT-MS technology. We have been unable to find any other cases where this has 
been described in the current literature.  
4.2.0 Methods 
4.2.1 Reaction sampling method 
A 670 mL polypropylene plastic (BPA free) clip lock tub with silicone seal (Keyways, 
Taiwan, China) was used as a chamber for the reactions to take place in. Two holes 
were drilled one, on either side, gas tight brass Swagelok (Swagelok Bristol, 
Almondsbury) reducing unions (½ inch to ¼ inch) were fitted. Hard plastic tubing was 
fitted to the ½ inch side of the union on the outside of the chamber; the ¼ inch side 
of the union inside the chamber had a brass ferrule fitted to ensure a tight seal with 
the chamber (Figure 4.40). The principle of using a chamber to perform and monitor 
a reaction is similar to that used in a flux chamber which is commonly used in soil 
sampling [221]. Since our reaction chamber was based on this principle it is 
recommended a flow rate of one to two times the volume of the chamber in mL/min 
is used [222]; this was supported by pilot data gathered in which the flow rate of the 
pump was adjusted. Figure 4.41 shows the whole sampling system which includes: 
1. the air inlet 2. Drechsel bottles to humidify the air in the reaction 3. chamber inlet 
4. NMP015B pump (KNF Neuburger UK Ltd) 5. analyte gas/ lab air mix is pushed 
over the SIFT-MS inlet capillary at a rate of 670 mL/min. To keep the humidity and 
the reaction rate constant the whole system is contained in a temperature-controlled 
incubator. For details on starting the reaction in the chamber see individual 
experimental sections (4.2.5- 4.2.8).  
 
Image redacted due to copyright permissions 
 
Figure 4.40 the polypropylene plastic chamber for chemical reactions to take place in. Brass 
Swagelok union adapters are used to secure the tubing in place and provide a gas tight seal. The 
pump draws the gas through the chamber and pushes the gas over the SIFT-MS capillary inlet. 
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Image redacted due to copyright permissions 
 
Figure 4.41 the sampling system for real-time SIFT-MS monitoring of the products from chemical reactions. 1. The air inlet 2. Drechsel bottles to humidify the air in the 
reaction chamber 3. Chamber inlet 4. NMP015B pump (KNF Neuburger UK Ltd) 5. Analyte air is pushed over the SIFT-MS inlet capillary at a rate of 670mL/min. 
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4.2.2 The EDX110 dressing 
To begin the reaction in the chamber for SIFT-MS monitoring the lid of the chamber 
is removed and the hydrogel is placed adhesive side up as pictured in Figure 4.38 
(right) in the chamber; the nitrite soaked mesh layer is then placed in the centre of 
the adhesive side of the hydrogel as shown in Figure 4.39 and the chamber 
immediately resealed. One quarter of the full hydrogel and mesh was used for all 
repeats each quarter mesh and hydrogel were weighed prior to being combined in 
the chamber (5 cm x 5 cm hydrogel target weight 500 mg and 2.5 cm x 2.5 cm mesh 
target weight 50 mg).  Each dressing was continuously monitored for 3 hours; the 
ppb output was then converted into total µg, nmol per cm2 mesh, nmol per mg nitrite 
solution, and nmol per mg sodium nitrite (see appendix i for calculations).  
For section 4.2.6 in which the UWE sampling method was replicated by Intertek GLP 
laboratory the mesh batch was: D020715B 2016-01 and the gel batch was: 
D030515B 2016-01. 
4.2.3 Voice 200 SIFT-MS 
A Voice 200 from Syft (Syft Technologies, Christchurch, New Zealand) has been 
used for this project. The Voice 200 has an internal validation procedure during which 
the detection parameters are tested and a test matrix of standard gases are tested. 
This standard test mix is comprised of benzene, ethylbenzene, ethylene, 
hexafluorobenzene, isobutane, octafluorobenzene, tetrafluorobenzene, and toluene. 
Prior to each day’s analysis both the NO and NO2 standard gases were tested to 
ensure that the sample inlet was operating correctly. To do this two 1 L Tedlar bags 
were filled, one filled with NO and one filled with NO2. These bags were attached to 
the SIFT-MS inlet arm directly with an approximately 10 cm piece of tubing. The gas 
was allowed to draw in at its own flow of approximately 30 mL/min. Since the Voice 
200 is capable of utilising multiple reagent ions on the same run this effectively 
negates the need for separate HONO analysis.  
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A batch scan of sequential 1000 s scans were run continuously for the duration of 
the analysis; this allowed the data to be saved at 1000 s second intervals. The 
number of scans varied dependent on the experiment being performed (see sections 
4.2.4 – 4.2.8). The method for the scan is shown in Table 4.51: 
Scan settings SIM scan 
Measurement limit: time 1000 ms 
Measurement limit: count Deselected 
Positive products scan time 1000 ms 
Settle time 0.00 
Flow measuring  0.00 
Flow setting 0.00 
Background and calibration Deselected 
Inlet port sample  Direct 
Background  Deselected 
Compound selection Nitric oxide, nitrogen dioxide, nitrous 
acid 
Inlet pipe heater 110oC 
Flow tube heater 125oC 
Sample plate heater 110oC 
Table 4.51 the method parameters for the Voice 200 SIFT-MS used to analyse the products of the 
acidification of nitrite in real-time. 
The O2+ nitrous acid masses 30 and 46 conflict with NO and NO2 so are deselected.  
Prior to the reaction being started in the chamber the laboratory air was monitored 
flowing through the sampling system to get a measurement of the laboratory air 
background. Once the background was steady (usually after approximately five 
minutes) the reaction was started in the chamber. The mean background for each of 
NO, NO2, and HONO was calculated this mean background level was then 
subtracted from each recorded data point for the corresponding compound; this 
ensured that the background levels did not contribute to the total outputs.  
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4.2.4 The effect of pH on the reaction of citric acid and sodium nitrite 
For this set of experiments 1 M sodium nitrite (Sigma Aldrich Company, Dorset, UK) 
was made by adding 689.95 mg sodium nitrite to a 10 mL volumetric flask and filling 
to the line with deionised water; a fresh solution was made for each day of testing.  
For the acid source a solution of 0.1 M citric acid (Health Supplies Ltd, Harrow, UK) 
was also made by adding 9.606 g of citric acid to a 500 mL volumetric flask; and 
filling to the line with deionised water. Sodium citrate (Fisher Scientific Ltd, 
Loughborough, UK) was also made to 0.1 M concentration by adding 12.903 g to a 
500 mL volumetric and again filling to the line with deionised water. The sodium 
citrate was used as a buffer solution for the citric acid, the two solutions were mixed 
in 100 mL volumetric flasks according to the formula as found in the buffer reference 
centre on the Sigma Aldrich website (shown in Table 4.52) [223], 50 mL deionised 
water was used to top up the flask. Table 4.52 shows only the solutions made for 
this phase of testing, the pH levels tested were 3.0, 3.2, 4.2, 4.8, 5.4, and 6.2. The 
pH of each solution was measured with a Mettler Delta 320 pH probe meter prior to 
reaction (for measurements see Table 4.52), the pH probe was calibrated before 
each measurement with pH 7 and pH 4 buffer tablet solutions. 
 
0.1 M citric acid (mL) 0.1 M sodium citrate (mL) pH Measured pH 
46.5 3.5 3.0 3.05-3.20 
37.0 13.0 3.6 3.65-3.75 
31.5 18.5 4.2 4.15-4.35 
23.0 27.0 4.8 4.65=4.85 
16.0 34.0 5.4 5.35-5.50 
7.2 42.8 6.2 6.05-6.25 
Table 4.52 shows the ratio of buffer to acid used for each pH concentration, each solution was 
topped up to 100 mL using deionised water.  
For the analysis a 1.25 cm x 1.25 cm piece of mesh was cut out and placed into a 
polystyrene weigh boat (0.46 cm x 0.46 cm x 0.08 cm); this weigh boat was placed 
onto a balance and 10 µL of 1 M sodium nitrite solution was injected onto the centre 
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of the mesh; the mass of the sodium nitrite solution was recorded. This weigh boat 
was then placed in the reaction chamber and 10 µL of the buffered citric acid solution 
was injected on top of the mesh and the lid immediately replaced. Each reaction was 
continually monitored for 1.5 hours and carried out in duplicate.  
4.2.5 Citric acid versus ascorbic acid in the reaction with sodium nitrite in the 
presence and absence of glycerol and Natrosol 
For this set of experiments 1 M sodium nitrite in deionised water was used in all 
cases. Where glycerol was used 0.689 g of sodium nitrite was dissolved in 5 mL of 
water in a 10 mL volumetric flask. 5 mL of glycerol (BDH analytical chemicals) was 
then added and the solution stirred with a magnetic stirring bar. A 2% weight in water 
solution of Natrosol (Vibe-Nation, Saltash, UK) was made (2 g in 100 mL deionised 
water), the water is stirred with a magnetic bead to form a vortex before the powder 
is slowly added, this is to ensure even dispersion of the powder and avoid clumps. 
Stirring is continued until the gel is thick and clear. 6.899 g of sodium nitrite was 
added to this gel to make a 1 M solution.  
For the acid source 1.761 g of ascorbic acid (ICN biomedicals Inc, California, USA) 
was added to a 10 mL volumetric flask and dissolved in deionised water to make a 
1 M solution. To make the citric acid solution 1.921 g of citric acid (Health Supplies 
Ltd, Harrow, UK) was added to a 10 mL volumetric flask and dissolved in deionised 
water.  
The analysis took place in the same way as in section 4.2.5 a 1.25 cm x 1.25 cm 
piece of mesh was cut out and placed into a small polystyrene weigh boat and 10 µL 
of 1 M sodium nitrite solution was injected onto it and the mass recorded. This weigh 
boat was then placed in the reaction chamber and 10 µL of the acid solution was 
injected on top of the mesh and the lid immediately replaced. Each reaction was 
continually monitored for 1.5 hours and carried out in duplicate.  
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4.2.6 Replication of UWE developed method by Intertek GLP laboratory 
The funders of this work required that the method be validated by an independent 
laboratory with ISO certification for regulatory approval. Dressings from the same 
batch were sent to the University of the West of England (UWE) and at Intertek 
pharmaceutical services (IPS) Manchester (Manchester, UK) for comparative 
analysis; five dressings were analysed at each site. IPS also used a Voice 200 SIFT-
MS (Syft technologies, New Zealand), and the methods used at UWE (as in sections 
4.2.2 and 4.2.3) were passed on for replication.  
Due to the availability of certain items there were two key differences between the 
UWE sampling rig and the Intertek version. Intertek used a larger reaction chamber 
(1100 mL). Moreover, the Intertek system did not use a pump, instead clean air from 
a cylinder was pushed through the whole system at the 670 mL/min.  
4.2.7 The effect of the addition of salt solutions and bovine serum albumin on 
the EDX110 dressing reaction 
Saline was made by dissolving 0.9 g sodium chloride (NaCl) (Fisher Scientific Ltd, 
Loughbourgh, UK) in 100 mL deionised water, in a 100 mL volumetric flask to result 
in a 0.9% NaCl solution. The Hanks balanced salt solution (HBSS) was purchased 
from Sigma Aldrich Company, for formulation see appendix ii. The bovine serum 
albumin (BSA) (Acros Organics, Geel, Belgium) was made by adding 3 g to a 1 L 
volumetric flask and filling to the line with deionised water to form a 3.0 g/L 
concentration. 
The dressing analysis took place in the same way as described in section 4.2.4, 
however, this time a 2.5 cm x 2.5 cm piece of filter was used to cover the mesh, the 
test solution (saline, HBSS, or BSA) was soaked onto this paper prior to adding it to 
mesh (250 mg of solution was used each time). A blank dry filter paper piece and a 
filter paper soaked in deionised water was used as controls to account for the 
physical presence of the paper and the additional moisture. Applying the soaked 
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paper to the dressing partially mimics the moisture and salinity that could be present 
in a wound.   
4.3.0 Results and discussion  
4.3.1 The effect of pH on the reaction of citric acid and sodium nitrite 
Since the reaction of the dressings is dependent on the presence of an acid source 
altering the pH has a strong impact on the reaction. The hydrogel utilises a carboxylic 
acid impregnated in the gel; changing the pH of the hydrogel would be both costly 
and time consuming it was decided that an alternate acid source would be used; in 
this case citric acid. Figure 4.42 shows the evolution of NO for each of the pH values 
tested.  
Image redacted due to copyright permissions 
 
Figure 4.42 shows the evolution of NO at 6 different pH values by reacting buffered citric acid 
(0.1M) with 1M sodium nitrite.  
Figure 4.40 clearly demonstrates the impact that the pH has on the rate of evolution 
of NO as the pH increases the rate of NO evolution decreases. The decrease in NO 
as pH rises has been implied in a work by Weller et al. (2001) in which they measure 
the antimicrobial effects of acidified nitrite at a pH range of 1.7-6 [224]. This group 
reacted potassium nitrite with hydrochloric acid to mimic physiological reaction. The 
results showed that in order to confer anti-microbial effect the increased levels of 
nitrite were needed as the acid pH increased; for instance for two hour exposure at 
pH 1.7 1660 µmol/L was required, however at pH 4 there was no anti-microbial effect 
[224]. This effect was attributed to the generation of reactive nitrogen species 
however no reaction products were measured in the Weller study. A literature search 
has failed to find any instance in which the acidification of nitrite has been carried 
out at a pH range while directly measuring NO evolution.  
Crucial to the dressing’s performance and safety is the ratio of NO to NO2 produced, 
as NO2 is a toxic by product of the reaction. Thus, it is an important factor in using 
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the acidification of nitrite to generate NO. Table 4.53 shows the mean mass (µgs) 
evolved of HONO, NO, and NO2 based on a 1.5-hour analysis time. Figures 4.43 
and 4.44 show the cumulative plots for NO and NO2 respectively in nmol per mg 
NaNO2, both figures show that both NO and NO2 have plateaued and both NO and 
NO2 are no longer being produced, this is indicative of a completed reaction.  
pH Nitrous acid mean Nitric oxide mean Nitrogen dioxide 
mean 
3 25 81 0.90 
3.6 3 57 1 
4.2 3 52 0.2 
4.8 2 37 0.8 
5.4 2 23 0.9 
6.2 0.6 7 0.0 
Table 4.53 total mean µg of gaseous species HONO, NO, NO2 evolved from the reaction of NaNO2 
with buffered citric acid over a 1.5-hour reaction time. 
Table 4.54 shows the ratio of NO to NO2 based on the measured mean total nmol 
per mg sodium nitrite at different pH.  
 
pH 3 3.6 4.2 4.8 5.4 6.2 
Ratio NO/NO2 134:1 88:1 331:1 67:1 42:1 347:0 
Table 4.54 shows the ratio of NO to NO2 based on the calculated nmol per mg sodium nitrite for the 
different pH values. 
Tables 4.53 and 4.54 show that very little NO2 is generated in this set of reactions. 
pH 6.2 yields the best ratio however this is primarily due to the NO2 being 
undetectable above the baseline value (also shown in Figure 4.44). pH 4.2 yields the 
next best ratio at 331:1; NO production for pH 6.2 is 7 µg compared to 81 µg at pH 
4.2 (Table 4.54). As the pH increases the NO production notably drops off; from 81 
µg at pH 3 to 7 µg at pH 6.2. After pH 4.2 the ratio between the NO and NO2 
decreases until the NO2 is no longer detectable. Figure 4.43 shows the cumulative 
plots for the evolution of NO for each pH. Each pH shows the same pattern of 
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evolution as is also evidenced in Figure 4.42; there is a rapid initial burst where the 
majority of the NO is formed which then decays as the reaction proceeds. Figure 
4.44 shows that the NO2 production does not follow the same pattern as NO. While 
there is an initial burst of NO2 as with NO, at pH 5.4 and 4.8 the NO2 is continuing to 
climb after the NO evolution has plateaued; at pH 4.2, 3.6, and 3 the NO2 has 
reached plateau. This might be attributed to the fact that NO2 reacts in aqueous 
solutions freely, while NO is only slightly soluble (1.94x10-6 mol/cm-3 [225]).   
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Figure 4.43 cumulative plot in nmol per mg nitrite of nitric oxide evolved by the reaction of 0.1 M 
citric acid buffered with 0.1 M sodium citrate with 1 M sodium nitrite at different pH values. 
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Figure 4.44 cumulative plot in nmol per mg nitrite of nitrogen dioxide evolved by the reaction of 0.1 
M citric acid buffered with 0.1 M sodium citrate with 1M sodium nitrite at different pH values. 
Given the crucial role the availability of H+ ions has in the acid/nitrite reaction it is not 
surprising that raising the pH would lower the rate of reaction. The next section 
details experiments to investigate the effects of different acids.  
4.3.2 Citric acid versus ascorbic acid in the reaction with sodium nitrite in the 
presence and absence of glycerol 
Two separate acid sources have been evaluated (n=6) for their reaction with sodium 
nitrite; in addition, viscous polyols (glycerol n=3 and Natrosol n=3) have also been 
introduced to the reaction on the basis that the hydrogel portion of the EDX110 
dressing has a glycerol base.   
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Table 4.55 shows the mean nmol per mg sodium nitrite for HONO, NO, and NO2. 
Table 4.56 shows the ratio of NO/NO2 derived from the means calculated in Table 
4.55.   
Figure 4.45 shows the rate of evolution for NO for each reach reaction, Figures 4.46 
and 4.47 show the cumulative plot for nmol per mg sodium nitrite of NO and NO2 
respectively for each reaction. Figures 4.45- 4.47, and Tables 4.55 and 4.56 clearly 
show a difference between the citric acid and ascorbic acid reactions. In the first 
instance there is significantly less NO2 evolved in the ascorbic acid reactions 
regardless of the presence of polyols; this is especially clear in Figure 4.47. This is 
due to the fact that ascorbic acid acts as a reductant [226]; this reaction occurs as 
follows: 
C6H8O6 + 2NO2 → C6H6O6 + 2HONO 
This means that for reducing the toxic by-product of the acidification of nitrite (NO2), 
ascorbic acid is excellent. 
 
 
 
 
Acid source 
Nitrous acid (nmol per mg 
nitrite) 
Nitric oxide  
(nmol per mg nitrite) 
Nitrogen dioxide 
(nmol per mg nitrite) 
1 M Citric acid 1 M sodium nitrite 1498 8721 842 
1 M ascorbic acid 1 M sodium 
nitrite 
641 5656 148 
1 M Citric acid with 1 M sodium 
nitrite in 50% glycerol solution 
2096 9441 430 
1 M ascorbic acid with 1 M 
sodium nitrite in 50%  glycerol 
solution 
586 4998 83 
1 M Citric acid with 1 M sodium 
nitrite in 10% Natrosol solution 
2133 6756 822 
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 1 M ascorbic acid with 1 M 
sodium nitrite in 10% Natrosol 
solution 
729 4069 24 
Table 4.55 mean nmol per mg sodium nitrite of nitrous acid, nitric oxide, and nitrogen dioxide 
evolved for the acidification of sodium nitrite with 2 different acid sources and polyol additions. 
  
Acid 
Source 
1 M Citric 
acid 1 M 
sodium 
nitrite 
1 M 
Ascorbic 
acid 1 M 
sodium 
nitrite 
1 M Citric 
acid with 1 M 
sodium nitrite 
in 50% 
glycerol 
solution 
1 M Ascorbic 
acid with 1 M 
sodium nitrite 
in 50% 
glycerol 
solution 
1 M Citric acid 
with 1 M 
sodium nitrite 
in 10% 
Natrosol 
solution 
1 M Ascorbic 
acid with 1 M 
sodium nitrite 
in 10% 
Natrosol 
solution 
Ratio 
NO/NO2 
10:1 38:1 22:1 60:1 8:1 171:1 
Table 4.56 the ratio of NO to NO2 based on the calculated nmol per mg sodium nitrite for the 
different acid sources and the addition of polyols.  
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Figure 4.45 the rate of evolution of nitric oxide from reacting citric or ascorbic acid with sodium 
nitrite with and without the presence of polyols. 
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Figure 4.46 the cumulative plots of nitric oxide in nmol per mg sodium nitrite comparing citric and 
ascorbic acid with and without the presence of polyols.   
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Figure 4.47 show the cumulative nitrogen dioxide in nmol per mg sodium nitrite comparing citric 
and ascorbic acid with and without the presence of polyols.    
However ascorbic acid has been shown to decrease the antimicrobial properties of 
the acidification of nitrite [226]. Fite et al., 2003 compared the antimicrobial effects 
of nitrite in the presence of ascorbic acid, glutathione, thiocyanate, and iodide at 
different concentrations (0, 125, 250, 500, 750, and 1000 µM). This paper showed 
that at pH 2 nitrite had a minimum bactericidal concentration of 292 µM without 
ascorbic acid and 1000 µM with ascorbic [226]. This is an important consideration 
when designing a wound dressing, especially considering that up to 50% of patients 
with diabetic foot ulcers will develop an infection at the ulcer site [227].  
When ascorbic acid was used the NO, evolution had a similar pattern when glycerol 
was added than without any polyol (see Figure 4.45). However, over the 3-hour 
analysis more NO was produced when no polyol was present (5656 nmol per mg 
nitrite) than with glycerol and Natrosol added (4998 and 4069 nmol per mg nitrite 
respectively). Moreover, as the NO decreased in the presence of polyols so too did 
the HONO, and NO2. One possible reason for this is owing to the viscosity of the 
solutions; the water at 25oC has a viscosity of 0.89 mPa.s [228] while the 50% 
glycerol 50% water solution has a viscosity of 6.8559 mPa.s [229]; and the Natrosol 
solution at 1% has a viscosity of 3400-5000 mPa.s [230] (glycerol and Natrosol 
values are also 25oC). It is possible that the gaseous compounds being measured 
are not as freely volatilised in more viscous solutions. Moreover there is evidence 
that the presence of the polyol compounds can alter water activity [231]; this could 
also support why the oxides of nitrogen are generated at a reduced rate versus water 
alone.  
Figures 4.45 and 4.46 and Table 4.55 clearly indicate that NO is produced in greater 
quantities when citric acid is used regardless of the presence or absence of polyols. 
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This may be due to the fact that there is evidence that suggests that the carboxylate 
groups of the citric acid act as a catalyst for the reaction [232]. Under ordinary 
circumstances the general equation for the conversion of HONO to NO is considered 
to be: - 
2HONO ↔ NO + NO2 + H2O 
However, in the presence of a carboxylate group the equation becomes: -  
 
HONO + H3O+ + RCOO- ↔ RCOONO + 2H2O 
RCOONO + NO2- ↔ RCOO-+ + N2O3 
So, in effect the presence of the carboxylate catalyses the production of N2O3, which 
then follows this path: - 
2N2O3 ↔ N2O4 (2NO2) + 2NO 
So, where there is no carboxylate two moles HONO are needed to form one mol of 
NO; however, where there is a carboxylate the ratio changes to one mol HONO per 
mol of NO. 
In the presence of metal iron, nitrite and nitrate can be reduced as in Alowitz and 
Scherer, 2002 [233]. Summers and Chang, 1993 hypothesise that in the early earth 
Fe (II) was oxidised to Fe (III) by nitrites and nitrites, forming ammonia which created 
a significant amount of nitrogen in the early earth [234]. Similarly, Kampschreur et 
al. 2011 [235] demonstrated that NO, and nitrous oxide (N2O) could be formed form 
the reduction of nitrite by Fe (II). This could have an impact of if the acidified nitrite 
reaction when used in a biological system as the reduction of nitrite could imbalance 
the reactions. However, citrate (from citric acid) acts as a complexing agent for Fe 
(II) [236] which should help prevent the Fe (II)/ nitrite interaction.  
Overall, we have shown that in addition to the pH having an impact on the reaction 
with sodium nitrite the source of the H+ ion also has a significant impact on the 
reaction.   
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4.3.3 Dressing analysis at UWE compared with dressing analysis from Intertek 
GLP laboratory 
Intertek Pharmaceuticals Services (IPS), Manchester, were asked to analyse the 
EDX110 dressings on the SIFT-MS using the same method as that developed at 
UWE. However due to pumps used at UWE being unavailable to IPS they instead 
pushed air through the whole system at the same flow rate (670 mL/min) as used at 
UWE. Importantly the same dressing batch numbers were used for both sites 
hydrogels: D020715B 2016-01 and meshes: D030515B 2016-01. Table 4.57 shows 
the mean totals for nmol per mg sodium nitrite where n=5 for both IPS and UWE, the 
difference for NO is 1014 nmol per mg sodium nitrite with IPS recording the higher 
value which is ca. 10% of the UWE mean total. The two biggest differences come 
from NO2 with 94 nmol per mg sodium nitrite more being detected at IPS, which 
represents a ca. 33% increase from the UWE mean total and HONO with a difference 
of 1713 nmol per mg sodium nitrite (826 UWE versus 2539 IPS). Figure 4.48 shows 
the NO evolution for three repeats of the five analysed at both UWE (4.48 a) and IPS 
(4.48 b).  
The three repeats analysed at UWE all show a very similar rate of evolution and all 
have a similar pattern as seen in the previous experiments there is a sharp initial 
burst a steep rate of decay that shallows over the three-hour period. The IPS 
analyses show a slightly different pattern to the evolution, in this case there is still an 
initial burst in NO production. However, in this instance the rate of decline for NO is 
much shallower, so while the peak is not as high it stays at a higher value for longer; 
as such the total evolution over a three-hour period shows good correlation between 
the two sets of experiments. As previously stated in section 4.2.7 there was a key 
feature of the IPS sampling system that was different to the setup at UWE; which 
was that IPS pushed synthetic air through the sampling rig and over the SIFT-MS 
capillary, while at UWE the air was pulled through the system with a pump and then 
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pushed over the SIFT-MS capillary. This could easily account for the difference in 
the pattern of evolution.  
It is very important to note that the standard deviation (s.d.) of the IPS samples is 
considerably larger than the analysis carried out at UWE. For HONO the s.d. is 175 
nmol per mg sodium nitrite for UWE and 667 nmol per mg sodium nitrite for UWE. In 
the case of NO the s.d.’s was 519 nmol per mg sodium nitrite and 2220 nmol per mg 
nitrite for UWE and IPS respectively. This trend continued with an s.d. of 48 nmol 
per mg sodium nitrite and 196 nmol per mg sodium nitrite for UWE and IPS 
respectively. 
 
 Nitrous 
acid 
Nitrous acid 
S.D. 
Nitric 
oxide 
Nitric oxide 
S.D. 
Nitrogen 
dioxide 
Nitrogen 
dioxide S.D. 
UWE 826 175 9044 519 72 48 
Intertek 2539 667 10184 2220 325 196 
Table 4.57 comparison of the mean totals for nmol per mg sodium nitrite of nitrous acid, nitric acid, 
and nitrogen dioxide evolved over three hours comparing sampling at UWE versus Intertek.  
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Figure 4.48 a) shows the evolution of nitric oxide from EDX 110 dressings analysed at UWE and b) 
shows the evolution of nitric oxide from the EDX110 dressing by IPS. Both analysed on the Voice 
200 SIFT-MS. 
4.3.4 The effect of the addition of salt solutions on the EDX110 dressing 
reaction 
Since the dressings have shown strong evidence of having a positive impact on 
wound healing it is important to determine the role if any that external influences can 
have on the dressing’s efficacy.  
Table 4.58 shows the mean (n=3) totals of HONO, NO, and NO2 in nmol per mg 
sodium nitrite evolved over a three-hour period. Table 4.58 also shows the presence 
of the water-soaked paper does significantly decrease the amount of HONO and NO 
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evolved, this is most likely to be a result of the physical obstacle of the paper, and 
also HONO is highly soluble in water which will prevent volatilisation. Interestingly 
the NO2 evolution increases by over double which is difficult to account for as we 
would expect the NO2 to decrease due to the high-water content. Figure 4.49 shows 
clearly that the large initial burst from the standard dressing does not occur when the 
paper and solution is added, the standard dressing reaches ca. 19.5 ppm at the peak 
while when the deionised water-soaked paper is added the peak is only ca. 5.5 ppm. 
This is also reflected in Figure 4.50 which shows the cumulative plot for NO evolution 
over three hours in nmol per mg sodium nitrite; it is clear that when the paper and 
solution is added the initial rate of reaction has a much shallower slope; Table 4.58 
shows that this does have the effect of reducing the total evolution of NO. Salt 
solutions are used in the cleansing of wounds; saline being most commonly applied. 
Saline does not affect the skin flora (which provides less opportunity of pathogen 
growth), and importantly it neither donates nor removes fluid from the wound 
preventing cellular damage [237]. Hanks balanced salt solution (HBSS) has many 
formulations however usually calcium, magnesium, potassium, and sodium salts are 
often included along with glucose and phenol red the later acting as a pH indicator. 
HBSS is used primarily as a wash for the tissue cell culture which maintains the 
physiological pH of the tissue and whilst providing the required inorganic ions and 
maintaining the osmotic pressure of the tissue keeping the cells viable for longer. In 
the 1970s HBSS was shown to promote wound healing in tadpole tailfin pieces [238]. 
Alginate based dressings, which derive calcium and sodium salts from alginic acid 
are utilised in dressings to assist healing of chronic wounds [239]. As such we have 
assessed the effect that salt solutions e.g. saline and HBSS have on the dressing 
reaction.  
Table 4.58 and Figures 4.49 and 4.50 show there is no significant difference in 
HONO and NO production between the deionised water, saline, and HBSS. Table 
4.60 shows that there is a similar ratio of NO: NO2 for the deionised water, HBSS, 
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and BSA dressings however the saline solution produces a NO: NO2 ratio of 47:1 
versus 30:1 and 26:1 for deionised water and HBSS respectively. This is due to 
reduced NO2 production in the presence of the saline solutions. We have not been 
able to find any cases in the literature where nitrite has been acidified in the presence 
of a salt solution, so it is difficult to speculate as to the mechanism of this reduced 
NO2 evolution. However, salt might alter the solubility of the NOx species and 
increase ionic strength. 
 
 Nitrous acid Nitric oxide Nitrogen dioxide 
Standard dressing 2502 5699 59 
Standard dressing water 697 3910 131 
Standard dressing saline 634 3860 82 
Standard dressing HBSS 704 4143 157 
Standard dressing BSA 487 2559 80 
Table 4.58 the mean totals in nmol per mg sodium nitrite for nitrous acid, nitric oxide, and nitrogen 
dioxide evolved over 3 hours from the EDX110 dressing with the addition of salt solutions and 
bovine serum albumin.  
 
 
Standard 
dressing 
Standard 
dressing 
with water 
Standard 
dressing with 
saline 
Standard 
dressing with 
HBSS 
Standard 
dressing with 
BSA 
Ratio 
NO:NO2 
256:1 30:1 47:1 26:1 32:1 
Table 4.59 the ratio of nitric oxide to nitrogen dioxide derived from the mean nmol per mg sodium 
nitrite using the standard dressing with additional salt solution and bovine serum albumin. 
By far the biggest feature of the results is the impact of BSA on the reaction. In the 
first instance Figure 4.50 shows very clearly that NO production is reduced, in the 
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presence of BSA the rate of decay is very shallow, such that it is almost unnoticeable. 
This is also evidenced in Figure 4.49 where the slope is very shallow in the initial 
phase, this is likely attributed to an interaction between the protein and NO. Figure 
4.51 shows a slow rate of evolution for NO2 in the initial portion of the reaction which 
increases after the first 1000 seconds. NO is a known part of the cytokine cascade 
and is known to promote angiogenesis, a review of the role of NO in wound repair 
has been carried out [240]. Neutrophils and monocytes which are activated when a 
wound is formed are essential to initiation of the cytokine cascade via the production 
of TNF-α; NO regulates the expression of TNF-α. NO plays a role in multiple other 
mechanisms within the body, for instance it can be used to produce reactive radical 
species, acts as a signalling molecule which activates cyclic guanosine 
monophosphate, and also can regulate gene expression by reacting with the thiol 
binding site of transcription factor NF-kappa beta [240].   
In 1976 Woolford, and Cassens showed that nitrite would react with BSA, in their 
experiments BSA and nitrite incubated together for 96 hours in solution buffered to 
pH 6.0 137 ppm of nitrite would be recovered from 200 ppm nitrite initial 
concentration. Under more acidic conditions with a pH of 4.0 the recovery of nitrite 
decreased to 51 ppm out of 200 ppm [241]. This would help to explain the 
suppressive effect the BSA has on the acid nitrite experiments (for example see 
Figure 4.47). Kharitonov et al., 1995 describe the process by which the NO reacts 
with the BSA thiols and calculates the reaction rates [242]. Ewing et al., in 1997 
described the pharmacological potential of using nitrosylated BSA as a NO congener 
and propose this as method of NO delivery for therapeutic purposes [243]. There is 
the added complication that in a biological system there tends to be a significant 
quantity of uric acid. Pietraforte et al, 2006 state that as nitrite is ingested in the acidic 
environment of the stomach NO and other potentially harmful oxide of nitrogen 
compounds can be released. They noted that BSA inhibited the release of NO in the 
acidified nitrite reaction. Moreover they report that in the presence of acidified nitrite 
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in normoxic conditions uric acid is significantly decreased due to reactions with the 
NOx species [244]. While there is no uric acid present in the experiments presented 
here it is important to consider the practicalities and the additional complications to 
the acid/ nitrite reaction when used for its intended purpose of wound care.  
There are other reactions that can occur in the wound in the presence of acid/ nitrite 
reactions. For instance, the HONO produced by the dressing when in contact with a 
wound can react with the hydrogen peroxide. Under slightly acidic conditions such 
as those provided by the dressing HONO and hydrogen peroxide can produce 
peroxynitrous acid which has been shown to be an efficient bactericidal of E. coli 
[245,246].  
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Figure 4.49 the rate of evolution of nitric oxide produced from 1 quarter EDX 110 dressing with 
added filter paper saturated with one of either water, bovine serum albumin solution (BSA), hanks 
balanced salt solution, and saline. 
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Figure 4.50 the cumulative plot of nitric oxide produced from 1 quarter EDX 110 dressing over 3 
hours with added filter paper saturated with one of either water, bovine serum albumin solution 
(BSA), hanks balanced salt solution, and saline. 
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Figure 4.51 the cumulative plot of nitrogen dioxide produced from 1 quarter EDX 110 dressing over 
3 hours with added filter paper saturated with one of either water, bovine serum albumin solution 
(BSA), hanks balanced salt solution, and saline. 
4.4.0 Conclusions  
This work was undertaken with a view of underpinning the mechanisms by which the 
EDX 110 dressing appears to be highly effective as a wound dressing, as evidenced 
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by a stage 3 clinical trial which showed a percentage area reduction in the wound of 
88.6% versus 46.9% for the standard care pathway.  
In this chapter a novel method for monitoring the evolution of HONO, NO, and NO2 
from the acidification of nitrite in real-time using a SIFT-MS is described.  
The method used for this real-time chemical reaction analysis has not been 
previously described, though it is loosely based on flux chambers used for soil 
monitoring. To achieve external validation from an ISO accredited laboratory the 
method designed at UWE was replicated by IPS, Manchester. The mean NO was 
very similar between the 2 sites at 9044 for UWE and 10184 for IPS. However, there 
were differences in HONO, and NO2 (HONO: 826 UWE 2536 IPS; NO2: 48 UWE 
196 IPS). There were also differences in the pattern of evolution. These differences 
could all be attributed to differences in the sampling most notably the air being 
pushed through the whole system at IPS and pulled through the system at UWE.  
Using citric acid at different pH values we showed that it is possible to produce large 
quantities of NO at a higher pH’s (e.g. 4.2 4.8), this capability is important as  at 
lower pH values (pH 3 or less) significant discomfort would occur when applied to a 
wound. We also showed the acid source used has an impact on the reaction beyond 
the mere presence of H+ ions. Ascorbic acid due to its powerful reducing capabilities 
means NO2 evolution over a three-hour period was 148 nmol per mg sodium nitrite 
compared to 842 nmol per mg sodium nitrite when citric acid is used. However citric 
acid due to the carboxylate groups has a catalytic effect allow for greater NO 
generation at a higher pH (8721 nmol per mg nitrite for citric and 5656 nmol per mg 
nitrite for ascorbic).  
To develop a dressing, it is important that there is no cross reactivity with other 
standard care pathways. Since saline is still commonly used to clean wound and 
many other ionic salts are found in the blood it is important to understand the impact 
of salts on the dressing reaction. NO production was not altered by the presence of 
NaCl or HBSS; the blank had a mean NO production 3910 nmol per mg nitrite 
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compared to 3860 nmol per mg nitrite with NaCl, and 4141 nmol per mg nitrite with 
HBSS. However, the presence of the BSA protein caused a significant decline in NO 
production of just 2559 nmol per mg nitrite. This in indicative of a reaction between 
BSA and some intermediate or product from the acidification of nitrite. According to 
Kharitonov et al., 1995 there is a known pathway for the reaction of NO and BSA 
[242]. 
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Chapter 5: Summary, future work, and closing remarks 
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5.0.0 Summary 
Over the last 4 chapters 3 novel mass spectrometry techniques have been described 
for biomedical applications.  
5.1.1 Chapter 1 conclusions 
Section 1.2 discusses and describes non-real time MS techniques and cites a 
number of studies in which these techniques have been used for biomedical 
applications. Chapter 1 describes how mass spectrometry has been developed over 
the years and is constantly being updated with ever increasing sensitivity and 
accuracy. Techniques such as two-dimensional gas chromatography time of flight 
mass spectrometry (GC-GC-TOF-MS) is providing such detailed information that we 
are able to gain new insights into the mechanisms underpinning the pathogenesis of 
disease states. In general, most chromatography-based techniques suffer from 
similar limitations; the time per analysis tends to range from 30 minutes to over one 
hour. Since there is so much data to process from a single sample data analysis can 
often be time consuming and require skilled personnel (as exemplified by chapter 3 
which took several months of methods development). Similarly, the method 
development of these instruments also requires experienced users and can take 
significant time. Often samples require pre-processing and pre-concentration such 
as SPME or TD; this allows detectable concentrations of VCs to be injected into the 
instrument and while TD offers significantly improved sensitivity over SPME it adds 
time and expense to the process. However, the metabolic insights they can deliver 
with their qualitative data makes the cost to benefit worthwhile. This is because the 
qualitative data and the identification of VCs is crucial to understanding the metabolic 
changes that take place during disease states and thus understanding how VCs can 
be used in the clinical forum. The quality of data that can be collected from these 
instruments makes the shortcomings worthwhile.   
Section 1.3 describes and discusses real-time techniques which, in general are 
simple to operate and can be done by semi-skilled operators. While non-real time 
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techniques can also be easy to operate, they do require significantly more method 
development which does require expertise. All the real time instruments discussed 
in chapter 1 are high throughput with very short time per sample analysis ranging 
from 1-10 minutes. This short analysis time means that it is possible to have these 
instruments at the point-of-care and perform the tests rapidly. Moreover, these 
instruments usually provide very high sensitivity and can often detect compounds 
that can-not be detected by non-real time techniques for instance thermally unstable 
compounds. SIFT-MS, PTR-MS, and PTR-TOF-MS are all quantitative with relatively 
good accuracy (usually within 20%). However, in order to achieve quantification a 
target analyte must first be identified; the biggest challenge facing real time 
quantitative techniques is the inability to differentiate between compounds with the 
same m/z value. This greatly limits the qualitative ability of these instruments.  
5.2.0 Chapter 2 conclusions 
In chapter 2 we present a novel instrument which couples a metal oxide sensor to a 
standard gas chromatography mass spectrometry instrument such that the GC 
column is split with half of the analyte gas entering the mass analyser and half 
entering the sensor chamber. Across the stool samples and bacterial headspace 
samples the sensor detected over 100 peaks that were not seen by the mass 
spectral analyser or were sub-threshold. We tested this system to 29 standards 
across a range of masses and functional groups. In all but two instances the MOS 
sensor showed superior or the same performance then the mass spectral analyser. 
By testing three complex matrices we have shown that this GC-MS-S system can be 
used for multiple applications. Although the response of MOS sensors is very fast, 
recovery, especially with high concentrations of VOCs can be slow, which may 
obscure very small peaks which subsequently elute from the column. Although this 
may also happen with the MS, it does possess faster response and recovery than 
the sensor and thus better peak resolution. In previous work the same sensor has 
been operated continuously for 6 months while assessing hundreds of stool samples 
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for C. difficile infection and has retained its sensitivity when tested to certified gas 
standards [83]. However, it is important to note that the sensor only provides a 
resistance output so the extra comes at the expense of any qualitative data. By 
coupling the two detectors on a binary output we are able to take advantage of the 
qualitative MS data and the extra sensitivity of the sensor by using this data for 
differentiation of samples into groups e.g. disease versus non-disease.  
5.2.1 Chapter 2 future work 
Currently our system is set up for SPME pre-concentration however we plan to adapt 
this system to use automated thermal desorption (ATD). As discussed in section 
1.2.1 the additional costs and time associated with ATD the increased sensitivity and 
efficient sample storage (particularly of breath) make it a very desirable technique. 
We believe that systems of this type which incorporate chromatographic separation 
with MOS, or other sensitive sensor technology have the potential for utility in 
analysing a range of samples including those that are medically derived. For stool 
and urine headspace this may be possible via direct headspace analysis, but for 
breath and other matrices then appropriate sample collection and pre-concentration 
may be required either in system or offline.  
Work is under way to compare our GC-MS-S system with both a SIFT-MS instrument 
and a FAIMS instrument with a view to diagnosing colorectal cancer in the fast track 
diagnosis pathway.  
 
5.3.0 Chapter 3 conclusions 
In chapter 3 a standard GC-MS system was coupled to an ATD unit for the analysis 
of the compounds from stool samples, again from healthy participants. In this case 
the goal was to quantify some common stool metabolites and test how this data 
could be applied for use (potentially clinically). This required the development of a 
novel sampling method which involved spiking the stool samples with a solution 
comprised of 13C labelled compounds. Dimethyl sulphide (26–2,5626 ng/g), acetone 
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(442–3006 ng/g), ethyl butanoate (39–2468 ng/g), ethyl 2-methylbutanoate (0.3–180 
ng/g), dimethyl disulphide (35–1303 ng/g), 1-octen-3-one (12 ng/g), dimethyl 
trisulphide (10–410 ng/g), 1-octen-3-ol (0.4–58 ng/g), ethanoic acid (672–1,2963 
ng/g), butanoic acid (2493–1,1553 ng/g), 3-methylbutanoic acid (64–8262 ng/g), 
pentanoic acid (88–2,1886 ng/g), indole (290–5,477 ng/g), and 3-methyl indole (37–
3483 ng/g). We have also made a subset of samples alkaline by adding sodium 
hydroxide and with this we have been able to detect and quantify trimethylamine 
(range 40–5312 ng/g). Additionally, we record 12 compounds that have not been 
previously recorded as being found in stool. We compared this data to the results 
from the UK participants to those from South America and found that there were five 
compounds that were significantly different between the two groups. This 
demonstrates that our novel method has the capability of differentiating samples into 
groups, which could have utility in future projects. Moreover, it highlights the idea 
that understanding what constitutes a healthy sample is important as ethnic origin 
can affect intestinal flora composition.  
5.3.1 Chapter 3 future work 
The technique described in chapter 3 could be used to quantify some of the 
compounds in clinical stool and/or urine. The data gathered from these could then 
be used to differentiate into disease positive and disease negative groups using the 
statistics described in section 3.3.3. It could even be possible to identify biomarkers 
that increase in proportion to disease progression and regression.  
There needs to be more work done identifying the human volatilome; a review has 
been carried out in which all of the healthy human volatilome compounds identified 
in the literature have been tabulated [25]. However, one could question if this goes 
far enough in trying to elucidate what a healthy volatilome is. Most studies focus on 
a cohort of patients and/or participants with a sample taken at one point in time. To 
develop a truly comprehensive overview of the healthy volatilome there would need 
to be multiple longitudinal studies across multiple populations over many years. 
 181 
 
5.4.0 Chapter 4 conclusions 
A real time technique using SIFT-MS has also been described for quantifying the 
oxides of nitrogen (HONO, NO, and NO2) evolved from the acidification of nitrite from 
the EDX110 dressing. This, therefore, shows that VC detection for biomedical 
applications is not limited solely to disease diagnosis and that the breadth of 
applications for MS even in the biomedical field is very wide. A novel method was 
used in this work for quantifying the products of the acidification of nitrite reaction in 
real-time. This method was reproduced by a second laboratory with ISO certification; 
while slight differences to the sampling system were noted the total amounts of NO 
evolved were very similar to those found at UWE with a mean NO of 9044 for UWE 
and 10184 for IPS. However, there were differences in HONO, and NO2 (HONO: 
826 UWE 2536 IPS; NO2: 48 UWE 196 IPS).  
Experiments comparing citric and ascorbic acid sources show the products of the 
reaction is not simply determined by the presence of the H+ ion but also the other 
functional groups of the acid. Ascorbic acid due to its powerful reducing capabilities 
yielded lower means of NO2 evolution over a three-hour period (148 nmol per mg 
sodium nitrite compared to 842 nmol per mg sodium nitrite when citric acid is used). 
However citric acid due to the carboxylate groups has a catalytic effect allow for 
greater NO generation at a higher pH (8721 nmol per mg nitrite for citric and 5656 
nmol per mg nitrite for ascorbic). Still being able to produce clinically useful quantities 
of NO at higher acid pH values is important as it can improve the comfort of the 
treatment for the patient and could lead to other internal medicine applications.  
Nitric oxide production was not altered by the presence of NaCl or HBSS; the blank 
had a mean NO production 3910 nmol per mg nitrite compared to 3860 nmol per mg 
nitrite with NaCl, and 4141 nmol per mg nitrite with HBSS. However, the presence 
of the BSA protein caused a significant decline in NO production of just 2559 nmol 
per mg nitrite. This in indicative of a reaction between BSA and some intermediate 
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or product from the acidification of nitrite. According to Kharitonov et al., 1995 there 
is known pathway for the reaction of NO and BSA [242]. 
5.4.1 Future work 
Chapter 4 presents many avenues for further inquiry. Testing the difference in the 
reaction with the dressing stuck down to the bottom of the chamber would partially 
mimic the dressing on a wound and so it would be interesting to see what compounds 
evolve through the gel and in what ratio. It would also be useful to assess the 
antimicrobial effects of the dressing by mimicking a wound with a nutrient broth flow 
cell. Moreover, beginning to analyse the surface chemistry of the dressing using 
techniques such as Raman spectroscopy. Raman spectroscopy has already been 
used analyse the ion exchange properties of alginate hydrogels, with a bands 
appearing that are indicative of partial sodium and oxygen bonding [247]. Raman 
spectroscopy has also been used to assess the decomposition of nitrite to nitrate in 
acid solutions [248]. Understanding the decomposition of nitrite to nitrate would also 
be very important in understand the mechanisms of the acid nitrite reactions.   
Similarly, high performance liquid chromatography (HPLC) could be used to 
determine some of the reactions in the solution reactions of citric acid or ascorbic 
acids with sodium nitrite. Work has already been done in which HPLC with a 
photocathode detector has been used to determine nitrite, nitrate, and ascorbic acid 
from canned foods [249]. Understanding the solution reactions could potentially lead 
to the development of new applications for this reaction in the administering of 
medicinal NO. 
5.5.0 Closing remarks 
Chapter 1 highlights some of advances in mass spectrometry and some of the new 
types of data that we can gather faster and more accurately than ever before. 
Moreover, chapter 1 shows there is an ever-expanding body of evidence that mass 
 183 
 
spectrometry and related analytical techniques could pave the way to providing low 
cost, rapid, and non-invasive testing for numerous disease states.  
In chapter 2 a standard GC-MS instrument is coupled to a MOS sensor such that 
from a single sample run a binary output achieved; an instrument of this type has not 
previously been reported in the literature. Chapter 2 demonstrates that the MOS 
sensor is capable of superior sensitivity in several cases and that this instrument can 
be used for a range of applications. By combining the enhanced sensitivity of the 
MOS sensor with the qualitative output of the GC-MS this instrument shows great 
potential for the clinical setting. 
Chapter 3 presents a novel method for the quantification of VCs in stool samples by 
using 13C labelled compounds as internal standards. This method was used 
successfully and quantifies the mass of compounds retained in the stool and not just 
what is evolved into the headspace. This chapter also presents analysis of stool 
samples after being made alkaline (pH 13), this had a profound effect on the 
compounds evolved and allowed for the identification and quantification of amine 
compounds. The literature search did not show any other instances in which stools 
samples had been made alkaline prior to GC-MS analysis. Several compounds 
identified from the NIST library had not been previously reported in stool. 
In chapter 4 a novel method for quantifying oxides of nitrogen evolved from the 
acidification of nitrite has been reported, this method records the quantities of NO, 
NO2, and HONO using SIFT-MS. This has helped develop a deeper understanding 
of the reactions taking place in the EDX110 dressing which has been developed to 
assist in chronic wound healing.  
This thesis presents three novel methods of the use of MS for biomedical 
applications. Thus, showing that despite recent advances in technology and large 
body of pre-existing literature there are still many methods and techniques yet to be 
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developed. As such this thesis shows that while mass spectrometry might be over 
120 years old it is more relevant today than it ever has been.  
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Appendix i 
Conversion ppb into µg 
The temperature of the reaction chamber was taken for each data run, for this 
example a temperature of 34oC will be used. NO gas will be used in this example 
but the process is repeated substituting the molar mass of the other compounds to 
be converted. 
1. 34oC is converted into K by adding 273.15 which gives 307.15K 
2. Next the volume of 1 M of gas at 307.15K in cm3 calculated, assuming 1 mol 
of gas at 0oC = 22.4 L. (22.4 L x 1000 = 22400cm3). 
3. (22400 cm3 x 307.15K)/ 273.15K = 25188.21 cm3 (2.d.p.); so at 34oC 1 M of 
a gas has a volume of 25188.21 cm3 
4. This allows for the calculation of a conversion factor: 30 (molar mass NO) x 
0.001 (number of billionths in 1 cm3) divided by 25188.21 cm3 = 1.19 x 10-6 
5.  For each ppb data point from the SIFT-MS first the mean baseline (BLC) 
value is subtracted. 
6. The baseline corrected ppb value is multiplied by the conversion factor (1.19 
x 10-6) 
7. Next the flow rate over the SIFT-MS capillary (11.17 cm3/s) must be taken 
into account so the now converted value is multiplied by the flow rate. 
8. Finally, there is a time delay between data points in order to factor this in the 
value is multiplied once more in by the time delay in seconds. 
9. The final equation is: - 
a. (ppb - baseline mean) x conversion factor (µg) x flow rate x time 
between data points. 
A worked example with 10 ppb measurement, and a baseline mean of 1: - 
(10 ppb – 1 ppb) x (1.19 x 10-6) x 11.17cm3/s x 6.46 s = 0.0011 µg 
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Conversion of ppb to nmol 
To convert ppb into nmol a conversion factor must again be calculated, the same 
steps 1-3 can be taken as for the conversion of ppb to µg. Again, this means 1 M of 
a gas has a volume of 25188.21 cm3. The conversion factor = 1/25188.21 cm3 = 
3.9701 x 10-5. Next steps 5-8 are followed substituting the µg conversion factor for 
the nmol conversion factor, this gives: - 
(ppb - baseline mean) x conversion factor (nmol) x flow rate x time between data 
points. 
Worked example again using a 10-ppb measurement with a 1 ppb baseline mean: - 
(10 ppb – 1 ppb) x (3.9701 x 10-5) x 11.17cm3/s x 6.46 s = 0.0235 nmol 
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